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Somatic cells can be reprogrammed to pluripotent state by ectopic expression of a defined set of 
transcription factors. These induced pluripotent stem cells (iPSC) hold great potential for biomedical 
applications, such as disease modelling, drug discovery and cell therapies. The derivation of iPSCs is a complex 
multistep process that can commonly result in inefficient or incomplete conversion of the cells. The 
reprogramming efficiency and the quality of the reprogrammed cells can be affected by various components 
of the reprogramming method, including reprogramming vectors, starting cell populations and the choice of 
reprogramming factors. The aim of this thesis was to explore novel approaches for improving the pluripotent 
reprogramming outcome. 
The particular aims of this thesis were to investigate the use of recombinant Adeno-associated virus (rAAV) 
as a gene transfer vector for cellular reprogramming, characterization of the effects of old donor age and 
long term passaging on the reprogramming of fibroblasts, and development of reprogramming methods 
based on CRISPR/Cas9-mediated activation of endogenous reprogramming factors. 
In this study, rAAV-mediated transduction of mouse embryonic fibroblasts with OCT4, SOX2, KLF4 and C-MYC 
was found to successfully induce reprogramming to pluripotency. Unlike initially expected, the AAV vectors 
were integrated with high efficiency into the host genome during the reprogramming process, resulting in all 
analyzed iPSCs containing vector integrations. The high frequency of vector integration may limit the use of 
rAAV for generation of genetically intact iPSCs, however this vector may be useful for more specialized 
reprogramming applications where vector integration may be desirable. 
Both donor age and passage number of human fibroblasts can affect the reprograming efficiency. In this 
study, we have characterized the reprogramming of 11 skin fibroblast lines from various ages and passages. 
Both donor age and the culture time of the donor fibroblasts correlated with reduction in pluripotent 
reprogramming efficiency. This effect was found to be associated with upregulation of cellular P21 expression 
and reduction in cell proliferation. Downregulation of P21 expression by siRNA treatment was able to 
promote reprogramming of late passage senescent fibroblasts. Therefore, this study demonstrated that the 
inhibition of P21 can be used as a mean to improve the reprogramming efficiency of late passage senescent 
donor fibroblasts. 
To promote activation of endogenous pluripotency genes in reprogramming, we developed a gene activation 
system based on CRISPR/Cas9. Using this system, endogenous reprogramming factors can be activated by 
targeting the gene promoter with a deactivated Cas9 protein (dCas9) fused to a transactivation domain. This 
process was shown to be temporally controllable by fusing the dCas9 with a chemically inducible degradation 
domain. By optimizing the reprogramming factor guide composition, CRISPR/Cas9-mediated gene activation 
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(CRISPRa) could be used to derive iPSCs reprogrammed fully by targeted activation of endogenous genes. 
The efficient reprogramming of somatic cells by CRISPRa was found to be dependent on the inclusion of 
additional guides targeting an embryonic genome activation enriched Alu-motif (EEA-motif). Due to the 
direct targeting of endogenous loci and the high multiplexing capacity of CRISPRa, the reprogramming 
approach has a high potential for mediating comprehensive and specific reprogramming. This system has 
also potential uses for elucidating the function of endogenous gene regulatory elements, such as the EEA-
motif or other endogenous transposable elements, on the reprogramming process. The CRISPRa-based gene 
activation tools developed in this study thus provide a powerful new way of affecting cellular reprogramming. 
Overall, this thesis provides a number of novel tools and insights into the pluripotent reprogramming process. 
The results of this work can be used to develop more robust reprogramming methods and to improve the 




3. List of Original Publications 
 
This thesis work is based on the following articles (I-IV), referred in the text by their Roman numerals. 
 
 
I. Weltner J, Anisimov A, Alitalo K, Otonkoski T, Trokovic R. Induced pluripotent stem cell clones 
reprogrammed via recombinant adeno-associated virus-mediated transduction contain 
integrated vector sequences. J Virol. 2012 Apr;86(8):4463-7. DOI: 10.1128/JVI.06302-11 
 
 
II. Trokovic R, Weltner J, Noisa P, Raivio T, Otonkoski T. Combined negative effect of donor age 
and time in culture on the reprogramming efficiency into induced pluripotent stem cells. Stem 
Cell Res. 2015 Jul;15(1):254-62. DOI: 10.1016/j.scr.2015.06.001. 
 
 
III. Balboa D, Weltner J, Eurola S, Trokovic R, Wartiovaara K, Otonkoski T. Conditionally Stabilized 
dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and 
Differentiation. Stem Cell Reports. 2015 Sep 8;5(3):448-59. DOI: 10.1016/j.stemcr.2015.08.001. 




IV. Weltner J, Balboa D, Katayama S, Bespalov M, Krjutškov K, Jouhilahti E M, Trokovic R, Kere J, 
Otonkoski T. Human pluripotent reprogramming with CRISPR activators. Nature 









5hmC  5-hydroxymethylcytosine 
5mC  5-methylcytosine 
AAV  Adeno Associated Virus 
AID  Activation Induced Cytidine Deaminase 
alt-NHEJ  Alternative Non-Homologous End Joining 
BMP  Bone Morphogenetic Protein 
cAMP  Cyclic Adenosine Monophosphate 
Cas9  CRISPR-Associated Protein 9 
CPP  Cell Penetrating Peptide 
CRISPR  Clustered Regularly Interspaced Short Palindromic Repeat 
crRNA  CRISPR RNA 
CTCF  CCCTC-Binding Factor 
dCas9  Dead Cas9 (catalytically inactivated) 
DMR  Differentially Methylated Region 
DNA  Deoxyribonucleic Acid 
DNMT  DNA Methyltransferase 
DOX  Doxycycline 
DSB  Double Strand Break 
EB  Embryoid Body 
EEA-motif  EGA Enriched Alu-motif 
EGA  Embryonic Genome Activation 
EMT  Epithelial To Mesenchymal Transition 
EpiSC  Epiblast Stem Cell 
ERV  Endogenous Retrovirus 
ESC  Embryonic Stem Cell 
FGF  Fibroblast Growth Factor 
gRNA  Guide RNA 
HDAC  Histone Deacetylase 
HDR  Homology Directed Repair 
HFF  Human Foreskin Fibroblast 
HMG  High Mobility Group 
ICM  Inner Cell Mass 
iPSC  Induced Pluripotent Stem Cell 
ITR  Inverted Terminal Repeat 
KLF4  Kruppel Like Factor 4 
LAD  Lamina Associated Domain 
LIN28A  Lin-28 Homolog A 
MBD  Methyl-CpG Binding Domain Protein 
MEF  Mouse Embryonic Fibroblast 
MET  Mesenchymal To Epithelial Transition 
miPSC  Mouse iPSC 
miRNA  Micro RNA 
10 
 
MMLV  Moloney Murine Leukemia Virus 
mRNA  Messenger RNA 
MYC  V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 
NHEJ  Non-Homologous End Joining 
NSC  Neural Stem Cell 
NT-ESC  Nuclear Transfer Embryonic Stem Cell 
NuRD  Nucleosome Remodelling and Deacetylation 
OCT4  Octamer-Binding Protein 4 
OSK  OCT4, SOX2 and KLF4 
ORF  Open Reading Frame 
p-TEFb  Positive Transcription Elongation Factor 
PAM  Protospacer Adjacent Motif 
PFA  Paraformaldehyde 
Pol II  RNA Polymerase II 
POU  PIT/OCT/UNC Family Transcription Factors 
POU5F1 (OCT4) POU Class 5 Homeobox 
PRC  Polycomb Repressive Complex 
PSC  Pluripotent Stem Cell 
rAAV  Recombinant Adeno-associated Virus 
RNA  Ribonucleic Acid 
RNAi  RNA Interference 
RNP  Ribonucleoprotein 
SCNT  Somatic Cell Nuclear Transfer 
sgRNA  Single Guide RNA 
siRNA  Small Interfering RNA 
SOX2  SRY-Box 2 
TAD  Topologically Associating Domain 
TALEN  Transcription Activator-Like Effector Nuclease 
TGF  Transforming Growth Factor Beta 
TE  Transposable Element 
TET  Ten Eleven Translocation 
TMP  Trimethoprim 
tracrRNA  Trans-activating crRNA 
TSS  Transcription Start Site 
UTR  Untranslated Region 






Induction of pluripotency and CRISPR/Cas9-mediated genome engineering have been two of the most 
impactful biomedical innovations affecting the stem cell field in the past decade. 
The pioneering work on cellular reprogramming by Takahashi and Yamanaka in 2006 1, spawned a 
subsequent boom in human pluripotent stem cell research. As induction of pluripotency allows generation 
of embryonic stem cell like pluripotent cells from adult donors, this method has enabled new kinds of in vitro 
research avenues using patient derived induced pluripotent stem cells (iPSC) for disease modelling. These 
cells can further be differentiated into affected somatic cell types, which may not otherwise be available for 
in vitro studies, e.g., neurons or cardiac cells. Additionally, iPSCs hold great promise for an easily available 
source of immune matched cells for cell replacement therapies. The first human trials using iPSC derived 
retinal pigment epithelial cells are currently ongoing for treatment of macular degeneration 2, and other trials 
are to be expected. One of the strongest examples speaking for the impact of iPSC induction on medical 
research and the expectations set for the method has been the 2012 Nobel Prize in Physiology and Medicine 
awarded to John Gurdon and Shinya Yamanaka for their contributions to the cellular reprogramming field. 
Even though iPSCs have a huge potential for medical research and cell therapies, the derivation of the 
reprogrammed cells is not without issues. The method has been shown to lead to improperly reprogrammed 
cells and to be associated with genetic aberrations, which may affect the downstream applicability of the 
resulting cells. Therefore, better understanding of the processes controlling cellular reprogramming and 
better methods for iPSC derivation are required for faithful conversion of somatic cell types to pluripotency 
and recapitulation of the pluripotent cell phenotype. 
The bacterial adaptive immune defence derived CRISPR/Cas9 system was first demonstrated to function as 
an RNA guided endonuclease in 2012 3,4. Although genome engineering approaches based on meganucleases, 
zinc-finger nucleases (ZFN), and transcription activator-like effector nucleases (TALEN) had previously been 
developed, the RNA guided target site determination of CRISPR/Cas9 simplified genome editing procedures. 
Later, CRISPR/Cas9 systems have been adapted for transcriptional control and epigenome editing. Combined 
with the high multiplexing capacity of the short guide RNA molecules, this makes the system very appealing 
for various cell biological applications, including cellular reprogramming. 
This thesis work aims at developing novel cellular reprogramming approaches for improving the outcome of 
pluripotent reprogramming. Specifically, this includes Adeno Associated Virus (AAV)-mediated 
reprogramming factor delivery (I), CRISPR/Cas9-mediated activation of endogenous pluripotency factors (III 




6. Review of the Literature 
 
This part of the thesis will first describe current issues of pluripotent stem cell research followed by concepts 
in transcriptional control of gene expression. Thereafter, the tools and methods for cellular reprogramming 
and artificial control of transcription with CRISPR/Cas9 tools will be described. 
 
6.1. Pluripotent Stem Cells 
Stem cells are capable of unlimited self-renewal and differentiation into other cell types and tissues. Stem 
cells can be divided into embryonic stem cells and adult stem cells. Adult stem cells are multipotent and 
limited in their differentiation capacity and generally only contribute to the formation of a specific tissue. 
Adult stem cells in the body are important for the maintenance of tissue homeostasis, such as intestinal stem 
cells or hematopoietic stem cells, which maintain the renewal of the respective tissues. In addition to somatic 
stem cells, adult tissues contain germ line stem cells that produce gametes and can reconstitute the 
pluripotent state after conception. Pluripotent stem cells (PSC) can differentiate into all tissues of the 
organism. They do not exist in the adult body but can clearly be identified as a transient cell population 
present in early embryos. Pluripotent stem cells can be captured in vitro in specific culture conditions, 
allowing for artificial long-term maintenance of the pluripotent cell population. In vitro cultured pluripotent 
stem cells are commonly referred to as embryonic stem cells. 
Due to their capacity to form all the different tissues of the body, pluripotent stem cells hold great potential 
for various medical applications. As PSCs can be differentiated into any tissues of the body, they are a great 
source for cells that cannot be easily obtained from adult tissues, such as neurons or cardiac cells. These cells 
can then be utilized for various applications, like drug screening, disease modelling and cell replacement 
therapies. 
 
6.1.1. Derivation and Types of Pluripotent Stem Cells 
Pluripotent stem cells can be considered as the in vitro equivalent of the blastocyst stage embryo cell 
populations that give rise to the embryonic tissues, i.e., epiblast precursor cells of the inner cell mass (ICM) 
and post implantation epiblast cells. Pluripotent stem cells can be derived either directly from early embryos 
as embryonic stem cells (ESC) 5–7, from germ cells 8,9, or by reprogramming somatic cells, either by nuclear 
transfer to oocytes (NT-ESC) 10,11, or by overexpression of specific sets of pluripotent state transcription 
factors (iPSC) 1. As the derivation of ESCs generally requires the destruction of a viable embryo, human 
embryonic stem cell research has historically been ethically controversial. The ability to produce pluripotent 
cells from adult cell sources by reprogramming has helped in this regard. 
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Pluripotent stem cells can exist in various states of pluripotency roughly equating to different developmental 
time points of the embryo. Two of the most commonly studied states are referred to as primed and naïve 
states. These are distinguished by various parameters like morphology, gene expression, epigenetic state and 
ability to contribute to chimera formation 12. Naïve state cells resemble the inner cell mass epiblast precursor 
cell population, whereas primed cells resemble more the single cell layer epiblast cell population of an 
embryo. It has been speculated that primed pluripotent cells could be more biased in their differentiation 
capacity towards some lineages due to intrinsic variation in priming of differentiation associated genes. In 
addition to the conventional naïve and primed states, a number of other alternative types of pluripotent 
states have been reported. These include for example the region-selective epiblast stem cells (EpiSC), which 
can only graft into posterior parts of post-implantation epiblast 13, various forms of 2-cell embryo-like 
extended potential pluripotent stem cells (EPS), which are capable of contributing to both embryonic and 
extraembryonic tissue development in vivo 14–17, and artificial pluripotent states maintained by transgene 
expression, like the F-class cells 18. 
 
6.1.2. Pluripotent Stem Cell Maintenance 
The maintenance of stable pluripotent stem cells in culture requires promotion of self-renewal of the 
pluripotent state and prevention of the differentiation of the cells. In vitro pluripotency is a transient state 
that is resolved by the cells differentiating into other tissues. The culture of pluripotent cells in vitro tries to 
capture the transient pluripotent state and the specific culture conditions are dependent on the desired state 
of potency. Mouse pluripotent stem cells are maintained in their conventional culture conditions in a naïve 
state. The naïve sate in mouse PCSs is generally maintained by LIF-signalling via STAT3 19, and can be further 
promoted by culture in the presence of MAPK pathway inhibitors and Wnt activators, to inhibit 
differentiation of the cells and to promote active cell growth 20. Mouse PSCs can also be derived in primed 
state as epiblast stem cells 21,22. EpiSC state is dependent on FGF- and TGF-signalling for its maintenance. 
Human pluripotent stem cells resemble more the epiblast stage of embryonic cells and are also dependent 





Figure 1. Sources and maintenance of pluripotent stem cells. Embryonic stem cells can be derived from early 
embryos and induced pluripotent stem cells can be reprogrammed from somatic cells. PSCs cultured in 
different conditions roughly equate to different developmental stages of an embryo.  
 
FGF controls both the differentiation of naïve state cells towards primed state and the maintenance of the 
primed pluripotent cells. The role of FGF-signalling in the maintenance of primed pluripotent state has been 
attributed to its role in promoting the activation of the PI3K pathway in the presence of SMADs and the 
absence of Wnt signalling 26. The maintenance of human PSCs with other PI3K pathway activating factors, 
such as IGF-1, Heregulin or Elabela, seems to support this notion 27,28. FGF signalling also activates MAPK 
signalling and ERK phosphorylation, which is a key factor in contributing to the differentiation of naïve state 
cells. In primed human PSCs ERK2 has been shown to target NFY and ELK1 bound active genes to promote 
self-renewal and pluripotency 29. Mechanistically ERK activation has been reported to promote Pol II Ser-5 
phosphorylation at developmental genes 30. Therefore, ERK signalling may contribute to priming of 
developmental genes for activation by additional signalling cues by promoting transcriptional initiation and 
proximal pausing of Pol II at the promoters 31. Although it has been reported that paused Pol II is detected 
primarily at signalling pathway genes and not at developmental genes in mouse PSCs 32, the study used cells 
cultured in the presence of MEK inhibitor, which may result in loss of Ser-5 phosphorylated Pol II at these 
genes, if they are differently regulated by ERK, as has been suggested 30. Combination of Hippo signalling, 
TGF-mediated promotion of Pol II Ser-7 phosphorylation and Wnt-mediated looping of enhancer and 
promoter regions of mesenchymal genes has been described as models for triggering mesenchymal 
differentiation of human PSCs 33. The active transcription of mesenchymal genes is promoted by removal of 
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YAP-mediated repression of switch enhancers, that are poised, switch-like regulatory elements that allow 
cells to differentially interpret the same SMAD2/3 signalling 34. As the same signalling factors, i.e. Wnt 
components, are required for the maintenance of naïve state cells and the initiation of primed cell 
differentiation, the primed cell state is not easily converted back to naïve state due to preference to 
differentiate. 
Primed mouse EpiSCs can, however, be converted into naïve state with low efficiency by culturing in naïve 
state promoting culture conditions 35. The conversion efficiency can be improved by overexpression of 
pluripotent factors that promote naïve state, such as Klf4, Tfcp2l1, Nanog, Esrrb, Myc, Stat3, Nr5a1 and 2, 
Klf2 and Prdm14 36–43. The conventional mouse naïve state culture conditions, containing LIF, MEK inhibitor 
and GSK3 inhibitor, do not support maintenance of naïve human stem cells, and only one human ESC line 
has reportedly been derived in these conditions 44. However, the overexpression of a number of pluripotent 
state factors can help induce and stabilize naïve-like stem cell state of human cells. The human naïve 
conversion promoting factors contain many of the same genes as mouse, including OCT4, SOX2, KLF4, MYC, 
NANOG, KLF2, NR5A2 and RARG 45–49. Additionally, overexpression of YAP has been reported to promote 
human naïve state acquisition in part by suppressing differentiation promoting effects of GSK3 inhibition 50. 
The maintenance of the human naïve pluripotent state is more demanding than mouse cell maintenance, 
and the culture medium needs to be supplemented with extra signalling inhibitors or activators. The methods 
described so far are quite variable and result in cell populations with varying level of resemblance to mouse 
naïve cells and human preimplantation embryo epiblast cells. Inclusion of extra small molecular compounds 
in the culture mix can help in converting and maintaining the human naïve state in the absence of transgenic 
pluripotency factor expression. The small molecular compounds and growth factors that have been used for 
naïve state maintenance of human cells include LIF, MEK inhibition, GSK3 inhibition, FGF signalling 
activation and inhibition, TGF signalling activation and inhibition, cAMP signalling activation, aPKC 
inhibition, p38 inhibition, JNK inhibition, BMP inhibition, ROCK inhibition, BRAF inhibition, SRC inhibition, 
Tankyrase inhibition and YAP activation 46,47,49–57. Due to the many versions of the human naïve culture 
conditions, it is not yet clear what exact conditions would best support the naïve state of human cells. A 
recent comparison of some of the most commonly used conditions suggests that the LIF, MEK inhibitor, aPKC 
inhibitor and titrated GSK3 inhibitor containing conditions may be the most optimal so far, as these 
conditions helped maintain the cells with best resemblance to embryo epiblast cells while exhibiting the least 
karyotypical abnormalities 58. However, these conditions may also still cause karyotypical abnormalities, 
which may be attributed to the MEK inhibitor used in the protocol, and substituting the MEK inhibitor with 
SRC inhibitor may help in maintaining normal karyotype and DNA imprinting of the cells in prolonged culture 




6.1.3.  Transcriptional Control of Cell Identity 
Gene expression is initiated at promoter sites which define the transcriptional start sites for mRNA 
production. As the transcriptional profile of a cell defines the cell type, transcriptional control lies in the heart 
of cell identity. Cell type specificity of promoters is commonly controlled by cis-acting DNA elements, known 
as enhancers 61. Enhancers can bind trans-acting factors, i.e. transcription factors, which can stimulate 
increased transcription from promoters, or mediate repressive function. Cell type specific expression of the 
enhancer binding transcription factors can therefore mediate cell type specificity of the associated 
promoters. The accessibility of enhancers and promoters can further be controlled by epigenetic chromatin 
and DNA modifications in these loci. Transcriptional activation of promoters is mediated by recruitment of 
the mediator complex by the enhancer bound transcription factors 62. The mediator complex further recruits 
the RNA polymerase II (Pol II), which can initiate transcription of the target gene into mRNA. Enhancer 
recruited transcription factors therefore define cell type specific transcription. 
More recently, clusters of active enhancers, deemed super-enhancers, have been described in controlling 
cellular identity 63. These elements show cell type specific activity and can accommodate binding of unusually 
high densities of interaction partners. The super-enhancers can be established by cell type specifying master 
transcription factors in combination with mediator complex 64. In pluripotent stem cells these enhancer 
domains are formed by the core pluripotency factors OCT4, SOX2, and NANOG. 
The function of the super-enhancers has recently been proposed to follow a phase separation model 65. This 
model presents separation of active enhancers and transcription promoting factors into non-membranous 
nuclear compartments by high density of intermolecular interactions of trans-acting factors and the super-
enhancer loci. These types of discrete transcriptionally active compartmentalized nuclear sites with 
enrichment of Pol II and transcription promoting components have also been deemed transcription factories 
66–68. Similar discrete compartmentalization of nuclear processes is also known for other nuclear organelles, 
including nucleoli, Cajal bodies and nuclear speckles. Phase separation has also been described in driving 
heterochromatin formation 69, therefore it may be an integral mechanism in controlling nuclear architecture 
and function. Important part of the phase separation model of enhancer function is its ability to explain the 
vulnerability of the active super-enhancer complexes to perturbations by interference with the ‘cross-linking’ 
interactions of the trans-acting factors. This kind of mechanism could explain the effect that external cues 
have in controlling enhancer activity. Sensitivity to external factors, which mediate commissioning and 
decommissioning of enhancers, may therefore be the basis for controlling cell type specific expression by 
signalling cues, i.e., this model may explain the mechanisms by which stem cell differentiation is controlled 





Figure 2. Nuclear compartmentalization in transcriptional control. Repressive heterochromatin is commonly 
located in lamina associated domains near nuclear periphery. Upon activation gene loci can be translocated 
to transcription factories containing transcriptional machinery components. Transcriptional activation can be 
maintained by phase separation mediated by transcription factors, co-activators and RNA polymerase 
interacting with regulatory DNA elements. DNA is organised into topologically associating domain (TAD) loops 
where loop anchor contains CTCF sites and intra loop interactions are mediated by YY1 and ZNF143. 
 
Chromosomes in nucleus primarily occupy spatially restricted areas called chromosome territories. These are 
further sub-divided into smaller DNA structures with high level of intradomain interactions called 
topologically associating domains (TAD). The TAD boundaries are generally conserved between cell types and 
are marked by CTCF binding sites and cohesin occupancy. These regions, termed insulated neighbourhoods, 
thus appear to form a DNA sequence specific structural feature for DNA looping 70. Gene expression control 
primarily occurs within these loop structures between enhancer and promoter regions located inside same 
TAD, intra TAD interactions forming approximately 90% of gene regulatory interactions. These DNA loop 
structures are generally associated with distinct patterns of histone modifications, and loop anchor sites 
typically bind CTCF and occur at TAD boundaries 71. TADs are thought to form by DNA loop extrusion and 
boundary formation by parallel CTCF-CTCF binding motifs 72. Possible factors mediating this process may be 
condensin, which has intrinsic ATP-dependent mechanochemical motor activity 73, and transcription-
mediated cohesin positioning in DNA 74. Transcription mediated TAD formation appears to be supported by 
presence of CTCF cohesin loops primarily in sites with higher transcription levels. However, single cell analysis 
of 3D chromatin structures in mouse ESCs indicated that TAD formation does not occur in all cases 75. Physical 
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proximity of genomic locations in nucleus governs the interactions of enhancer and promoter sites 76. 
Dynamic intradomain looping of DNA between enhancer and promoter regions can be mediated by common 
transcription factors such as YY1 and ZNF143 77–79. Intradomain promoter-enhancer interactions in ESCs have 
also been shown to be mediated by mediator and cohesin co-localizing with OCT4, SOX2 and NANOG, 
indicating a role for cell type specific transcription factors in controlling chromatin architecture 80,81. Indeed, 
functional interaction of ZNF143 and OCT4 has been demonstrated in controlling NANOG promoter activity 
82. On the other hand, KLF4 has been shown to control long-range interchromosomal interactions in the Oct4 
locus 83. Therefore, transcription appears to be controlled by cell type associated factors within the TADs, 
and longer-range interactions may further affect nuclear compartmentalization. Overall, it has been 
proposed that chromatin regulation can be divided into two main types of control over chromatin 
architecture 84. On a larger level long-range chromatin interactions appear to be defined by open/closed 
characteristics of chromatin, both inter- and intra-chromosomally. On a shorter range genomic regions are 
more likely to interact if they share similar regulatory proteins, such as pluripotency factors or PRC complexes 
84. Therefore, a simplified view of the mechanism suggests that proteins preferably controlling short range 
interactions within TADs may be more important in mediating transcriptional control of target genes by 
mediator and cohesin complexes, and the factors preferably mediating long-range interactions may be more 
important in localizing genomic areas between open and closed chromatin compartments. This may further 
link the chromosome architecture to the phase separation model of transcriptional control. 
Closed heterochromatin in cells is usually spatially segregated into nuclear lamina associated domains (LAD), 
near nucleoli or in pericentromeric heterochromatin 85. LADs in cells are generally divided into cell type 
invariant constitutive LADs, and variant facultative LADs, which interact with nuclear lamina in a cell type 
dependent manner. Physical interaction of genomic loci between LADs have been shown to change in stem 
cells upon differentiation, reflecting the transcriptional changes of the associated genes. For example, the 
physical localization of multiple pluripotency genes, including Oct4, Rex1 and Nanog, changes closer to 
nuclear periphery when differentiating PSCs into neural cells 86. Additionally, targeting of genes with synthetic 
transactivator domains will relocate the genomic loci from LADs towards the nuclear interior in a chromatin 
remodelling dependent way 87. This likely allows the loci to relocate to transcription factories upon gene 
activation. Knock down of YY1 can shift LADs towards nuclear interior, indicating a possible role for the factor 
also in heterochromatin maintenance in addition to mediating enhancer looping 77,85,88. Nuclear 
compartmentalization in transcriptional control is summarised in Figure 2. 
TAD compartments disappear in mitotic cells 75. Therefore, chromosomal 3D structure has to be re-
established at G1 phase. In order to know which genes to start transcribing after division, a set of 
transcription factors stay attached to the mitotic DNA. This is known as mitotic bookmarking. Many 
pluripotent stem cell specific factors, including ESRRB, KLF4, OCT4 and SOX2, as well as epigenetic 
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modifications have been shown to have mitotic bookmarking function 89,90.Therefore, these factors may also 
be important in re-establishing the pluripotent stem cell transcriptional program after cell division. 
Conversely, inhibition of the factors binding these epigenetic modifications, implied in the mitotic 
bookmarking, can be used to promote transcriptomic changes aimed at converting cell types. This kind of 
mitotic de-bookmarking has been used for example to mediate induction of pluripotency by inhibiting 
fibroblast transcriptional program 91. It has also been argued that mitotic exclusion of transcription factors 
may be a cell fixation artefact and that many transcription factors will bind mitotic DNA in a dynamic manner 
92. In addition mitotic cells appear to maintain their transcriptional program, albeit at lower levels 93. 
Therefore it is possible that cell type specific transcription in mitotic and interphase cells is primarily different 
by the magnitude of transcription, which may be due to more stable transcription factor interphase 
interactions with DNA mediated by transactivation domain interactions 92. 
 
6.1.4. Transcription Factors Regulating Pluripotency 
There are two major models for the maintenance of the mammalian pluripotent state. These models depict 
the pluripotent state either as a ground state or a balanced state. In the ground state model the pluripotent 
state is seen as an intrinsically stable state in which the self-regulatory nature of the pluripotent factors can 
maintain the expression of the pluripotent gene network in the absence of external signalling cues 12,20. This 
interpretation is more prominent in the context of mouse pluripotent stem cells, which can be more readily 
maintained in a naïve state of pluripotency. This has been predicted to be linked to the transcriptional control 
of diapause in rodents. The other model describes pluripotent state as a balanced state between opposing 
pro-differentiation cues 94. This kind of ‘see-saw’ model is based on the fact that overexpression of 
pluripotency factors can promote destabilization of pluripotent state and differentiation of pluripotent cells. 
For example, ectopic expression of SOX2 or NANOG can promote differentiation of ESCs into neural and 
mesendodermal lineages respectively 95,96. In the balance model the opposing effects of divergent lineage 
specifying transcription factors form a cross-regulative network in which the balancing of antagonistic pro-
differentiation cues results in the emergence of pluripotent differentiation capacity. This model is possibly 
more suited for the primed pluripotent state, predominant in human PSC culture, in which cells are poising 
the differentiation associated genes for activation. It may thus be that the differentiative capacity of the 
pluripotency factors results from excessive activation of poised genes in the presence of excessive amounts 
of particular pluripotency factors. 
The gene regulatory network for pluripotency in human embryonic stem cells was initially described to be 
governed by the core transcription factors OCT4, SOX2 and NANOG 97. These factors are also required for 
proper embryo development. OCT4, SOX2 and NANOG were found to co-occupy many of their target sites, 
with over 90% of OCT4 and SOX2 bound promoter regions being also bound by NANOG. These factors occupy 
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sites in multiple genes which have been implicated in embryo development, including signalling and 
transcription factors controlling differentiation and pluripotency, as well as OCT4, SOX2 and NANOG 
themselves. Therefore, the core pluripotency factors form a basis for a regulatory network governing the 
expression of differentiation associated factors as well as self-regulatory loops maintaining their own 
expression and pluripotency. OCT4 and SOX2 bind DNA as a heterodimer in closely spaced composite motifs 
containing POU domain (OCT4) and HMG domain (SOX2) recognition sites 98. The interaction between HMG 
domains and POU domains has been evolutionally conserved 99. One way of controlling the differentiation of 
pluripotent cell is a switch between SOX2 and SOX17 expression, which redistributes OCT4 binding to distinct 
‘compressed’ composite DNA motifs in endodermal differentiation 100,101. 
In addition to OCT4, SOX2 has been shown to interact physically with NANOG 102. Interaction with the core 
pluripotency regulatory factors and co-occupancy of genomic sites has been used to identify additional 
factors contributing to the pluripotency maintenance network, like SALL4, ESRRB, TET1, TET2 and PRDM14 
103–107. Further integration of transcriptional and binding data of transcription factors has expanded the 
pluripotency regulatory network to include factors outside of the core set, like SMAD1, STAT3, TCF7, NR5A2 
(LRH1), NR0B1 (DAX1), NACC1, ZFP42 (REX1), ZFP281, TBX3, TCF7L1 (TCF3), KDM3A and TRIM24 108–111. More 
comprehensive analysis of gene expression differences in numerous tissue types, larger set of transcription 
factor binding data and transcriptomic perturbations of transcription factors has led to the characterization 
of even wider set of candidate tissue type defining master regulatory factors, some of which may contribute 
to the pluripotent gene regulatory circuitry as well as cellular reprogramming 112–115. Notable pluripotency 
factors in these sets of candidates include factors like ZSCAN10, OTX2, ZIC2, ZIC3, MYCN, FOXH1, NR6A1, 
LIN28A, LIN28B, FOXO1, RARG, MYB, RORA and SOX21. Overall, these transcription factors form a widely 
interconnected regulatory network, which maintains the pluripotent state. The network still needs to be 
responsive to signalling cues to mediated context dependent differentiation of pluripotent cells. Additional 
differences in factors contributing to the pluripotent gene regulatory network may result from species 
specific differences in pluripotency maintenance and the type of pluripotent state, i.e., primed or naïve state. 
 
6.1.5. Epigenetics of Pluripotent Cells 
Epigenetics is a layer of control over DNA, which defines how DNA is interpreted without affecting the 
genomic sequence. Epigenetics is generally mediated by chemical modifications of DNA or by controlling the 
composition, positioning and tail modifications of histones, around which DNA is wrapped 116. On a general 
scale epigenetics functions to divide chromatin into active euchromatin and repressive heterochromatin. 
Epigenetic modifications of DNA and histones are written by enzymes that catalyse the addition and removal 
of chemical groups and read by proteins that recognise these modifications. 
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The primary chemical modifications in mammalian DNA are methyl groups and their subsequent derivatives 
on cytosine residues 117, but other rare modifications, like adenine methylation, have also been reported 118. 
Cytosine methylation is catalysed either by the maintenance DNA methyltransferase DNMT1 or by the de 
novo DNMT3 DNA methyltransferases. DNA demethylation can be mediated either by passive demethylation 
by cell replication or by active DNA demethylation by DNA damage repair following 5-methylcytosine (5mC) 
oxidation by TET enzymes into 5-hydroxymethyl- (5hmC), 5-carboxyl- and 5-formylcytosine 117. The effect of 
DNA methylation on gene expression is mediated either by directly affecting the DNA binding affinity of 
transcription factors to the methylated sequences, or by recruiting methyl-CpG binding factors. These 
factors, like MeCP2 and MBDs, can further recruit other repressive complexes, like the SIN3A histone 
deacetylation (HDAC) complex or histone-lysine N-methyltransferase SUV39H1, that catalyses histone 3 
lysine 9 trimethylation, to the methylated DNA sites 117,119. 
 
 
Figure 3. Major epigenetic modification in pluripotent cells. DNA modifications are primarily targeted to 
cytosine residues and are catalysed by DNMT enzymes. DNA demethylation can occur via hydroxylated 
intermediate catalysed by TET enzymes. Methylated cytosine residues can recruit histone methyltransferases 
that promote repressive heterochromatin formation by HP1. Histone 3 methylation at lysine 4 and lysine 27 
control promoter activity via Trithorax and Polycomb complexes respectively. BRD4 promotes active 
transcription. 
 
Histone tails can be modified in various ways including methylation, acetylation, phosphorylation, 
ubiquitination, sumoylation and others 120. These modifications form a histone code that is specifically 
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recognised by other effector proteins. The most widely studied of these modifications are histone arginine 
and lysine methylation 120,121, and histone lysine acetylation 122. Methylated and acetylated histone tails can 
be recognised by chromodomain and bromodomain containing factors respectively, which mediate the effect 
of the modified histone tails on gene expression. Notable complexes associated with histone lysine 
methylation are the histone 3 lysine 4 trimethylation (H3K4me3) associated Trithorax complex and the 
histone 3 lysine 27 trimethylation (H3K27me3) associated Polycomb comlex 123. H3K4me3 marker is 
commonly associated with active gene promoter areas whereas promoter H3K27me3 is associated with gene 
repression. These two modifications can also occur simultaneously in a bivalent manner on a gene promoter 
poised for activation 124,125. This way the cell can switch on or off a gene for example according to its 
differentiation path. Third notable histone modification is the methylation status of the histone 3 lysine 9 
(H3K9) residue. This residue is primarily methylated by the KMT1 members G9a, SUV39H and SETDB 121, and 
in its trimethylated state (H3K9me3) binds the heterochromatin protein HP1 (CBX in mammals) 126, which 
mediates the phase separation and packaging of repressed DNA into heterochromatin 69. Histone acetylation 
is commonly associated with active gene expression. On one hand, histone acetylation prevents the 
methylation of the corresponding lysine residue, preventing for example repressive marker addition. On the 
other hand, acetylated lysine residues are recognized by transcription promoting bromodomain containing 
factors. For example, BRD4 binds histone 3 lysine 14, histone 4 lysine 5 and histone 4 lysine 12 acetylated 
histones and mediates histone 3 lysine 122 acetylation, promoting nucleosome eviction from chromatin 127. 
BRD4 also promotes P-TEFb activity leading to increased Pol II Ser-2 phosphorylation and Pol II pause release 
128–130. Specific genomic elements can also be defined by the histone marks they bear. Commonly used 
markers for defining promoter regions include the previously mentioned H3K4me3 and H3K27me3, whereas 
histone 3 lysine 4 mono and di methylation (H3K4me1/2) and histone 3 lysine 27 acetylation (H3K27Ac) can 
be used to distinguish active enhancers and histone 3 lysine 36 trimethylation (H3K36me3) is commonly 
found at expressed gene bodies 116,121. Major epigenetic modifications of pluripotent cells are summarised in 
Figure 3. 
Overall, pluripotent stem cells have more open chromatin structure than somatic cells 131,132. This is 
characterized by large poorly defined regions of HP1 in pluripotent cells compared to discrete foci in 
differentiated cells and hyperdynamic plasticity of chromatin proteins 133, and widespread transcription of 
coding and non-coding genomic regions 134. This open heterochromatin state is controlled in part by Nanog 
and Sall1 135, and possibly by active chromatin modelling by pluripotent state specific chromatin remodeling 
factors 132. The globally more permissible chromatin structure in pluripotent cells may function to make 
chromatin more accessible for epigenetic priming or transcriptional activation upon differentiation, but it 




6.2. Cellular Reprogramming 
The term cellular reprogramming refers to the process of converting one type of differentiated cell into either 
a stem cell or into another type of differentiated cell. However, cellular reprogramming is most commonly 
used to refer to induction of pluripotency, and conversions between differentiated cell types are referred to 
as transdifferentiation. Cellular reprogramming into pluripotent state can be achieved by somatic cell nuclear 
transfer (SCNT), fusion with embryonic stem cells or overexpression of defined sets of transcription factors. 
The reprogramming process is intrinsically an epigenetic reprogramming event by which the transcriptomic 
program of a cell, which defines the cellular phenotype, is reset and replaced with a transcriptomic program 
of another cell type. This type of process was initially demonstrated by John Gurdon in the sixties by transfer 
of somatic cell nuclei into enucleated frog eggs. This lead to successful development of the frog embryo and 
demonstrated the fact the differentiation did not require changes in the genetic code of the organism 136. 
Later SCNT was also demonstrated to work with mammalian cells by the cloning of the sheep Dolly 137. The 
SCNT experiments indicated that the components driving the process of nuclear reprogramming in the 
oocytes were present in the oocyte cytoplasm. Although SCNT results in the emergence of a totipotent cells, 
cell fusion experiments using pluripotent cells demonstrated the presence of a pluripotent reprogramming 
factor set in embryonic stem cells 138,139. 
The ingenious approach by Takahashi and Yamanaka aimed at defining this set of pluripotency associated 
reprogramming factors by combinatorial screening of a limited set of candidates 1. Similar approaches have 
since been taken to find alternative sets of factors which can mediate transdifferentiation of somatic cells 
into other lineages, including neurons, hepatocytes and cardiac cells 140–144. Newer more sophisticated 
methods rely on predicting gene regulatory networks governing cell type specific gene expression. This is 
done to limit the number of candidate reprogramming factors while simultaneously aiming to maximize the 
effect of the factors on the gene regulatory network. These types of approaches have yielded encouraging 
results and will likely aid in developing more efficient ways of controlling cellular phenotypes 113,145,146. 
 
6.2.1. Induced Pluripotent Stem Cells 
The specific set of factors capable of converting differentiated somatic cells to pluripotent cells was first 
described by Takahashi and Yamanaka in their pioneering paper in 2006 1. They initially screened a set of 24 
selected pluripotency associated candidate factors for their ability to activate Fbx15 locus targeted Neo 
selection marker in mouse embryonic fibroblasts (MEF). Transduction of MEFs with a mixture of the 24 
factors resulted in the emergence of G418 resistant colonies. No single factor was able to convert the cells 
to pluripotency by themselves, indicating that a combination of factors was needed for the process. Removal 
of individual factors from the set of 24 factors revealed a smaller set of 10 factors which were required for 
colony formation within the first 10 days of induction. Further removal of individual factors from this set of 
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10 factors pinpointed the factors Oct4, Sox2, Klf4 and c-Myc, which were required for successful induction of 
pluripotency. The combination of the four factors was also able to reprogram adult mouse tail tip fibroblasts. 
This core set of reprogramming factors is nowadays commonly referred to as ‘Yamanaka factors’, and has 
been subsequently used to reprogram somatic cells of various types and species. Although the initially 
described iPSCs showed pluripotent characteristics, many of the first iPSC clones were not fully 
reprogrammed. The induction of germ-line competent iPSCs were shown to be mediated by changing the 
Fbx15 selection into a more specific Nanog selection 147. Finally, the most stringent measure of pluripotency 
of iPSCs was demonstrated by tetraploid complementation assay 148. As tetraploid cells in an embryo can only 
contribute to the development of the extraembryonic tissues, the whole embryo has to be derived from the 
engrafted pluripotent stem cells. 
Shortly after the induction of pluripotency was described in mouse, it was also replicated using human cells. 
This was initially demonstrated in three papers using either the same set of ‘Yamanaka factors’ 149,150, or a set 
of OCT4, SOX2, NANOG and LIN28, later deemed ‘Thomson factors’ 150. The induction of pluripotency in 
human cells demonstrated the robustness of the reprogramming approach and conservation of the 
mechanisms behind the process between mouse and human. It was also revolutionary by allowing derivation 
of patient specific pluripotent stem cell lines for disease modelling without SCNT, as this abrogated many of 
the ethical hurdles regarding the use of embryos. Induction of pluripotency was also technically easier than 
SCNT, making it more accessible to larger research community. 
 
6.2.2. Requirements of Reprogramming Factor Function 
In general, reprogramming factors should fulfil two major criteria: they should function both as master 
transcription factors and as pioneering factors. Master transcription factors are factors which define a cell 
type specific gene expression program. These factors can determine the binding specificity of other more 
common transcription factors. This type of function has been shown for example for Oct4, PU.1 and MyoD 
in controlling Smad3 binding specificity in pluripotent cells, pro-B cells and myotubes 151. This way, the cell 
type specific transcription factors can control cell type specific effects of common transcription factors, for 
example the cell type specificity of cellular signalling, which generally uses common downstream effectors. 
Pioneering factors are defined as transcription factors which can bind into chromatinized DNA sequences, 
where binding sites may be occluded by histones and higher-order chromatin structures, and mediate local 
DNA opening. Therefore, pioneering factor occupancy at genomic loci has been proposed as a mechanism 
for priming genes for competency for transcriptional activation. This type of function has been described for 
example for FoxA and GATA factors 152, both of which are used in hepatic transdifferentiation methods 141. 
Moreover, some FOX factors, like FoxA1 and FoxI1, have been shown to associate with mitotic chromatin, 
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indicating an additional bookmarking potential for these factors 153,154. It is therefore likely that pioneering 
factor properties are required for reprogramming factors to mediate efficient targeting of genes that are to 
be activated in the reprogramming process. Additionally, mitotic bookmarking activity may further help 
maintain the desired transcriptional changes upon cell proliferation. The pluripotent reprogramming factors 
Oct4, Sox2 and Klf4 have also been shown to have pioneering factor activity, being able to bind to 
nucleosomal DNA with partial recognition motifs at the surface of nucleosomes 155. The pioneering activity 
of these factors may therefore be an important part of their function in reprogramming somatic cells to 
pluripotency. 
 
6.2.3. Factors Used for iPSC Derivation 
The induction of pluripotency was initially described using the factors OCT4, SOX2, KLF4 and C-MYC in mouse 
and human cells or OCT4, SOX2, NANOG and LIN28 in human cells. The initial work was focused on 
characterizing the minimal set of factors which could reprogram cells, and further development has been put 
into replacing the reprogramming factors with other means to reduce this set of factors even more. There 
are still numerous different factors, which can replace the canonical ‘Yamanaka’ or ‘Thomson’ sets, as long 
as they meet the functional requirements for the reprogramming process. The following section will describe 
some of the reprogramming factors, their function in reprogramming and their substitutes in more detail. 
 
6.2.3.1. POU5F1 (OCT4) 
Oct4 is an important factor in embryo development. It is expressed maternally in the oocytes and the zygotic 
Oct4 is activated at embryonic genome activation stage 156. Thereafter Oct4 expression is restricted to the 
epiblast and germ cell lineages in mouse. Disruption of Oct4 expression in mouse embryos leads to failure in 
ICM formation and diversion of the Oct4 negative cell population to a trophoblast fate 157. In human embryos 
OCT4 expression is not as clearly restricted, and OCT4 can be seen expressed in both trophectodermal and 
ICM compartments 158. Accordingly, OCT4 expression seems to be more commonly required in human 
embryos for proper development, as knockout of OCT4 expression in human embryos leads to failure in both 
ICM and trophectoderm formation 159. Curiously, even though OCT4 expression is required for proper embryo 
formation, maternal Oct4 is not needed for the establishment of totipotency 160. Therefore, it is possible that 
the totipotent nuclear reprogramming machinery, mediating EGA, does not depend on Oct4 function, and 
that Oct4 is needed only for the later stages of embryo development, i.e. differentiation into 
trophectodermal and ICM lineages and establishment of pluripotency. OCT4 knockdown in human 
pluripotent stem cells leads to disruption in the maintenance of pluripotency and upregulation of 
trophectodermal and endodermal genes 161. 
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In pluripotent reprogramming OCT4 is probably the most crucial reprogramming factor 162. Ectopic expression 
of just OCT4 can be used to convert neural stem cells into induced pluripotent stem cells 163. OCT4 appears 
to be a unique reprogramming factor in the ‘Yamanaka’ set as it is the only one, which cannot be readily 
replaced by other OCT family members. OCT4 mediated maintenance of pluripotency and reprogramming 
function appears to be dependent on its heterodimerization with SOX2. A related factor OCT6 (POU3F1) 
cannot normally reprogram somatic cells to pluripotency. Introduction of point mutations in the OCT6 
protein, which change its sequence binding preference from palindromic OCT-OCT motifs to heterodimeric 
SOX-OCT motifs and promote its interaction with SOX2, can convert OCT6 into a reprogramming factor, 
whereas introduction of the same OCT6 mimicking mutations into the OCT4 sequence abolishes the OCT4 
reprogramming function 164. The interplay between OCT4 and SOX2 thus appears to be important for 
successful induction of pluripotency. Conversely, limiting the availability of OCT4 to the initial phase of 
reprogramming can bias the cell fate towards neural lineages and be used to induce neural stem cells 165. 
Some factors, such as NR5A2, TET1 or SALL4 and NANOG, which have been used to replace OCT4 in the 
pluripotent reprogramming factor mixture, have been implicated in the activation of the endogenous OCT4 
gene 162,166–168. OCT4 has also been reported to be replaceable by E-cadherin over expression 169, or by cAMP 
signalling activation 170. A particularly interesting group of OCT4 replacing reprogramming factors is formed 
by lineage specifiers. OCT4 has been reported to be replaceable by GATA3 fused with a VP16 activation 
domain in human reprogramming 171, and by multiple mesendodermal factors in mouse reprogramming 172. 
This suggests a role for these factors in countering the neuralising effect of ectopic SOX2 expression in the 
absence of OCT4. It also supports interpretation of the reprogramming process as a balancing equilibrium 
between different differentiation pathways, similar to what has been proposed for the maintenance of the 
pluripotent state 94. 
Pluripotency maintenance and reprogramming function of OCT4 seems to primarily be due to its association 
with transcriptional activation. Fusions of OCT4 with activator domains support induction of pluripotency, 
whereas repressive domains prevent reprogramming 173. Additionally, versions of OCT4 fused with extra 
activation domains, i.e., MYOD, YAP, VP16 and MYC transactivation domains, have been described to have 
enhanced potential in cellular reprogramming 174–177. 
 
6.2.3.2. SOX2 
In the early embryo development Sox2 is expressed maternally at the oocyte. Subsequently zygotic Sox2 
expression is seen throughout the preimplantation embryo development in various tissues. Although in 
mouse Sox2 expression is primarily restricted to the ICM lineage at the blastocyst stage, maternal Sox2 is 
important for the trophectoderm development, as Sox2 knock down in mouse embryos leads to 
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developmental arrest after compaction at the morula stage 178. In blastocyst, Sox2 expression becomes 
primarily limited to the epiblast cell population, and primitive endoderm cells show upregulation of Sox17. 
After gastrulation Sox2 expression gets restricted mainly to the neuroectodermal cell populations, however 
Sox2 has additional roles later on in embryo development in both endodermal and mesodermal tissues 179. 
At neural differentiation additional SoxB1 family members Sox1 and Sox3 become upregulated 179,180. 
SOX2 can be replaced in pluripotent reprogramming with certain other members of the SOX family. These 
include the other neural SOXB1 members, SOX1 and SOX3, and a SOXG member SOX15, which shows reduced 
reprogramming capacity compared to SOX2 181. In addition to SOX1 and SOX3, other neuroectodermal 
factors, like GMNN and ZNF521, have also been used to replace SOX2 in reprogramming 171,172, similar to 
OCT4 replacement with mesendodermal factors. SOX17 cannot normally replace SOX2, however, 
introduction of point mutations to the SOX17 sequence, which mimic the SOX2 interaction with OCT4, can 
convert SOX17 into a pluripotent reprogramming factor 182. This further emphasises the importance of the 
OTC4-SOX2 interaction in the context of pluripotency. Apart from pluripotent reprogramming, SOX2 alone 
can also be used for induction of neural cells from fibroblasts in permissive conditions 183. 
In pluripotent reprogramming exogenous SOX2 expression appears to be temporally required throughout 
the early- and mid-stages of the reprogramming process 184. This may be due to the late activation of the 
endogenous SOX2 locus in fibroblast reprogramming 168, and the requirement of exogenous SOX2 protein 
until the processes maintaining endogenous SOX2 expression have been properly established. 
 
6.2.3.3. KLF4 
KLF4 is expressed in the early embryo, starting at the two cell stage in mouse embryos and at the eight cell 
stage in human embryos 185,186. Klf4 expression in an embryo coincides with the expression of Klf5. In mouse 
embryos Klf2 is also expressed and restricted primarily to the epiblast cells, whereas in humans Klf2 
expression is replaced by KLF17 186. Klf5 knock out in a mouse embryo results in defects in pre-implantation 
development, particularly in the ICM and epiblast compartments 187. Klf4 knock out shows post-natal 
lethality, indicating a possible redundancy between the different KLF factors in the early embryo 185. In the 
maintenance of in vitro pluripotent state, Klf2, 4 and 5 show redundant function, and a triple knock down of 
the factors results in impaired maintenance of the pluripotent state 188. Later in development Klf4 is 
expressed in various tissues, particularly in epithelial and endothelial cells. 
In reprogramming KLF4 can be replaced with KLF2 and KLF5 181,189. KLF4 overexpression is not essential for 
successful reprogramming, as it has been replaced by other factors, notably in human reprogramming with 
the ‘Thomson’ set 150. Transgenic KLF4 replacement has also been described with various small molecular 
inhibitors and signaling factors, like BMP signaling 190,191. The role of BMP signaling in KLF4 replacement is of 
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particular interest as BMP has been linked to mesenchymal to epithelial transition (MET) of the 
reprogramming cells 192, and KLF4 requirement in reprogramming has been proposed to be related to its 
function in promoting epithelialization of the reprogramming cells 193. In line with the role of KLF in MET, 
KLF4 is also replaceable with TGF signaling inhibitors, which prevent TGF-mediated epithelial to 
mesenchymal transition 193. It may thus be that the other KLF family members, capable of replacing KLF4 in 
reprogramming, also mediate their effect via promotion of MET. In this context the characterization of KLF17 
function in human pluripotent reprogramming is of interest, as KLF17 has been implicated in epithelial 
phenotype in breast cancer metastasis and it is expressed at the early human embryo in place of KLF2 186,194. 
Even though exogenous KLF4 expression can be redundant in reprogramming, the expression level of KLF4 
has been implicated in the progression of the reprogramming process. Reduced KLF4 expression has been 
described in inducing partially reprogrammed iPSCs paused at intermediate stages of reprogramming 195. On 
the other hand, persistent KLF4 expression levels or improper transgene silencing may be associated with 
aberrant reprogramming outcomes, like defects in iPSC differentiation 196,197. Curiously, the differentiation 
defective state also shows increased activation of specific LTR7/HERV-H retroviruses, which have been 
implicated in a naïve-like stem cell state in primates 198,199. This phenotype may thus be somehow related to 
the function of KLF4 in promoting primed to naïve state conversion of pluripotent stem cells 36. 
 
6.2.3.4. MYC (C-MYC) 
MYC is a well-known oncogene that is part of a family of MYC genes consisting of MYC (C-MYC), MYCN (N-
MYC) and MYCL (L-MYC). It was initially found by integration of an oncogenic virus in birds leading to the miss 
expression of the MYC gene. MYC is also commonly found either translocated or amplified in cancer, leading 
to its increased expression. MYC expression can promote cell proliferation, which is one of the mechanisms 
that can contribute to its oncogenic potential 200. MYC binds to E-box motifs in DNA as a heterodimer with 
MAX 201. MYC can recruit histone acetyl transferases and P-TEFb to its binding sites to mediate transcriptional 
activation 202, or function as a context dependent repressor by interacting with factors which may displace 
co-activators and recruit co-repressors 200. As a transactivator, MYC has been shown to regulate Pol II 
transcriptional pause release 203. This way MYC expression can function as a universal amplifier by promoting 
transcriptional output of expressed genes 204,205. 
Myc is important for many developmental processes in mammalian embryo. Particularly, Myc has been 
shown to drive endogenous cell competition in early embryo, in which high Myc expressing cells are favoured 
over low expressing ones leading to elimination of low Myc expressing cells in mosaic embryos 206. In 
embryonic stem cells, c-Myc and n-Myc double knockout has been shown to induce a diapause-like 
biosynthetically quiescent state 207. However, this state has been described to show dissimilarities compared 
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to diapause epiblast cells and paused pluripotent cells induced by mTOR inhibition 208. The transcriptional 
network controlled by MYC in PSCs appears to be separate from the core pluripotency network, which may 
be why MYC knockout does not impair pluripotency. The activity of the MYC network has been linked to cell 
proliferation and appears to be the cause of similarities of stem cell and cancer transcriptional networks 209. 
Somatic cells can be reprogrammed in the absence of C-MYC, albeit with reduced efficiency, or C-MYC can 
be replaced by other members of the MYC family, N-MYC and L-MYC 181. A lot of effort was initially put into 
replacing MYC in reprogramming due to its known function as an oncogene and association of increased 
tumour risk with incomplete MYC transgene silencing 147. The development of non-integrative 
reprogramming methods has reduced the risk of using C-MYC as a reprogramming factor. In the 
reprogramming process MYC binds to partially degenerate E-boxes near OCT4, SOX2, and KLF4 (OSK) clusters 
and mediates OSK binding to nucleosomal DNA 155,210. As OSK appear to function as pioneering factors, 
guiding MYC binding in reprogramming, it may be relevant to control the stoichiometric amounts of MYC 
compared to OSK to limit off-target binding and to promote optimal reprogramming effect of MYC. In 
pluripotent cells the number of OSK and MYC co-bound sites are reduced compared to early induction cells, 
indicating a possible change in MYC function from induction to pluripotent state 210. 
 
6.2.3.5. NANOG 
NANOG expression in the embryo occurs in the ICM and is later restricted to the epiblast cells. The knockout 
of NANOG in embryos causes defects both in epiblast and hypoblast development, however hypoblast 
defects appear to be due to lack of signalling from epiblast 211. Although NANOG is part of the core 
pluripotency regulatory network it is not absolutely required for the induction or maintenance of 
pluripotency. NANOG negative iPSCs can be induced and maintained in the presence of vitamin C 212. NANOG 
function in PSCs has been linked to pericentromeric heterochromatin regulation with SALL1 and more open 
chromatin in the pluripotent state 135. It is possible that vitamin C complements for the lack of NANOG by 
promoting open chromatin state by KDM3A mediated H3K9 demethylation 213. NANOG overexpression in 
general appears to be beneficial for reprogramming and it has been shown that NANOG can improve 
reprogramming kinetics by promoting acquisition of a pluripotent state in a cell cycle independent manner 
214. 
 
6.2.3.6. LIN28A (LIN28) 
LIN28 is an RNA binding protein that has a role in controlling Let-7 family microRNA biogenesis 215. LIN28 
inhibits Let-7 production by binding to the terminal loop of the precursors of the Let-7 miRNA and preventing 
its processing into mature miRNA. Let-7 miRNAs become upregulated in cells upon differentiation, which 
30 
 
coincides with reduction in LIN28 expression. Let-7 miRNAs are known to target cell cycle and reprogramming 
associated genes such as MYC and Cyclin D1 216. In mouse reprogramming LIN28 has been shown to improve 
reprogramming kinetics in a cell cycle dependent manner 214. This may contribute to the role of LIN28 in the 
‘Thomson’ set of factors which lacks MYC transgene and the reported requirement of LIN28 in 
reprogramming of senescent cells 217. Both LIN28A and LIN28B paralogs can be used to mediate 
reprogramming to pluripotency, and knocking down either of these factors reduces reprogramming 
efficiency 218. In addition to the more thoroughly characterized role of LIN28 as an RNA binding protein, LIN28 
has also been reported to bind DNA 219. In this context, LIN28 is found enriched around transcription start 
sites, and mechanistically LIN28 appears to help recruit TET1 to genomic sites. 
 
6.2.3.7. Other Factors 
In addition to the more commonly used ‘Yamanaka’ and ‘Thomson’ sets of reprogramming factors, many 
other factors have been published in either replacing the commonly used factors or improving the 
reprogramming efficiency with the common factors. As the reprogramming factors form part of the 
pluripotent gene regulatory network, non-conventional reprogramming factors can aid in reprogramming by 
activating either the commonly used reprogramming factors or complementary parts of the gene regulatory 
network. Activation of reprogramming factors was demonstrated by Buganim et al. by replacing all of the 
‘Yamanaka factors’ with various combinations of ESRRB, NANOG, SALL4, LIN28, DPPA2 and EZH2 168. Another 
way to replace the commonly used reprogramming factors is to use replacement factors that complement 
the function of the conventional factors. An example of this type of approach is the replacement of 
pluripotency factors by lineage specifying factors with opposing effects 172, or replacement of KLF4 with 
factors that promote MET 191. Combining the common reprogramming factor activation and functional 
replacement approaches can also be used to replace all the common reprogramming factors. Particularly Liu 
et al. used C-JUN inhibiting protein JDP2, H3K36 demethylase JHDM1B (KDM2B), BMP downstream factor 
ID1 and transcription factors GLIS1, SALL4 and NR5A2 to achieve this in mouse reprogramming 220. Other 
noticeable factors, which can replace more than one commonly used factors, include combinations of SALL4, 
SALL1, NANOG, UTF1 and MYC 221, OCT4 with BMI1 or ASF1A or TET1 222–224, and miR302 family of microRNAs 
with or without mir200c 225,226.  
 
6.2.4. Mechanisms of Cellular Reprogramming 
Somatic cell reprogramming to pluripotency with defined factors is a lengthy and inefficient process 
compared to nuclear reprogramming by SCNT. SCNT results in complete reprogramming within one cell cycle 
whereas iPSC induction is a stochastic multistep process consisting of various intermediate cell populations. 
Consequently, completing the reprogramming process can take considerably long. The mechanisms of the 
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induction of pluripotency have been widely studied, which has led to better understanding of the processes 
governing pluripotent reprogramming. The following section will describe the main characterised phases of 
pluripotent reprogramming and how they form reprogramming barriers, which need to be overcome for 
successful reprogramming. However, these studies have primarily been made with fibroblasts using OCT4, 
SOX2, KLF4 and MYC transgenes, and how well these mechanisms translate to other cell types and other 
reprogramming factors is still a somewhat open question. The main phases of cellular reprogramming are 
summarised in Figure 4. 
 
 
Figure 4. Summary of the main phases of pluripotent reprogramming. Induction of pluripotency is a multistep 
process with stochastic events dominating the early and mid-induction phases and increase in deterministic 
events towards the end of the process. 
 
6.2.4.1. Cell Cycle Changes 
The reprogramming process is initially marked by an early rapid shift in the cell proliferation rate of the 
reprogramming fibroblasts227. Active cell proliferation is generally considered to mediate the stochastic 
events required for proper reprogramming, and factors which can promote active cell proliferation can be 
used to improve reprogramming efficiency 214,216. The role of cell proliferation in the first part of the 
reprogramming process is also supported by transcriptomic analysis of reprogramming cell populations 228. 
The transcriptomic changes in the reprogramming cells happen primarily in two waves. The genes 
upregulated in the first transcriptional wave, after the first three days of induction, are mainly involved in 
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controlling DNA replication and cell proliferation, whereas downregulated genes are associated with cell 
adhesion and cell-cell contacts 228. MYC is the likely primary factor mediating the first wave of transcriptional 
activation, and the rapid change in cell proliferation, by promoting activation of cell cycle promoting genes. 
OSK targeted genes show equal numbers of upregulated and downregulated genes in the first transcriptional 
wave, whereas MYC targeted genes are mostly upregulated. This may be associated with the preferential 
initial binding dynamics of the reprogramming factors. OSK target nucleosomal DNA at the surface of the 
histone octamers, mainly distally from transcription start sites (TSS), whereas MYC binds preferentially to 
open DNA near TSSs or along OSK in reprogramming 210. The role of these factors in the reprogramming 
process may thus vary. OSK may contribute more in the initial wave to the epigenetic remodelling of their 
target enhancers and promoters to permissive state, as has been demonstrated for OCT4 mediated MYOD 
and NANOG targeting 229,230, whereas MYC ends up transcriptionally upregulating genes which already have 
open and accessible promoter areas. Curiously, the nucleosome depletion mediated by OCT4 has been 
reported to be inhibited by the DNA methylation status of the OCT4 target regions 230. The OCT4 
inaccessibility to methylated DNA may therefore partially explain the need for early cell cycle changes by 
proliferation mediated stochastic overcoming of reprogramming barriers, possibly by passive DNA 
demethylation 231. This may also explain the effect of TET1 overexpression on reprogramming 167,224. On the 
other hand, it has also been proposed that DNA replication in cell proliferation could mediate reprogramming 
by transiently providing DNA access for non-pioneering factors, which work co-operatively with OSK, before 
new nucleosomes are assembled at the newly replicated DNA 232. 
 
6.2.4.2. De-differentiation and Mesenchymal to Epithelial Transition (MET) 
The genes affected in the first transcriptional wave of the reprogramming process have been described to be 
KLF4 regulated, determined by the affected genes and KLF4 distribution in pluripotent cells. The KLF4 
targeted genes appear to be mostly differentiation associated, and thus KLF4 has been proposed to function 
in the suppression of the differentiation associated genes in the first transcriptional wave 228. However, 
analysis of epigenetic changes in active H3K27Ac markers in fibroblast enhancers by OCT4 and KLF4 would 
indicate that KLF4 targeting by itself would not lead to reduction in H3K27 acetylation, whereas OCT4 does, 
possibly by recruiting HDAC1 233. Therefore, the initial de-differentiation steps may be controlled co-
operatively by both OCT4 and KLF4. This view is also supported by sequential introduction of reprogramming 
factors which appears to favour initial introduction of OCT4 and KLF4 234. Along the proposed role of the 
reprogramming factors in the initial de-differentiation of the reprogramming cells, co-operative OSK 
mediated re-distribution of somatic transcription factors away from somatic enhances, to sites elsewhere 
bound by OSK, has been proposed as an additional mechanism for the initial de-differentiation 233. KLF4 has 
also been shown to control the epithelialization of the reprogramming cells 193. MET is commonly considered 
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to be an early event in the initiation of the pluripotent reprogramming of mouse fibroblasts 192. The 
transcriptional changes associated with KLF4 function in the early reprogramming may be related to its role 
in MET. Decommissioning the cells of their fibroblast-like transcriptional program, by inhibiting the H3K79 
methyltransferase DOT1L, can also promote reprogramming by affecting the mesenchymal regulators SNAI1 
and 2, ZEB1 and 2 and TGFB2 235. MET is not, however, an absolute requirement in the early reprogramming 
process, as mesenchymizing signalling factors have been reported to improve the reprogramming of 
epithelial cell types, and the E-cadherin / N-cadherin ratio in the starting cells seems to correlate with the 
reprogramming response of the cells to TFG signalling and TGF inhibition 234. The initial role of these factors 
may therefore be to destabilize the starting epithelial or mesenchymal transcriptional program to help in the 
initial de-differentiation of the starting cells. Due to the reported roles of KLF4 in controlling long range 
chromosomal interactions, and the role of TGF in cell type-specific super enhancer formation 63,83,151, it is 
tempting to speculate that the molecular functions of these factors may be related to the same processes, 
i.e., sub-localization of their target regions into active/repressed regions in the nucleus in an epithelial or 
mesenchymal expression program related manner. 
 
6.2.4.3. Stress Response 
Induction of pluripotency leads to activation of tumour-suppressive mechanisms in the early stages of the 
process, indicating that cellular senescence is a barrier to pluripotent reprogramming 236. As an immediate 
response to reprogramming factor expression, the upregulation of CDKN1A (P21) and CDKN2A 
(P16INK4A/P14ARF), which are potent effectors of different tumour suppressor pathways, can be seen in 
transcriptomic analysis of reprogramming cells 237. The anti-proliferative, senescence-inducing and pro-
apoptotic effect of the reprogramming factor expression has been widely reported 238–242. One of the major 
barriers for the efficient reprogramming thus appears to be the activation of the cellular stress response, 
which leads to reprogramming failure. P53 controls the decision between cell death and cell cycle arrest by 
inducing PUMA or P21 as a response to reprogramming induced cellular stress 243. The expression of only 
OCT4 and SOX2 or MYC is sufficient to induced the upregulation of p53, p21 and p19 in infected MEFs 239. 
Inhibition of these pathways has been shown to alleviate the reprogramming induced senescent effect and 
improve the reprogramming efficiency 242. Additionally, the reprogramming efficiency of older mouse 
fibroblasts can be improved by knock down of the Ink4/Arf transcript, which is upregulated in older cells 241. 
Although the inhibition of these pathways can improve reprogramming efficiency, it may also risk 
reprogramming aberrant cells, resulting in increased aneuploidies and mutations in the resulting iPSC clones 
240. The activation of these stress pathways commonly happens as a response to DNA damage. Many possible 
options have been proposed for the source of the DNA damage response in cellular reprogramming, including 
oxidative stress, replicative stress, transcription and chromatin remodelling 244. Different means to reduce 
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the reprogramming induced stress have also been proposed, including increasing the levels of CHK1 to reduce 
replicative stress or supplementing the reprogramming cells with antioxidants, nicotinamide or N-acetyl-
cysteine 245–247. However, the DNA damage response that inhibits reprogramming efficiency may not be 
completely avoidable as it might be intrinsically tied to the transcriptional and epigenetic mechanism 
governing reprogramming. For example, BAF60B mediated P53 activation has been reported to occur as a 
response to chromatin opening in transdifferentiation 248, and DNA break induced signalling has been 
implicated in transcriptional elongation 249. The cellular stress response may thus be commonly activated just 
by forcing a drastic change in the transcriptional program of the cells. 
 
6.2.4.4. Metabolic Switch 
During the reprogramming process, cells go through a metabolic switch. This constitutes a change from 
primarily oxidative phosphorylation of the somatic cell to primarily glycolytic metabolism of pluripotent cells. 
This change in metabolism functions to accommodate the rapid requirement of ATP needed for high rate of 
cellular proliferation and the changes in biosynthetic needs and epigenetic processes 250. In pluripotent cells 
many metabolites produced by glycolysis, including S-adenosylmethionine, NAD+ and Acetyl-CoA, function as 
co-factors and substrates for different epigenomic processes. Therefore, the changes in cellular metabolism 
may end up directly contributing to epigenetic and transcriptional changes occurring in reprogramming. The 
metabolic switch in reprogramming is initiated by estrogen-related nuclear receptor-mediated burst of 
oxidative phosphorylation activity which leads to increase in NFR2 activity and subsequent HIF activation 251–
253. This HIF activation initiates the switch towards glycolytic metabolism. Affecting the reprogramming 
associated metabolic switch can also be used to promote pluripotent reprogramming by promoting the 
conversion into glycolytic metabolism. A good example of this is the culture of the reprogramming cells in 
hypoxic conditions, which facilitates the metabolic conversion and improves reprogramming efficiency 254. 
Alternatively, the glycolysis promoting metabolic changes can be mediated by chemical and genetic means 
by PS48 and TCL1 255,256, whereas inhibiting glycolysis can reduce reprogramming efficiency 257. 
 
6.2.4.5. Reprogramming Phases and Heterochromatin Barriers 
The reprogramming process has been described to occur in two primary phases 228. The first transcriptional 
changes initially affect chromatin areas that are permissive to initial reprogramming factor binding. These 
preferentially targeted areas are marked by general chromatin openness 258. The initiation of the 
reprogramming process appears to also be sensitive to the expression level of the reprogramming factors, as 
extra factors can promote the reprogramming of otherwise refractory populations and highly expressed 
inducible secondary reprogramming constructs can yield very high reprogramming efficiencies 228,259. The 
initial stages of high efficiency reprogramming are also characterized by global reduction in repressive H3K27 
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methylation by increased expression of H3K27 demethylases combined with low expression of PCR2 complex 
members, which mediates a more open chromatin state and more plastic phenotype 259. The reprogramming 
events are marked by preferential initial binding site selection by the reprogramming factors and dynamic 
binding site changes along the reprogramming process 233,258. OCT4, SOX2 and KLF4 cooperate in binding site 
selection and the sites co-bound by OSK differ from single factor bound sites 233. Although MYC has been 
reported to not affect the OSK site genomic distribution 233, it has been reported that MYC co-binding with 
OSK increases the OSK occupancy at OSK and MYC co-bound regions 210. It has been proposed that the 
presence of MYC in OSK bound regions could help by recruiting chromatin modifying factors which may 
stabilize OSK binding to DNA 260. Similar mechanism may mediate the reprogramming effect of MYC 
transactivation domain fusion with OCT4 177. 
After the early reprogramming events, the cells enter a mid-induction phase, which is characterized by 
stochastic progression of the reprogramming process. The progression of the mid phase appears to be limited 
by the accessibility of the reprogramming factors to the late activated genomic loci, which are enriched for 
pluripotency factors. A major barrier for the progression seems to be formed by DNA CpG methylation and 
H3K9me3 marked heterochromatin in the late pluripotency factor loci, resulting in large differentially bound 
regions, lacking initial reprogramming factor binding, and late activation of many CpG methylated regions 
210,261. The importance of the heterochromatin factors and histone and DNA modifications in limiting the 
pluripotent reprogramming efficiency is evident from the effect that targeting these factors has on the 
reprogramming efficiency. DNA methyltransferase inhibitors, like 5’-azacytidine, can be used to enhance 
reprogramming, whereas knock down of the Tet2 in MEFs abolished iPSC colony formation 237,262,263. This 
indicates that DNA demethylation either by preventing re-methylation or by promoting DNA 
hydroxymethylation can help in overcoming reprogramming barriers. As DNA methylation primarily functions 
to recruit H3K9 histone methyltransferases, which mediate HP1 binding and DNA compaction into 
heterochromatin, DNA demethylation can alleviate gene repression. Accordingly, affecting the expression of 
multiple heterochromatin associated histone writers and readers can influence reprogramming efficiency. 
These include reduction in reprogramming efficiency by knock down of H3K9 demethylases KDM3A, KDM3B, 
KDM4C or increase in reprogramming efficiency by knock down of H3K9 methyltransferases SETDB1, 
SUV39H1, EHMT1 and EHMT2 or H3K9 binding HP1 family factor CBX3 235,264,265, as well as increase in 
efficiency by over expression of H3K9 demethylase KDM4C 265. In addition, knock down of TRIM28 (KAP1), 
which recruits SETDB1 to ERV elements and mediates heterochromatin formation, can promote efficient 
reprogramming 266. Knock down of the replication associated chromatin assembly factor complex CAF-1 
factors Chaf1a and Chaf1b can also promote mouse pluripotent reprogramming by promoting local depletion 
of H3K9me3 in subset of reprogramming resistant regions 267. Curiously, these reprogramming resistant 
regions have initially been described in limiting the efficiency of mouse SCNT, and factors that can affect their 
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methylation status, like Kdm4d over expression or Suv39h1/2 siRNAs, can promote successful SCNT 268. 
Therefore, the barriers limiting SNCT and pluripotent reprogramming are likely to be related. 
Most powerful effects on pluripotent reprogramming can be achieved by interfering with chromatin 
repressive complexes. These methods can mediate high efficiency deterministic reprogramming, alleviating 
the reprogramming barriers so much that the stochastic phase is practically abolished and the whole cell 
population progresses towards pluripotency in a highly synchronous manner. This can be achieved for 
example by depleting the NuRD complex component MBD3 which results in nearly 100% reprogramming 
efficiency 269. MBD3 has been reported to bind to hydroxymethylated DNA 270, and its function in 
reprogramming may be linked to the function of TET enzymes. On the other hand, the role of MBD3 as a 
5hmC binding factor has been questioned, as MBD3 appears to have a higher preference for 5mC instead of 
5hmC 271,272. Therefore, the exact function of MBD3 in reprogramming is not fully clear. Curiously, MBD3 
ablation has also been reported to decrease reprogramming efficiency, indicating context dependence of its 
function 273. Another practically deterministic reprogramming process can be seen in B cell reprogramming 
with transient C/EBP overexpression 274. This has been linked to granulocyte/macrophage progenitor like 
conversion of the B cells and has been association with increased TET2 and KLF4 expression and LSD1 
(KDM1A) and BRD4 function 274,275. 
After the stochastic mid phase, the late part of the reprogramming process is characterized by a second main 
wave of transcriptional changes which are mostly affecting genes associated with embryonic development 
and stem cell maintenance 228. This late phase has been deemed hierarchical so that the activation of certain 
late stage markers happen in a sequential manner in correctly reprogramming cells. Activation of some 
predictive markers, such as Esrrb and Utf1, have been proposed as potential key events in initiating the late 
hierarchical phase 168. It is possible that the hierarchical phase is initiated when sufficient amount of 
pluripotency factors are stochastically activated to mediate more active dissolution of the reprogramming 
barriers and more effective targeting of late pluripotency control regions leading to full reorganization of the 
pluripotent regulatory network. Interestingly the proposed predictive marker Esrrb has been shown to 
promote rapid and more efficient co-operative binding of OCT4, SOX2, KLF4 and MYC to late accessible 
pluripotent enhancer loci in MEF reprogramming 233.Thus, inclusion of Esrrb in the reprogramming factor 
cocktail also leads to increase in reprogramming efficiency. Overall, this may suggest a possible optimal 
reprogramming method by which the late-stage deterministic reprogramming events can be actively 
promoted. This could be done by maximising the relevant set of rate-limiting pluripotent reprogramming 
factors to maximise the co-operative binding effect of the pluripotency factors to critical control elements. 
This could also be speculated to function by promoting more efficient establishment of active pluripotent 
cell super-enhancers and phase separation of pluripotent loci into active regions by increasing the amount 
of interactions in the pluripotent loci 65.  
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6.2.4.6. Stabilization of Pluripotency and Aberrant States 
Throughout the reprogramming process the cells have been described to go through various somatic cell like 
states, including epidermal, primitive streak-like mesendodermal and pre-implantation-like populations 276–
278. The transient cell states and the plastic phenotype associated with mid-induction may be useful for 
promoting targeted differentiation after de-differentiation with the pluripotent reprogramming factors 
144,279. Towards the end of the reprogramming process, there is a transition from a pluripotent maturation 
state towards pluripotency stabilization. This transition is dependent on the absence of ectopic transgene 
expression and is marked with changes in expression of genes associated with the transient somatic- or 
preimplantation-like cell states 280. Curiously, the late stabilization phase may also be associated with 
decrease in the chimeric capacity of the iPSCs, possibly due to more stable pluripotent state promoted by 
cell culture adaptation 281. The late stabilization step is also generally associated with silencing of retrovirally 
delivered transgenes and independence of transgene expression for the maintenance of the pluripotent 
state. Persistent maintenance of the reprogramming factors has been shown to be associated with 
incomplete reprogramming and induction of epigenetically stable aberrant pluripotent states 18,278,280.  
 
6.2.4.7. Other Reprogramming Barriers 
In addition to the previously described reprogramming barriers, a number of other factors limiting the 
efficient pluripotent reprogramming of somatic cells have been reported 282. Many of these factors are 
associated with ubiquitination and sumoylation processes and have been found by RNAi screens, or more 
recently by CRISPR screens, of reprogramming cell populations. Depletion of Small Ubiquitin-Like Modifier 2 
(SUMO2) has been reported to increase both mouse and human iPSC induction efficiency 283. Although the 
role of this protein in reprogramming has not been properly characterized, the authors speculate that its 
depletion may be related to de-repression of epigenetically silenced pluripotency loci and histone and 
protein synthesis genes. The depletion of the SUMO-conjugating enzyme Ubc9 (Ube2i) also promotes 
increase in reprogramming efficiency 267,284. Similarly, factors functioning in protein ubiquitination have been 
reported to affect reprogramming efficiency, including enhanced efficiency by depletion of FBXW7, a subunit 
of E3 ubiquitin ligase complex 284–286, or related genes UBE2D3, UBE2E3 or RNF40 285, and reduction in 
efficiency by depletion of the proteasome subunit Psmd14 286. This indicates that post-translational 
modifications play an important role in successful reprogramming and in the control of pluripotent state 287. 
A number of cell adhesion and motility associated factors have been implicated in reprogramming barrier 
function. These include many members of the ADAM family, depletion of which results in increased human 
cell reprogramming efficiency 285. A proposed function for these factors is in inhibiting an integrin switch 
occurring in reprogramming from fibroblasts to iPSCs. Additionally, many factors associated with endocytosis 
have been reported as reprogramming barriers via the TGF pathway 285. 
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Apart from the factors affecting heterochromatin formation, other epigenome editing factors have also been 
implicated in inhibiting efficient reprogramming. This includes the gene transcription associated H3K36 
methylation marker and the respective lysine demethylases KDM2A, KDM2B 121. Knockdown of these 
enzymes has a negative impact on reprogramming whereas overexpression of KDM2B promotes 
reprogramming with OCT4 in a PCR1.1 variant dependent manner 285,288. The role of these factors in 
reprogramming may therefore be in repressing the expression of differentiation associated factors, which is 
supported by the OCT4 and KDM2B mediated repression of mesendodermal genes SOX17, GATA4 and TBX20 
in reprogramming 288. Similar type of function has been implicated for the transcription associated H3K79me2 
and the knockdown of the respective methyltransferase DOT1L, which also represses EMT associated genes 
235,289. Interference with the active transcription associated chromatin markers may therefore contribute to 
more efficient loss of the mesenchymal starting state or inhibition of aberrant mid-induction 
mesenchymalization. 
 
6.2.4.8. Epigenetics of Reprogramming 
The reprogramming process is marked by a wide scale remodelling of the cellular epigenome. The process 
initiates with rapid remodelling of histone modifications in a large set of target loci followed by slower 
changes in DNA methylation 232,290. 
 
6.2.4.8.1. Histones and Nucleosomes 
The rapid changes in histone tail modifications are initially preferentially targeted to open and chromatinised 
DNA but not to heterochromatin 210. The expression of the reprogramming factors results in rapid emergence 
of H3K4me2 at targeted genomic loci, a marker of poised promoters and poised and active enhancers 
depending on the presence of H3K27Ac 232,290. The initial function of the factors thus appears to promote 
epigenetic histone modifications that can poise genes for activation or inhibition. This may be related to the 
role of the reprogramming factors in controlling pluripotency by priming genes to be responsive to signalling 
cues that mediate differentiation. Perhaps the most prominent reprogramming factor controlling this process 
is OCT4. Accordingly, OCT4 has been reported to interact with a wide range of active and repressive 
chromatin complexes. These include PRC1 complex factors, LSD1 complex factors, and various chromatin 
remodelling complexes including SWI/SNF family BAF complex factors like SMARCA4 and SMARCC1, CHD 
family NuRD complex factors like HDAC1/2 and MBD3, ISWI family factors like SMARCA5, INO80 family 
factors like INO80, TRRAP and EP400, and histone chaperone complex factors like ASF1A and HIRA 291–293. 
Especially the roles of SMARCA4 and CHD4 have been pinpointed as important for OCT4 function in 
reprogramming. A single amino acid mutation in an OCT4 linker domain, which interacts with these factors, 
has been shown to abolish OCT4 reprogramming function 294. The role of PARP1 interaction with OCT4 may 
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also be linked to its role in histone mobilisation 292,295. It could thus be speculated that OCT4, as a pioneering 
pluripotency and reprogramming factor, functions to mediate chromatin remodelling of its target loci, which 
could promote binding of non-pioneering factors and signalling factors, while simultaneously repressing 
spurious activation of the sites. This could explain the effect of fusing transactivation domains with OCT4 to 
promote only OCT4 mediated reprogramming 174, if OCT4 by itself lacks transactivation capacity which may 
be promoted by other factors. It could also explain the signalling dependence of OCT4 mediated 
reprogramming with some of its interaction complex components, like GFD9 dependence of OCT4 and ASF1A 
reprogramming 223, and BMP4 interference of OCT4 and KDM2B reprogramming, which depends on PRC1.1 
288. Additionally, the lack of sufficient amounts of signalling factors, like TGFsignalling effectors SMAD2/3, 
may be a limiting step in reprogramming 296. 
 
6.2.4.8.2. DNA Methylation 
Although changes in histone modifications emerge rapidly in the reprogramming process, DNA methylation 
changes occur gradually. Binding sites of activated factors have been reported to exhibit focal DNA 
demethylation during reprogramming whereas wider neighbourhood demethylation is seen only later in 
pluripotent state 261. The gradual resetting of the DNA methylation status may result in persistent epigenetic 
footprints of the starting somatic cell type, which are erased only in long term expansion of the iPSCs 297. The 
ineffective resetting of the DNA methylation status of the somatic cell loci may cause unwanted epigenetic 
aberrations in the resulting iPSCs. Particularly, large scale differentially methylated regions (DMR) have been 
reported in human cell reprogramming, the resulting iPSC demonstrating aberrant non-CpG hypomethylation 
near centromeric and telomeric regions 298. These non-CpG DMRs tend to also harbour partially CpG 
methylated sequences reminiscent of the starting cell type. However, these incomplete CpG modifications in 
the subtelomeric non-CpG DMRs appear to be caused by aberrant DNA hydroxymethylation 299, as bisulphite 
sequencing cannot distinguish between 5mC and 5hmC modifications 300. Overall, the DMRs overlap with 
H3K9me3 markers in the starting cell populations. They also overlap with the initial reprogramming factor 
binding resistant regions, indicating a link between somatic cell heterochromatin status and reprogramming 
associated aberrations of DNA methylation 210,232,298. 
Active DNA demethylation has also been implied in pluripotent reprogramming. This has been reported to 
be Activation Induced Cytidine Deaminase (AID)-dependent in mouse ESC and human fibroblast cell fusion 
heterokaryons 301. Curiously, the role of AID in transcription factor mediated reprogramming appears to be 
reprogramming stage dependent. The absence of AID appears to accelerate the reprogramming in the 
beginning of the process, whereas AID in the later stages helps in stabilizing the pluripotent state 302. AID 
functions as a cytosine and 5mC deaminase, which targets single stranded DNA and converts cytosine and 
5mC to uracil and thymine respectively 303,304. The resulting mismatches can then be repaired to mediate 
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cytosine demethylation. Insufficient AID activity at the later stages of reprogramming may thus limit the cell 
type conversion to stable pluripotent state by limiting active demethylation 302. The early role of AID is not 
quite clear, but it is possible that initial DNA methylation may function in reprogramming factor targeting, as 
KLF2, 4 and 5 have been reported to be 5mC readers 271. The choice of the reprogramming factors may further 
affect the outcome of the aberrant DNA methylation in reprogramming, as ‘Yamanaka factors’ may promote 
more CpG demethylation failures and ‘Thomson factors’ may promote more CpG methylation failures 305. On 
the other hand iPSC CpG-DMRs have also been reported to be primarily hypomethylated and associated with 
both KLF4 and FOXL1 motifs 298. Therefore, the role of the reprogramming factors in this process is still 
unclear. In addition to AID, active DNA demethylation can also be promoted by TET mediated 5mC and 5hmC 
oxidation to 5-carboxycytosine and 5-formylcytosine followed by TDG-mediated cytosine excision 306–308. The 
limiting availability of TET enzymes in the beginning of the reprogramming process may therefore limit active 
DNA demethylation and prolong the reprogramming process. 
The reprogramming process can also result in aberrations in DNA methylation in imprinted loci, in which the 
maternal and paternal alleles normally have different methylation patterns. The imprinting defects in human 
pluripotent cells were recently reported in a large scale study, which concluded that iPSCs contain more 
commonly imprinting defects than ESCs and that the loss of imprinting is more commonly targeting the 
paternal allele 309. The reprogramming conditions may also contribute to the loss of imprinting occurring 
during reprogramming. For example, the imprinted mouse Dlk1-Dio3 locus has been reported to be shielded 
from hypermethylation and loss of imprinting by addition of ascorbic acid, a cofactor for TET 310,311, and 
prolonged culture in the presence of MEK inhibition may cause aberrant hypomethylation of imprinted genes 
by downregulation of DNA methyltransferases 59. 
 
6.2.4.8.3. X-chromosome Inactivation 
During reprogramming of mouse cells the X-chromosome state of female cells changes from the somatic 
state with one inactivated X-chromosome and one active X-chromosome (XiXa) to the pluripotent state with 
two active X-chromosomes (XaXa). The second X-chromosome is normally silenced upon differentiation by 
XIST, which coats the X-chromosome with XIST RNA. This leads to subsequent compaction of the X-
chromosome marked by repressive H3K27me3 foci. Unlike mouse iPSCs, that contain two active X-
chromosomes, human iPSC X-chromosome activation status after reprogramming is not as definite 232. 
Human iPSCs have been reported to both maintain somatic cell X-chromosome inactivation status and to 
activate the second X-chromosome. The differences between different reports may be caused by different 
culture conditions, as induction of pluripotency on LIF producing SNL feeders (STO cell line transformed with 
neomycin resistance and murine LIF genes) can produce human iPSC lines with XaXa status 312. In addition, 
human pluripotent cells have been shown to go through loss of XIST expression, while maintaining Xi status, 
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and gradual partial degradation of X-chromosome silencing, deemed erosion of dosage compensation 313. 
This is a process that can lead to leaky activation of X-chromosomal genes that should be silenced and can 
result in aberrant X-chromosome epigenetic states. Therefore, it is important to characterize the X-
chromosome status of female iPSC lines, as aberrant X-chromosome inactivation may affect the behaviour 
of the cells in downstream applications. 
 
6.2.4.8.4. Resetting the 3D Genome 
The reprogramming process efficiently resets the global genome 3D architecture, removing the starting cell 
type chromatin conformation and replacing it with pluripotent cell specific conformation both in TAD and in 
sub-TAD level 314. Early passage iPSCs have, however, been found to contain some cell-of-origin specific DNA 
topological features, which do not appear to be somatic cell derived memory, but established during the 
reprogramming process in a replicable cell type specific manner 314. These atypical features do not appear to 
correlate with the expression of the genes associated with them, so it is possible that the topological changes 
can be tolerated in iPSCs as long as they do not affect the establishment or maintenance of pluripotency. The 
atypical domains in early passage iPSC can distinguish iPSC form different cell type sources. As the features 
are established in the reprogramming intermediates, this indicates a differing path for pluripotency for the 
different somatic cell types. Aberrantly rewired chromatin topology has also been detected in iPSC derived 
from NSC 315. These interactions appear to particularly affect pluripotency genes, which are expressed at the 
NSC state. The affected genes appear to be hyper connected, meaning that they still retain some of the NSC 
specific interactions as iPSCs. These aberrant interactions also seem to correlate with CTCF sites, since extra 
connections can be retained in NSC-specific persistent CTCF sites while ESC-specific CTCF connections can be 
depleted 315. This would suggest a model by which erroneous chromatin interactions may be retained from 
reprogramming intermediate states if they support expression of pluripotency-associated factors, which 
have been activated at the intermediate states, in the absence of proper ESC specific CTCF site associated 
connections. These aberrant interactions can be reset either by extended passaging or by more specific 
growth conditions, like 2i 314,315. Both of these cases may be linked to DNA methylation changes, as suggested 
by several lines of evidence: a) naïve state culture conditions have been liked with global hypomethylation 
316, b) long term expansion erases somatic cell footprints 297, and c) CTCF binding is known to be affected by 
DNA methylation 317. 
Affecting the 3D conformation of DNA may also contribute to reprogramming efficiency. This is suggested by 
the observation that knockdown of YY1 improves the reprogramming efficiency of human fibroblasts 235. It is 
possible that transiently downregulating the expression of YY1 may help in destabilising the enhancer-
promoter interactions of the starting cell type 79, thereby promoting the initial de-differentiation of the cells. 
Restructuring the chromatin 3D conformation may also be important for the activation of pluripotency loci. 
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A recent paper studying the chromatin conformation changes in high efficiency blood cell reprogramming by 
C/EBP priming described initial changes in the open vs repressed chromatin localization of genes occurring 
before transcriptional changes 318. Therefore, one requirement for efficient activation of a gene, and 
activation of pluripotency program, may be initial reorganisation of chromatin 3D structure. 
 
6.2.4.9. Small Molecules to Enhance Efficient Reprogramming 
Small molecular compounds offer versatile tools for pluripotent reprogramming. Small molecules are easy to 
use as they can be supplemented in the cell culture medium, allowing good temporal control over their 
effects. Small molecular compounds have primarily been screened for their effect in either improving the 
reprogramming efficiency or replacing reprogramming factors 319. Many of the compounds used for 
pluripotent reprogramming are agonists or antagonists of epigenetic enzymes or enzymes functioning in 
signalling pathways. Although small molecular compounds are convenient to use, they generally affect 
common pathways and intrinsically lack the sequence level specificity of transcription factors. Therefore, 
small molecules may be most useful when combined with transgenic transcription factors for affecting the 
reprogramming process. 
Many different compounds have been studied in the context of pluripotent reprogramming. The first reports 
were on factors affecting the epigenetic state of the reprogramming cells, like the DNMT inhibitor (5’-
azacytidine) or HDAC inhibitors (suberoylanilide hydroxamic acid, trichostatin A and valproic acid) 262. Other 
molecules acting on epigenetic enzymes and improving reprogramming efficiency were later reported. These 
included HDAC inhibitor (sodium butyrate) 320,321, H3K9 mono and di methylase, G9A, inhibitor (BIX-01294) 
322, DNMT inhibitor (RG108) 323, H3K4 demethylase, LSD1, inhibitors (parnate and RN-1) 278,324, H3K79 
methyltransferase, DOT1L, inhibitor (EPZ004777) 235, and vitamin C, a cofactor for TET dependent DNA 
demethylation and JHDM1A/1B dependent H3K36 demethylation 325–327. Many small molecular compounds 
affecting different signalling pathways have also been reported for iPSC induction, including calcium 
signalling agonist (BayK8644) 323, TGF signalling inhibitors (A-83-01 in combination with AMI-5, 616452, and 
SB431542 in combination with MEK inhibitor PDD0325901) 328–330, cyclic AMP analog (8-Br-cAMP) 331, Wnt 
signalling activator (CHIR99021) 324, SRK family kinase inhibitors 332, and retinoic acid signalling agonists 
(CD437 and AM580) 48. Additionally, a set of compounds, deemed OAC for OCT4 activating compound, have 
been described to promote reprogramming efficiency, although the mechanism of the effect was not 
resolved 333. Different combinations of the inhibitors have been used to replace many of the conventional 
reprogramming factors. In human reprogramming, SOX2, KLF4 and MYC can be replaced by small molecular 
compounds, enabling induction of pluripotency with only OCT4. This can be achieved by reprogramming 
epithelial human cells with OCT4 overexpression in the presence of butyrate, A-83-01, PD0325901, 
CHIR99021, parnate and a PDK1 activator PS48 255. A similar cocktail of molecules, containing valproic acid, 
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CHIR99021, 616452 and parnate, has been reported to promote mouse fibroblast reprogramming with 
transgenic OCT4 334. Finally, by screening for Oct4 activating compounds, cAMP signalling activator forskolin 
was identified as a replacement for transgenic OCT4 335. By combining the chemical conditions which allow 
reprogramming with only OCT4 (valproic acid, CHIR99021, 616452 and parnate) with the chemical conditions 
which allow activation of OCT4 (forskolin), cells can be reprogrammed to pluripotency with addition of two 
extra molecules (S-adenosylhomocysteine hydrolase inhibitor (3-deazaneplanocin A) and a retinoic acid 
receptor ligand (TTNPB)) 335. This chemical reprogramming method depends on the activation of endogenous 
Sox2 and Sall4 followed by the activation of Gata4, Gata6, Sox17 and Oct4 in response to the treatment with 
CHIR99021, 616452 and forskolin. Therefore, the pre-existing transcriptional control program in the 
reprogrammable somatic cells needs to be properly responsive to the chemical cues for the system to work. 
Related fully chemical reprogramming approaches have later been described also for various 
transdifferentiation approaches, primarily using mouse cells 336. 
 
6.2.4.10. Alternative Starting Cell Types and Pathways 
The majority of studies regarding the pathways to pluripotency have been made using fibroblasts. The 
starting cell population may affect the way the cells behave in the reprogramming process and the nature of 
the barriers for efficient reprogramming. Therefore, it is important to characterise the events that govern 
the reprogramming processes of cell types other than fibroblasts. To this end, both similarities and 
dissimilarities in the reprogramming processes have been reported between different starting cell types. 
Analysis of the gene expression of different types of human cells has indicated various general similarities in 
the early, mid and late stages of reprogramming 277,337. The early stage changes share a gradual 
downregulation of extracellular matrix organization associated factors and TGF signalling factors. 
Expression of innate immune response factors can be seen at early to mid-stages, which may be related to 
the reprogramming vector expression 337. Genes that present a transient peak of expression in the mid-stage 
of reprogramming are primarily associated with cell junction assembly and differentiation-associated terms, 
like epidermis development. Late upregulated and gradually upregulated genes are mainly associated with 
neural development and cell cycle 337. The fact that mid stage expressed genes have been associated with 
differentiated lineages may be due to the effect of the pluripotent reprogramming factors redistributing the 
somatic cell transcription factors to new sites away from their primary somatic binding sites 338,339. The 
persistent expression of somatic cell specific transcription factors could thus affect the reprogramming 
process, particularly during the early and mid-stages of reprogramming. 
The cell type of origin has also been reported to define the reprogramming path that the cells take and to 
affect differentially the reprogramming of different cell types 340. Particularly genes that are downregulated 
or transiently upregulated are affected in a cell type specific manner. This is likely due to downregulation of 
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somatic cell programs in the de-differentiation phase and transient upregulation of off-target genes in the 
presence of persistent somatic transcription factors with the reprogramming factors. The reprogramming 
cells of different origins also demonstrate different order of pluripotency marker acquisition. For example, 
neutrophils have been reported to primarily upregulate Oct4 before becoming SSEA-1 positive, whereas 
keratinocytes show early expression of epithelial markers and late activation of Oct4 expression 340. 
Keratinocyte reprogramming also indicates that changes in the mesenchymal and epithelial status of the 
cells, e.g. MET, is not required for reprogramming per se, but that the cells maintain their original epithelial 
expression program. The reprogramming of different cell types also shares certain features. For example, the 
main activated targets of the reprogramming factors are associated primarily with pluripotency in all cases 
340. The reprogramming culture conditions may further affect the route that cells take to become pluripotent. 
In the chemical reprogramming of mouse fibroblasts, the cells go through a transient extraembryonic 
endoderm-like state, unlike in the transgenic transcription factor mediated reprogramming 341. Although the 
transient cell populations described for reprogramming intermediates resemble certain other cell types, they 
do not always translate to functional equivalents. For example the primitive streak-like mesendodermal state 
which has been described for reprogramming intermediates does not necessarily result in protein level 




6.2.4.11. What Are the Requirements for Optimal Reprogramming? 
In summary, the efficient reprogramming of somatic cells to pluripotency can be simplified to three basic 
principles. 
(1) The process needs to mediate efficient decommission of the pre-existing somatic cell program. This notion 
is supported by the observations that the reprogramming efficiency can be increased by inhibition of factors 
that maintain active transcription markers in the early reprogramming, such as DOT1L and BET inhibitors 
91,235, and downregulation of somatic cell specific factors, like Egr1 or AP-1 factors 339,340. It is, however, 
important to keep in mind that these mechanisms maintain the proper growth of the starting cells and too 
low expression of these factors may decrease the viability of the reprogramming cells. 
(2) Efficient activation of crucial facultative heterochromatin located genes. This is supported by the 
restricted initial binding of the reprogramming factors to some of the heterochromatin located pluripotency 
associated sites 210, and the fact that inhibition of repressive chromatin modifications and heterochromatin 
components increase reprogramming efficiency 265,321,343. 
(3) Comprehensive targeting of pluripotency network factors. It has been reported that the targeting of the 
pluripotent reprogramming factors to relevant pluripotency associated on-target sites is improved by 
including additional pluripotency factors in the core factor set, like Esrrb 233. Therefore, incorporation of more 
pluripotent gene regulatory network components in the reprogramming mixture should result in improved 
fidelity of reprogramming. This should also promote more efficient activation of the pluripotent state gene 
regulatory network by maximizing the network nodes targeted. With the recent development of CRISPR 




6.2.5. Cellular Reprogramming Vectors 
As the reprogramming process relies on the delivery of a defined set of reprogramming factors into the cells, 
many different means have been developed to achieve this goal. These include viral and non-viral delivery, 
integrative and non-integrative vectors and DNA, RNA and protein based transduction 344. The following 
section will describe the main aspects of the various methods. A summary of cellular reprogramming vectors 
is presented in Figure 5. 
 
 
Figure 5. Summary of cellular reprogramming vectors. 
 
6.2.5.1. Retroviruses 
Retroviral vectors were used for the first iPSC induction experiments 1. The genome of retroviruses consists 
of RNA which is reverse transcribed into DNA and integrated into the host genome upon infection. This allows 
for a persistent expression of the delivered transgenes. The retroviral gene transfer vectors have had most 
of the viral components removed and only contain the essential viral elements required for gene expression 
and delivery, including the  packaging signal, primer binding sequence, polypurine tract, and long terminal 
repeats (LTR) 344. The retroviral gene transfer systems most commonly used for iPSC induction are primarily 
based on either mouse -retroviral vectors derived from the Moloney Murine Leukemia Virus (MMLV) or 
Lentiviral vectors derived from Human Immunodeficiency Virus 345,346. These vectors have different 
properties when it comes to infectivity and expression. -retroviral vectors are ecotropic and normally only 
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infect mouse cells. These viruses can, however, be pseudotyped with the vesicular stomatitis virus G protein 
(VSV-G) which increases their infectivity to wide variety of cells. The -retroviral vectors require active cell 
proliferation for successful infection. Lentiviruses, on the other hand, can infect also non-dividing cells. Most 
-retroviral vectors used for iPSC induction rely on the viruses endogenous LTR promoter for gene expression, 
and get silenced towards the end of the reprogramming process by ZFP809, TRIM28 and CHAF1A mediated 
mechanisms 347. Lentiviruses have commonly been engineered to contain exogenous promoters, which allow 
more control over their expression and for example the use of inducible promoters for secondary induction 
systems 348. The problem with using retrovirus-based gene transfer methods for iPSC induction is the 
uncontrolled integration of the vector and the effects of the insertional mutations. It has been reported that 
high multiplicity of infection (MOI) with lentiviruses can mediate reprogramming of fibroblasts to 
pluripotency in the absence of transgenic transcription factors 349. This has been linked to aberrant gene and 
miRNA expression caused by the vector integration. 
 
6.2.5.2. Non-integrative Plasmids 
Induction of pluripotency can be achieved with transient plasmid DNA transduction based reprogramming 
factor delivery methods. The first reports of this required either serial plasmid transfections or transfection 
of more plastic cell types, like adipose stem cells, due to the transient nature of plasmid expression 350,351. 
This also generally resulted in inefficient reprogramming. The need for serial plasmid transfections was 
removed by introduction of replicative episomal plasmid vectors for reprogramming, which allowed for more 
persistent reprogramming factor expression until the endogenous pluripotency transcriptional program was 
properly established 352. These vectors contain the Epstein-Barr virus derived oriP and EBNA1 (Epstein-Barr 
nuclear antigen-1) sequences, which mediate the replication of the plasmids once in a cell cycle. The EBNA1 
protein recognises the oriP sequence and recruits the cellular DNA replication machinery to the origin. This 
system has later been further optimized for reprogramming factor composition to mediate more robust 
reprogramming of primary human cells 353. As the reprogramming vectors are transiently lost during cell 
proliferation due to imperfect plasmid retention 344, the system allows for derivation of iPSCs without 
genomic vector integration. 
 
6.2.5.3. DNA Transposons 
In addition to transiently replicating episomal plasmids, integrative plasmid systems, based on DNA 
transposons, have been used for reprogramming. These systems consist of a vector donor plasmid, 
containing the transgenic cargo flanked by the terminal repeat sequences of the transposon, and a second 
helper plasmid expressing the transposase. Most commonly used DNA transposon reprogramming systems 
are based on the moth derived PiggyBac (PB) transposon, which efficiently transposes in PSCs 354,355, and can 
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mediated reprogramming of both mouse and human cells 356,357. Additionally, DNA transposon vectors based 
on the Sleeping Beauty (SB) transposon, engineered from ancestral Tc1/mariner transposable elements from 
fish genomes, have been used for reprogramming 358,359. As these vectors are integrated in the host genome, 
they can provide stable expression of the delivered transgenes. They can also be combined with inducible 
systems to control the temporal expression of the transgenes and to mediate secondary reprogramming of 
differentiated cells 356. Compared to retroviral vectors, DNA transposons have higher cargo capacity, making 
them useful for delivery of larger constructs. SB and PB transposons are based on a cut-and-paste 
transposition model. This allows the removal of the reprogramming transgenes from the recipient genomes 
upon re-expression of the transposase protein. PB transposons integrate into the host genome at TTAA sites 
and can be precisely excised from the genome enabling the generation of transposition footprint-free iPSCs 
360. 
 
6.2.5.4. RNA Mediated Reprogramming 
Modified mRNA mediated reprogramming relies on serial transfection of chemically modified mRNA 
molecules encoding the pluripotent reprogramming factors into the reprogramming cells 361. Unlike 
transgenic DNA, transduced mRNA does not risk integration into the host genome. However, transfection of 
unmodified RNA generally causes an antiviral innate immune response in the cells resulting in increased 
interferon production and growth inhibition. The unmodified RNA is detected by RIG-I, PKR and TRL7/8, 
which can further lead to MAVS-mediated caspase activation and apoptosis 362–365. Therefore efficient mRNA 
transfection requires inhibition of the innate immune response, which can be mediated by targeting the 
innate immune response factors for downregulation or inhibition 366,367, or by preventing the mRNA 
recognition by removal of terminal 5’-phosphates and introduction of modified ribonucleoside bases, such 
as 5-methylcytidine and pseudouridine 361. These modifications, along with stabilizing UTR sequences, 
additionally increase the mRNA half-life, allowing for longer expression of the transduced mRNA and less 
frequent transfections. The mRNA transfection system is still relatively labor intensive method, requiring 
daily transfections of mRNA for approximately two weeks for proper reprogramming of fibroblasts. The 
system is also not quite as robust as the other commonly used non-integrative methods, episomal plasmid 
transfection and Sendai viral transduction 368. The mRNA reprogramming efficiency can, however, be 
improved by simultaneous delivery of reprogramming promoting miRNAs 368. These miRNAs are usually 
pluripotency associated micro RNA, like miR200c, miR302a-d, miR367, miR369 or miR372 225,226,369–372. In 
addition to promoting reprogramming, knock out of the miR302 cluster abolishes pluripotent 
reprogramming, demonstrating the importance of these miRNAs for the process 373. The targets of these 
miRNAs in reprogramming include factors involved in cell cycle control, glycolytic metabolism, MET and gene 
repression 371.  
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6.2.5.5. RNA Episomes 
Episomal RNA replicon vectors are based on alphavirus genomes. Alphaviruses are single stranded, positive 
sense, RNA viruses with 5’-capped and 3’-polyadenylated genome. Alphaviruses replicate via a double 
stranded RNA intermediate, which is polymerised by the viral non-structural proteins. The (-) sense RNA 
functions as a template for production of (+) sense full length genomic RNA and a shorter sub genomic (+) 
sense RNA, produced from an internal promoter. Alphavirus genomes contain two open reading frames 
translated from the genomic and sub-genomic RNAs. The first ORF encodes non-structural proteins 1-4, 
which are cleaved from a longer peptide, and the second ORF contains the viral structural proteins, which 
are important for producing virions 374. As the structural proteins in the second ORF are not important for 
the virus expression or replication, they can be replaced with transgenic cargo. The alphavirus replicons are 
normally highly cytopathic, leading to apoptotic cell death in a few days, and the transgene vectors normally 
need to contain mutations, which can promote persistent maintenance of viral replicons. Multiple different 
alphavirus based transgenic replicons have been reported, including Sindbis Virus (SIN) 375,376, Semliki Forest 
Virus (SFV) 377, Chikungunya Virus (CHIKV) 378, and Venezuelan Equine Enchephalitis Virus (VEEV) 379. Many of 
the alphavirus replicons are still highly cytopathic, limiting in their host cell options, and only persist in 
selected cell lines like BHK-21. The cytopathic effect is caused by the cells innate immunity factors, like RIG-
I, MDA5 and PKR recognizing the viral double stranded RNA and initiating interferon response, MAVS-
mediated apoptotic signalling and viral factor-mediated translational shut off 380–385 However, some new 
world alphavirus replicons, like VEEV, can be persistently maintained in various cell lines 379. These vectors 
have turned out to be useful also for cellular reprogramming 386. By replacing the viral structural proteins in 
the sub-genomic RNA with OCT4, SOX2, KLF4 and C-MYC encoding cassette, the vector can be used to derive 
iPSCs from human fibroblasts 386. This way the (+) sense RNA replicon can be introduced by transfection or 
electroporation into cells, where it functions as an mRNA template for translation, and initiates replication 
of the delivered RNA construct and subsequent expression of the reprogramming transgenes. The double-
stranded RNA is still toxic to the cells, which necessitates interferon inhibition for persistent maintenance of 
the replicon. On the other hand, removal of the interferon inhibition can be used for selection of vector-free 
clones by innate immunity response mediated removal of replicon containing iPSCs. As the whole system is 
based on RNA, it does not pose a risk for genomic integration.  
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6.2.5.6. Protein Transduction 
Recombinant protein transduction relies on the fusion of the cargo proteins with a cell penetrating peptide 
(CPP), which allows for the translocation of the protein across the cell membrane from extracellular space 
into the cell. The CPPs are short peptide sequences, which can be divided into three categories, cationic, 
amphipathic and hydrophobic, based on the physical properties of their amino acid sequences 387. Cationic 
peptides, like HIV-TAT peptide or polyarginines, contain multiple positively charged residues, like lysines and 
arginines, which promote cell entry by interacting with negatively charged groups of cell membrane 
constituents. Many amphipathic CPPs are chimeric peptides between hydrophobic domain and a cationic 
nuclear localization signal, and hydrophobic CPPs consist of nonpolar residues, which have high affinity for 
hydrophobic domains of cell membranes 387. CPPs can exploit different mechanisms for cell entry, but most 
CPPS are internalized by endocytosis followed by escape from endosomes. This process can be promoted for 
example by addition of extra histidine residues to the peptide tag, which adsorb protons at endosomal pH 
leading to increase in osmotic pressure and endosomal vesicle membrane rupture 388. Pluripotent 
reprogramming attempts have been reported with both TAT and polyarginine fused reprogramming factors. 
Although the reported TAT fusion factors did not translocate properly in the cells, transduction with 
polyarginine fused factors can mediate reprogramming of both mouse and human fibroblasts 389–391. Direct 
protein transduction of reprogramming factors is still an inefficient method. The first reported human iPSC 
derived by protein transduction were derived from fibroblasts with abnormal karyotypes 390. Later advances 
have improved the protein transduction reprogramming approach by including an innate immunity signalling 
activating dsRNA analog (poly- inosinic-polycytidylic acid), which promotes polyarginine fused protein-
mediated reprogramming 392. Additionally, less specified somatic cell pluripotent reprogramming approaches 
have been reported by using streptolysin O–mediated reversible permeabilization with ES cell protein extract 
transduction 393. 
 
6.2.5.7. Episomal Viruses 
In addition to the integrative retroviral approaches, various non-integrative virus vectors have been used for 
induction of pluripotency. These include both episomal DNA and RNA viruses, like adenovirus or Sendai virus 
(SeV). Adenoviral vectors can have large cargo capacity if all viral proteins are removed and only necessary 
packaging signals are left. The vector carries a linear double stranded DNA molecule in the cells and provides 
a transient expression in proliferating cells 344. Adenoviral reprogramming factor delivery has been used to 
derive integration free mouse iPSCs, but the efficiency of the system is low 394. Sendai virus is a single stranded 
negative sense RNA virus capable of efficient transduction of various cell types. Sendai viral proteins NP, P 
and L form a ribonucleoprotein complex with the viral genome and mediate its replication in the cytoplasm. 
The other proteins, M, HN and F, mediate the formation of virus particles and viral infection. F-defective 
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Sendai viruses are incapable of producing infective viruses and have thus been developed as gene transfer 
vectors 344,395. Due to the episomal replication of SeV genomes, SeV vectors are capable of persistent 
expression of transgenes and do not require repeated transduction. This makes SeV vectors attractive tools 
for pluripotent reprogramming. F-defective SeV vectors have been used to reprogram somatic cells 396. The 
vector provides high transgene expression levels and can mediate efficient reprogramming. The replicons 
tend to be lost over time, but they can persist quite long. The clearance of the transgenic replicons can be 
promoted by using temperature sensitive mutants of the virus and transfer of the infected cells to higher 
temperature 397. Sendai viral reprogramming has also been reported using an alternative virus strain capable 
of persistent long term replication 398. This vector has additional M and HN protein deletions, and can 
incorporate all reprogramming transgenes in a single cassette, providing more control over factor expression 
stoichiometry. The clearance of the vector can be mediated either by transfection with siRNA targeting the 
SeV genome or by incorporating miR302 recognition sites in the vector sequence 399. This provides more 





6.3. Adeno Associated Virus (AAV) 
Adeno-associated virus (AAV) is a small non-pathogenic parvovirus that is dependent on a helper virus, such 
as adenovirus or herpesvirus, for productive infection. It was initially found contaminating Adenoviral 
preparations and has later on been developed as a gene transfer vector 401,402. AAV genome consists of a 4.7 
kb single stranded DNA, containing three promoters and two open reading frames flanked by hairpin forming 
inverted terminal repeat (ITR) sequences. The left half contains the Rep gene encoding the non-structural 
proteins Rep78, Rep68, Rep52, and Rep40, which bind to the Rep binding elements in the ITR and exhibit 
DNA helicase and endonuclease activity at the ITR terminal resolution site 403,404. The Rep proteins control 
the AAV gene expression in response to the helper virus and are required for AAV DNA replication and 
accumulation of single stranded viral DNA for packaging 404,405. The right half contains the Cap gene producing 
the structural proteins, VP1, VP2 and VP3, which form the viral capsid. Additionally, the AAV replication is 
dependent on helper virus factors, like the adenoviral E1, E2A, E4orf6 proteins and VA1 RNA 402. Upon 
infection, AAV can establish a latent state in the absence of helper virus when conditions are not permissive 
for productive replication. Infection of the latent AAV containing cells with a helper virus can re-establish 
infective AAV production 402. The latency of the AAV provirus can be established by circularization of either 
singular or concatenate AAV genomes into extrachromosomal episomes in non-dividing cells or by 
integration into the host genome. The integration of the wild type AAV happens preferably into the AAVS1 
locus in human chromosome 19q13.3-qter and is mediated by the viral Rep proteins 406,407. This is due to the 
presence of a Rep binding element sequence in close proximity to a terminal resolution site in the AAVS1 
locus, rep binding elements in the AAV ITR sequences and p5 promoter, and tethering of AAVS1 and AAV 
genomes by Rep68 404. The exact integration site itself is imprecise. The ITRs are approximately 145 bp long 
sequences, containing the AAV replication origin, and are required for the viral genome packaging into the 
virions. After infection and viral DNA entry into the host cell the ITRs mediate the second strand DNA 
synthesis by self-priming 404, and the circularization of the AAV episomes by DNA damage repair 408. AAV 
enters into the cells via cell surface receptors, including the recently described AAVR 409, and gets internalised 
into endosomal vesicles, which it exits upon acidification. AAV is actively transported into the nucleus, which 
allows AAV-mediated transduction of non-dividing cells. Cellular processes that mediate AAV entry, 
trafficking and viral uncoating can limit AAV transduction efficiency 410. Different serotypes of AAV can 
mediate these processes to varying extent. At least 13 different AAV serotypes have been described so far, 






6.3.1. Recombinant AAV (rAAV) as a Gene Delivery Vector 
 
 
Figure 6. Schematic representation of AAV genome structure. 
 
The fact that AAV is a non-pathogenic and non-toxic virus, capable of long term persistent tissue specific 
transduction of non-dividing cells, makes it an attractive tool for a gene transfer vector, especially from a 
gene therapy point of view. To this extent, gutless recombinant AAV vectors have been developed, which 
lack all of the viral genes. As the ITR sequences mediate both the genomic DNA packaging to the virions and 
the second strand DNA synthesis priming in the transduced cells, they are the only viral sequences required 
for rAAV gene transfer vectors. Therefore, recombinant AAV vectors can be generated by flanking a 
transgene with ITR sequences and providing the AAV proteins and helper virus proteins in trans for virus 
production and packaging. As the wild type AAV genome is relatively small, the carrying capacity of rAAV 
vectors is also quite limited. Maximal capacity of 5.2 kb has been reported to be the upper limit for rAAV 
packaging 413, but longer constructs may work by annealing or recombination of truncated vector sequences 
or by trans-splicing between two vector constructs 414. Small genes can also be packaged into self-
complementary rAAV vectors. Self-complementary rAAV vectors can fold back onto themselves removing 
the need for the rate limiting step of second strand DNA synthesis 415–417. The easy pseudotyping of rAAV 
vectors with different capsid proteins and the variety of available AAV serotypes makes possible to engineer 
rAAV with desired target tissue specificity. Moreover, targeted capsid tyrosine mutations, DNA family 
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shuffling and in silico reconstruction of ancestral AAV sequences can yield highly improved rAAV gene 
transfer vectors 418–420. Schematic representation of AAV genome structure is presented in Figure 6. 
As the rAAV is lacking the viral Rep proteins it cannot meditate site specific targeting to the chromosome 19 
AAVS1 locus. Therefore the rAAV vectors preferentially tend to form monomeric and concatemeric circular 
episomes, as has been reported for mouse muscle tissue transduced rAAV vectors 421. rAAV vectors can 
however integrate into the host genome, but appear to do so in a more opportunistic way by utilising 
genomic DNA double strand breaks (DSB) 422. rAAV integration in vivo has also been reported in the male 
germ cell lineage 423. The integration of rAAV genomes appears to have a preference for expressed genes 
424,425, and therefore it is possible that the rAAV integration is liked to transcription-associated DNA DSBs 249. 
As AAV genome processing co-localizes with DNA damage response factors of the MRN complex (MDC11-
RAD50-NBS1) 426, it is possible that the AAV genome processing is also linked to the integration mechanisms 
and that the integration to DNA DSB sites occurs by microhomology mediated alt-NHEJ pathway, as 
suggested by the vector integration junction sequences 422,427. The integration of rAAV vectors is still a 
relatively rare occurrence and the integration frequency has been estimated to be in the range of 0.2-1.0 × 
10-3 per infectious vector genome 428. This makes rAAV vector a potentially useful tool for applications that 
require transient expression in replicating cells and a subsequent absence of integrated vector sequences, 





6.4. CRISPR/Cas Systems 
 
 
Figure 7. Classification of CRISPR-Cas systems and schematic representation of Class 2 Type II CRISPR system 
of Streptococcus pyogenes. Genome editing tools are primarily based on single Cas interference complex 
containing Class 2 Type II and V systems. Streptococcus pyogenes CRISPR locus contains Cas1, Cas2 and Csn2 
proteins that mediate new spacer acquisition in the CRISPR array, and Cas9, tracrRNA and CRISPR array that 
mediate interference of invading genetic material. 
 
The research of clustered regularly interspaced short palindromic repeats (CRISPR) sequences traces its origin 
to the study of repeat motifs in prokaryotes and archaea in the late eighties and early nineties 429. Short 
repetitive sequences containing variable spacer regions were initially described in various bacteria, including 
E. coli, and halophilic archaea 430–433. These repeats were later named CRISPR and found to contain nearby 
protein coding genes named CRISPR-associated (Cas) 434. The function of these repeat regions was not initially 
understood, but discovery of matching spacer sequences in bacteriophages and plasmids implicated a 
potential role of these loci in bacterial immunity against foreign DNA 435. The empirical evidence for CRISPR 
function in bacterial adaptive immunity was demonstrated in 2007 when a phage sensitive strain of 
Streptococcus thermophilus was shown to incorporate phage protospacer sequences into its CRISPR1 locus 
upon acquisition of phage-resistance after phage challenge 436. Moreover, removal of the spacers from the 
resistant strain re-sensitized the bacteria to the phage infection, and replacement of the wild type CRISPR1 
locus with phage specific spacer containing sequence-conferred resistance to the phage. The role of CRISPR 
RNAs in guiding the immune response and the mechanism of target DNA cleavage were subsequently 
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demonstrated 437,438, followed by the requirement for a trans-encoded CRISPR RNA (tracrRNA) for S. pyogenes 
phage resistance 439. The characterization of the necessary components eventually allowed reconstitution of 
the RNA reprogrammable Cas9 endonuclease function from its minimal constituents 3,4. This enabled the 
further development of the system as a genome-engineering tool and lead to the rapid expansion of CRISPR 
research and applications. 
CRISPR-Cas is a widely spread adaptive immunity system present in approximately 47 % of bacterial and 
archaeal genomes. CRISPR systems can be classified into two classes, based on the presence of either multi 
subunit (class 1) or single protein (class 2) interference complexes, and subsequently into six types based on 
the presence of unique signature proteins, Cas3 (type I), Cas9 (type II), Cas10 (type III), Csf1 (type IV), Cpf1 
(Cas12) (type V) and the RNA targeting Cas13 (type VI) 440,441. In CRISPR-Cas immunity, the first step is 
adaptation to infection by insertion of invading genetic material into the CRISPR locus by Cas1 and 2 442, which 
is promoted by defective phage infection 443. Thereafter, the CRISPR locus is expressed and the precursor 
CRISPR RNA (crRNA) are bound to the multi subunit or singular Cas interference complexes and processed. 
In the final step the interference complexes mediate target sequence recognition and cleavage 440. The 
primarily bacterial class 2 single protein interference complex systems have been a major focus for the 
biotechnological development of CRISPR-based applications due to their relative simplicity. Particularly class 
2 type II Cas9 proteins and class 2 type V Cpf1 proteins have been developed as genome editing tools. These 
systems in bacteria usually consist of a CRISPR locus containing the crRNA sequences, Cas1 and Cas2 
containing adaptive complex, Cas9 or Cpf1 containing interference complex, and in case of type II systems 
tracrRNA, which is needed for proper crRNA targeting 3,4,440. The crRNA processing additionally requires 
RNAse III. The crRNA, or guide RNA, consists of a repeat sequence, which mediates Cas interaction, and a 
spacer sequence, which defines the genomic target specificity. The spacer sequences are derived from 
protospacer sequences that usually originate form invading genetic material. The CRISPR/Cas9 system 
requires a tracrRNA 3,4, whereas CRISPR/Cpf1 system is dependent on only one guide RNA molecule, which is 
processed by the intrinsic RNase activity of Cpf1 444,445. For DNA targeting, the Cas protein needs a 
protospacer adjacent motif (PAM) next to the guide target site. PAM sequences are specific to different Cas 
proteins and are recognised by the Cas RNP complex in a spacer sequence independent manner in the first 
step of target site binding 446. This is followed by sequence specific spacer RNA annealing to the target DNA 
leading to a conformational change in the Cas9 protein, which promotes catalytic activation of the protein 
447. In case of Cas9 the cleavage is mediated by nicking of each DNA strand by the HNH and RuvC domains of 
the protein, producing a blunt end double strand cut 4, whereas Cpf1 cuts the DNA strands sequentially and 
produces a staggered cut with 5’ overhangs 444. A schematic representation of CRISPR systems is presented 




6.4.1. CRISPR/Cas9 as a Genome Editing Tool 
 
 
Figure 8. Basic principle of CRISPR/Cas9-mediated gene editing. A programmable nuclease is introduced to a 
cell to generate a site-specific DNA double strand break. Thereafter the cell intrinsic DNA repair mechanisms 
correct the DNA double strand break using either homology directed repair (HDR) or non-homologous end 
joining (NHEJ). NHEJ mediated error prone repair can produce insertions and deletions that interfere with the 
original sequence. HDR can be used to introduce donor DNA cassettes into the targeted site. 
 
CRISPR/Cas9 has attracted lot of attention as a potent genome editing tool. Genome editing with 
programmable nucleases relies on targeted introduction of a DNA double strand break, which will be 
corrected by the cells intrinsic DNA repair machinery primarily via either recombination by homology 
directed repair (HDR) or non-homologous end joining (NHEJ). These targeted DNA DSBs can be used to 
produce mutations, such as small insertions and deletions, which can interfere with open reading frames, or 
to increase the rate of HDR occurring at the breakage site 448,449. First genome editing approaches relied on 
either meganucleases, zinc-finger nucleases (ZFN) or transcription activator-like effector nucleases (TALEN). 
Meganucleases are restriction enzymes, which have large recognition sites that are generally uncommon in 
the genome, making it possible to target the genomic sites with some specificity 449. However, the recognition 
sites are protein specific and the proteins are difficult to engineer, making the use of meganucleases 
impractical for genome editing. ZNF are fusions of zinc-finger domains of DNA binding proteins to a catalytic 
domain of FokI endonuclease. Zinc-finger domains recognise DNA sequences in triplets and fusion of multiple 
zinc-finger domains can be used to extend the target site sequence of the constructs. ZFNs are used as pairs 
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and recruited to two recognition motifs spaced 5-7bp apart. This promotes FokI dimerization in the middle 
and DNA cleavage at the site 448,450. ZFNs can be reprogrammed by modular assembly of the domains, but 
construction of functional high activity ZFNs is generally still a quite challenging and lengthy process. More 
efficient generation of modular reprogrammable nuclease proteins can be achieved using TALENs. TAL 
effectors originate from the plant pathogenic Xanthomonas bacteria and are naturally modular DNA binding 
proteins 451. TAL effector DNA binding domain monomers recognise single bases in DNA and can be combined 
together for longer target sequences. This can be used to mediate DNA DSB generation by paired TALEs fused 
with FokI domains, similar to ZFNs, or to mediate endogenous gene activation with activator domain fusions 
452,453. Like ZFNs, TALENs also require extensive protein engineering to reprogram their target site specificity, 
which may complicate their use. 
As the class 2 CRISPR-Cas interference systems only require one protein component for DNA cutting, these 
systems are good candidates for genome engineering tools. Particularly the type II system Cas9 proteins have 
been utilized for this approach. As the Cas9 targeting is achieved with two short RNA molecules, or one single 
guide RNA with fused crRNA and tracrRNA molecules, the system does not need protein engineering for re-
targeting 3,4. This makes it easier and faster to target new sites for genome engineering with CRISPR/Cas9 
than with ZFNs or TALENs. By incorporating a nuclear localization signal and relevant expression control 
elements into the Streptococcus pyogenes Cas9 protein, this system can be used to edit human genes 454,455. 
Moreover, as the Cas9 protein is targeted to DNA by short guide RNA molecules, it is easy to simultaneously 
target the system to multiple sites using one constant protein component and multiple guide RNA molecules 
455. Basic principle of CRISPR/Cas9-mediated gene editing is presented in Figure 8. 
 
6.4.1.1. SpCas9 
The most commonly used CRISPR system for human cell engineering is based on the Streptococcus pyogenes 
Cas9 (SpCas9) and guides. SpCas9 normally binds two RNA molecules, but in biotechnological applications 
these are normally fused together with a hairpin loop to mediate easier expression 4. The Cas9 protein 
contains two nuclease domains, HNH and RuvC, which each nick one strand of DNA, protospacer 
complementary strand and protospacer non-complementary strand respectively, producing DNA DSB. These 
sites can be inactivated by incorporating point mutations into the catalytic sites of the domains, the most 
commonly used mutations being D10A in the RuvC domain and H840A in the HNH domain 4. Incorporating 
only one of these mutations causes the Cas9 to have nicking activity, cutting only one strand of DNA, which 
can be a useful way of reducing off target mutagenesis as no DNA DSBs are created by default. By combining 
two guides with a nicking Cas9 protein, the off target mutagenicity of the system can be reduced from 50- to 
1500-fold, as creation of DSBs will require two closely spaced target sites 456. As the guide RNA starts to bind 
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DNA from the PAM proximal sequences, mismatches close to the PAM are generally less tolerated than 
mismatches further away from the PAM, especially close to the 5’ end of the RNA 457,458. Additionally, the 
guide nucleotide composition may affect the effectivity of the guides, with certain bases preferred over 
others in different parts of the guide sequence 459. Enhanced specificity versions of the protein have been 
rationally designed based on the crystal structure of the SpCas9 protein 460,461. These versions reduce the 
Cas9 affinity with the non-target DNA strand (eSpCas9) or the target DNA strand (SpCas9-HF1), thus 
decreasing the affinity of the protein to mismatched sites 462,463. More recently, additional high specificity 
versions of Cas9 have been reported, with mutations primarily in the REC3 lobe. One of these variants has 
mutations affecting the threshold for conformational shift required for the Cas9 catalytic activation 464, and 
another one was identified in an in vivo yeast screen for Cas9 specificity 465. 
The SpCas9 is generally considered to recognise the consensus DNA sequence NGG as a PAM motif. The 
recognition of the motif is however dependent on the surrounding nucleotide sequences and variants of this 
motif have been characterised, often with an A in the second position 466. As the PAM specificity is defined 
by the Cas9 protein, targeting of PAM variants that differ from the SpCas9 PAM consensus sequence require 
modifications in the Cas9 protein or the use of orthogonal Cas9 or Cpf1 systems 467,468. Reported modified 
SpCas9 variants can recognise PAM variants NGA, NGAG and NGCG instead of the wild type NGG consensus 
469–471, or more broad PAM sequences including NG, GAA and GAT 472. 
Incorporating inactivating mutations in both of the catalytic domains of the Cas9 protein, it can be converted 
in to a dead Cas9 (dCas9) version which does not cut DNA upon binding. This can be utilised as a 
reprogrammable DNA binding protein and a scaffold with which other functional components can be 
recruited to specific genomic loci 473. The use of trans-activator fusions and epigenetic dCas9 effectors will be 
discussed later. Other mentionable uses include dCas9-mediated induced chromosome looping 474,475, 
visualization of DNA loci in live cells 476–478, enrichment of chromosome locus interacting factors 479–481, and 
DNA base editing 482. DNA base editing is of particular interest for genome editing as it directly converts DNA 
bases in the presence of the Cas9 binding site without the need for a DNA DSB. Nicking activity of the Cas9 
protein can, however, help bias editing to the right DNA strand. Base editing relies on the fusion of nicking 
Cas9 with APOBEC1 cytidine deaminase, for C to T conversions, or evolved tRNA adenosine deaminase, for A 
to G or conversions 482,483. Fusion of these components with orthogonal Cas9 proteins and SpCas9 PAM 
variants can further expand the targeting range of these tools 484. 
 
6.4.1.2. Orthogonal Class 2 CRISPR Systems 
Although Streptococcus pyogenes CRISPR/Cas9 system is most commonly used for mammalian genome 
engineering, many other orthogonal CRISPR systems have been characterised. The main benefit of using 
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orthogonal Cas9 systems comes from the varying PAM specificities of the proteins, which help expand the 
genomic targeting range of the method. Frequently used alternative class 2 CRISPR systems include Neisseria 
meningitidis and Staphylococcus aureus Cas9 485,486, and Acidominococcus and Lachnospiraceae Cpf1 444. 
Orthogonal CRISPR systems may be useful in applications where multiple genomic loci need to be affected 
simultaneously with different proteins, since the different Cas9 and Cpf1 proteins have their own specific 
guide RNA structures, allowing designs with minimal guide RNA cross recognition 487. Additional benefits may 
include smaller size of the Cas9 proteins, as in the case of Staphylococcus aureus Cas9, allowing the use of 
the system in limited capacity vectors like rAAV 486, or increased thermal stability of the Geobacillus 
stearothermophilus Cas9, which promotes higher stability in vivo and use in higher temperature 
biotechnological applications 488. 
 
6.4.1.3. Guide RNAs 
In bacteria, the CRISPR locus is expressed in a single polycistronic transcript, which is processed into individual 
crRNAs and bind to Cas9 with the tracrRNA 439. Separate crRNA and tracrRNA molecules work in mammalian 
cells but, to mediate more efficient utilisation of this system, the two small RNAs are commonly fused into 
one single guide RNA molecule (sgRNA) with a short hairpin loop 4,455. The guide RNAs are usually expressed 
under ubiquitously expressed Pol III promoters, such as U6 or H1, with specified start nucleotide and 
terminator sequences. Multiplex guide assembly is commonly achieved by Golden Gate cloning, which allows 
rapid concatenation of modular repetitive sequence motifs, such as the guide expression cassettes, into 
single vectors 489–492. Other means for guide concatenation include expression from a single transcript and 
subsequent processing by incorporation of external RNA endonuclease sites 493, tRNA promoters and 
intervening tRNA sequences 494–496, self-cleaving ribozymes 497,498, and intervening miRNA or shRNA 
processing by DROSHA 499,500. On the other hand, the use of Cpf1 allows direct concatenation of the guide 
sequences, due to the intrinsic RNA processing capacity of the enzyme 445, and more straight-forward guide 
multiplexing without intervening sequences or tracrRNA 501–504. Additional guide mediated Cas9 
functionalisation can be achieved by shortening the guide RNA molecules so that the guide 5’ end binding 
dependent Cas9 conformational change does not take place. This prevents the wild type Cas9 from cutting 





6.4.2. CRISPR-Mediated Transcriptional Control 
 
 
Figure 9. Basic principle of CRISPR/Cas9-mediated transcriptional control. Cas9 enzymatic activity is 
deactivated by mutations in the catalytic domains or by truncation of the guide RNA to prevent 
conformational changes required for DNA cleavage. Targeting dCas9 downstream of transcription start site 
can be used to interfere with transcription machinery. Fusion of dCas9 with repressive domains can be used 
to epigenetically silence target genes. Fusion of dCas9 with transactivation domains can be used to 
epigenetically open target regions or to recruit RNA polymerase II to activate gene transcription. 
 
Cas9 or Cpf1 proteins, which lack DNA cutting activity, can be used for transcriptional control of genes. In its 
simplest form dCas9 recruited downstream of the transcription start site or in core promoter elements can 
be used to interfere with transcriptional elongation or RNA polymerase binding to reduce gene expression 
507. In the case of RNA elongation interference downstream of the TSS, the dCas9 protein needs to be targeted 
to the non-template DNA strand for proper inhibition, possibly due to more efficient physical interference 
with the polymerase. Various activator and inhibitor domain fused dCas9 constructs can also be used to 
control transcription in bacteria and in eukaryotes 508–514. The most commonly used effector domains for gene 
regulation are Krüppel-associated box (KRAB) domains for gene repression and NF-kappa B p65 subunit trans-
activation domain and multimeric repeats of the acidic activator peptide of the HSV1 VP16 trans-activator 
protein for gene activation 509,515. These domains help recruit effector complexes to the dCas9 bound region. 
These are either repressive complexes, in case of KRAB, or various activator complexes, including basal 
transcription machinery and histone acetyl transferases, in case of p65 and VP16. dCas9 activators help 
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recruit the RNA Pol II to the gene promoter and to initiate transcription if the guide RNAs are targeted 
upstream of the TSS. Generally, recruiting multiple guides to a promoter or increasing the number of repeats 
of the trans-activator domains appears to increase gene activation potential 510–513. The most drastic 
examples of multiple trans-activation domain recruitment to the dCas9 protein have been demonstrated by 
using multimeric peptide tags, such as SunTag, utilizing GCN4 antibody-peptide pair, or GFP11, utilizing the 
pairing of the 11th strand of the GFP -barrel and the non-fluorescent GFP1-10 fragment 516,517. In addition to 
fusing the activator domain directly with the Cas9 protein, the domain can be linked to a protein motif 
recognizing an RNA aptamer incorporated into the guide RNA molecule 513,518,519. The benefit of this system 
is that by including multiple aptamers in the RNA, multiple activator domains can be recruited to one dCas9 
RNP complex 518. Additionally, various aptamer sequences, recognized by different protein motifs, can be 
used to define guide specific trans-activation effects without changing the dCas9 protein core 520. 
Recruitment of multiple different trans-activation domains to the Cas9 protein can also help in improving the 
activation potential of dCas9 effectors. This has been reported either by recruiting P65 and the heat shock 
factor 1 (HSF1) transactivation domain to guide RNA aptamers by the MS2 motif 518, or by direct fusion of the 
p65 and the viral Rta transactivation domain to a dCas9VP64 core 521. These transactivation domains are 
generally highly potent in endogenous gene activation and can even be used with single guide RNAs targeted 
per promoter. However, they appear to hit an efficiency threshold, as recruitment of multimeric repeats of 
these domains does not appear to further enhance their gene activation potential 522. Basic principle of 




6.4.2.1. Inducible CRISPR Systems 
 
 
Figure 10. Summary of inducible CRISPR systems. 
 
To gain more control over the activity of the CRISPR genome editing and transcriptional regulation, various 
inducible systems have been developed 523. These systems can work either by controlling the Cas9/Cpf1 
protein component or the guide RNAs. The simplest systems use inducible promoters to control the 
expression of the CRISPR transcripts. A commonly used method is to put the Cas9 protein under a doxycycline 
inducible promoter and insertion into the AAVS1 locus, alongside constantly expressed reverse tetracycline 
trans-activator 524,525. Inducible guide RNAs can be engineered by incorporating ligand-responsive 
riboswitches into the guide RNA sequence. These systems rely on an antisense oligo sequence in the guide 
RNA that inhibits the guide binding to its DNA target site in the off-state. After ligand binding to the RNA 
aptamer, the molecule goes through either a cleavage or a conformational change that removes the 
antisense oligo binding to the guide sequence and releases the guide to bind to its target DNA. Riboswitch 
guide constructs have been reported for both Cas9 526–528, and Cpf1 systems 529, with various input ligands, 
such as small molecular compounds and signalling factors. Protein mediated control of CRISPR/Cas9 activity 
can be achieved using multiple different means, including conditional degron fusions, induced proximity, 
inducible conformational changes, and subcellular localization control. These systems also use various 
different activating components, like external and cell intrinsic proteins, small molecular compounds and 
64 
 
light, enabling complex multimodal control over gene editing and transcriptional regulation 530. Reported 
induced proximity methods have utilised, for example, rapamycin or blue light inducible split Cas9 
architecture for genome editing 531,532. For transcriptional and epigenetic control, light, abscisic acid, 
gibberellin or rapamycin have been used to induce binding of effector domains to dCas9 533–537. Inducible 
degrons rely either on default degradation and inducible stabilisation or inducible degradation of Cas9 or the 
activator domain. CRISPR/Cas9 systems utilising the inducible degradation approach have been reported with 
auxin, trimethoprim, tamoxifen and Shield-1 inducible systems 520,538,539. Inducible conformational changes 
have been utilised with tamoxifen controllable allosteric changes and intein splicing 540,541, light inducible 
conformational changes 542, and chemically inducible interference of Cas9 intramolecular autoinhibition 543. 
Subcellular localisation of Cas9 or split Cas9 has been controlled by ERT2 fusions and tamoxifen inducible 
nuclear import 544,545, and by glucocorticoid receptor fusion 546. In addition to the external light and small 
molecular inducers, Cas9 and Cpf1 systems that are inducible by synthetic receptor interactions and signalling 
factor binding guide aptamers can be used to control the system activity in response to the cellular 
microenvironment 527,529,547–549. Inducible CRISPR systems are summarised in Figure 10. 
 
6.4.3. CRISPR-mediated Epigenome Editing 
In addition to directly affecting gene transcription from promoters, the reprogrammable genome targeting 
tools have also been applied for modifying the epigenetic state of targeted loci 514. This is commonly done 
either by fusing an interaction domain with dCas9 that can recruit chromatin modifying enzymes or by 
directly fusing the catalytically active domain of these enzymes to the dCas9. For example, the fusion of P300 
catalytically active domain with dCas9 has been shown to affect target site H3K27 acetylation and activate 
genes from enhancers 550, and the fusion of dCas9 with human HDAC3 has been demonstrated to reduce 
H3K27 acetylation at its target sites 551. Additionally, dCas9 fusion with the catalytic domain of the LSD1 
histone demethylase has been demonstrated to cause enhancer position specific histone modifications and 
transcriptional changes that differ from those caused by the commonly used KRAB repressive domain 552. 
Fusion of dCas9 with catalytic domains of DNA modifying enzymes have also been described for editing DNA 
methylation status. Particularly, DNMT3a catalytic domain fusion with dCas9 can mediate de novo 
methylation of CpG sites 553,554, and TET1 catalytic domain fusion with dCas9, or in combination with the 
SunTag system, can mediate targeted DNA demethylation 554,555. 
In addition to dCas9 fused with effector domains, the Cas9 binding itself can cause changes in the local 
chromatin structure at the target site. The binding of the dCas9 protein in nucleosomal DNA can open the 
chromatin next to the dCas9 target site and promote binding of transcription factors to the target site 
proximal regions up to 100 bp form the guide binding site 556. The effect can also be utilized to improve 
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specificity of DNA editing by promoting SpdCas9 mediated local chromatin opening in combination with Cas9 
and Cpf1 orthologues, which by default target nucleosomal DNA with low efficiency 557. 
 
6.4.4. CRISPR-mediated Control of Cell Fate 
Due to the fact that CRISPR-mediated transcriptional control targets endogenous genes for activation or 
inhibition, the system appears useful for cell type conversions, such as reprogramming, where stable changes 
in endogenous gene expression programs are required. CRISPR-mediated endogenous gene targeting may 
help overcome reprogramming barriers, for example by directly targeting genomic loci which are normally 
not efficiently targeted by limited sets of reprogramming factors, or by targeting gene control regions that 
help maintain gene expression, such as enhancers. Additionally, as the CRISPR system relies on short gRNA 
molecules for defining the Cas9 binding sites, the system has a high gene targeting capacity with relatively 
small constructs. This means that instead of optimising gene regulatory network targeting for a minimal set 
of reprogramming factors, the targeting can be done with a more comprehensive approach aimed at 
maximising the number of targeted genes. The easy programmability of the Cas9 targeting allows the use of 
the CRISPR system for many types of cell fate control approaches, including reprogramming, 
transdifferentiation and differentiation. So far CRISPR-mediated transcriptional control has been used to 
mediate differentiation of cells towards neural lineages 521, endodermal lineages 558, and adipocyte-like cells 
559, transdifferentiation of mouse embryonic fibroblasts towards myocytes 560, and neurons 561, and 
conversion of mouse hepatic cells towards pancreas by Pdx1 activation in vivo 562. In pluripotent 
reprogramming context, CRISPR-mediated gene activation has been used for activation of pluripotent 
reprogramming factors in human fibroblasts 563, conversion of human PSCs to naïve state by NANOG 
activation 525, and replacement of transgenic Oct4 in mouse pluripotent reprogramming by enhancer 
targeted dCas9 activators 564. The reprogramming of mouse fibroblasts to pluripotency was also recently 
demonstrated by endogenous Oct4 and Sox2 activation by CRISPRa 565. The mouse reprogramming process 
was shown to be improved by a cocktail of small molecular compounds, demonstrating the potential in 
combining targeted epigenome editing with additional reprogramming enhancing approaches. However, 
replication of transgenic transcription factor mediated cell type conversions with CRISPR-mediated gene 
activation have so far only been limited, and the methods thereof need to be further developed for robust 




6.5. Transposable Elements in Human Genome 
A major portion of human genome consists of transposable elements (TE). These are generally divided into 
DNA transposons, LTR retrotransposons, or endogenous retroviruses, and non-LTR retrotransposons 
including long interspersed nuclear elements (LINE) and short interspersed nuclear elements (SINE) 566. 
Majority of human TEs have lost their capacity to actively transpose, but some elements, such as some HERV-
K and LINE-1 copies, may still actively move 566. Therefore, it is important for a cell to control the transposition 
of mobile elements, to limit the insertional mutagenesis caused by TE integrations. Cells thus employ a large 
set of KRAB zinc-finger proteins and other factors to target endogenous TEs and to control their expression 
347,567. In addition to direct insertional mutations, integration of TEs near genes may affect the expression of 
the associated genes and result in rewiring of gene regulatory networks, for example by providing new 
enhancer elements, alternative promoters or mRNA splice sites. Integration of new TEs and exaptation of 
ancestral TEs by point mutations can contribute to evolutionary adaptation and the species specific 
differences in transcriptional networks 568. It has been reported that only a minority of OCT4 and NANOG 
binding sites occur in homologous sites between mouse and human pluripotent stem cells and that TEs 
contribute to a large fraction of the binding sites of these factors 569. 
 
6.5.1. Expression of Transposable Elements in Development, Pluripotency and 
Reprogramming 
Early development mammalian embryos express distinct classes of transposable elements. Some of the 
proteins important for the early embryo development, such as the trophoblast expressed Syncytin, are 
originally of viral origin 570, and it has been reported that human embryos can even produce virus-like 
particles from endogenous retroviral sequences 571. The role of transposable element expression in early 
embryo development is not fully clear, but mouse embryo experiments suggest a role for some TEs in 
promoting global chromatin opening in embryonic genome activation 572,573. The expression of transposable 
elements in embryo development is dynamically regulated and early embryonic cells show distinct cell type 
specific and temporal patterns of transposable element expression 574. The dynamic pattern of TE expression 
in embryos can be used to distinguish various pluripotent states in cell culture, likely reflecting the differences 
in expression of the factors targeting the TEs. For example, the blastocyst expressed HERVH derived LTR7 
promoter has been used to distinguish naïve-like pluripotent cell populations 198,574, although contradicting 
results have later been reported 575, possibly reflecting differences in the various human naïve states. In 
mouse pluripotent stem cells, the early embryo expressed MERVL LTR, which is activated by DUX protein, 
has been used to mark rare sub populations of cultured cells that are capable of chimeric contribution into 
both embryonic and extraembryonic tissues 14,576. Overall, due to the high number and differential expression 
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of transposable elements in pluripotent cells, their expression pattern has been suggested as a method to 
characterise alternative pluripotent states 575. 
In reprogramming, transposable elements have been reported to lose their repressed status resulting in 
transient activation of TE expression 577. This appears to also affect the expression of TE associated genes, 
indicative of promoter or enhancer-like effect of the elements in the process 577. Many of the transiently 
activated TEs are later re-silenced in the fully reprogrammed pluripotent cell populations, possibly due to re-
activation of the TE targeting factors, such as the KRAB-ZFPs. The role of the TE activation in the 
reprogramming process is not fully understood, however, it has been reported that knock down of the HERV-
H LTR7 transcript negatively affects reprogramming and greatly reduces reprogramming efficiency 199. The 
same LTR7 expression, along with KLF4, has also been implicated in the differentiation defective phenotype 
of human iPSCs, and therefore the proper silencing of these elements may be required for stable pluripotency 
196. Additionally, retroelement re-activation during reprogramming has been reported to result in 
retrotransposition of endogenous Alu- and L1-elements 578. The activation of transposable elements during 
the reprogramming process may thus additionally contribute to mutations occurring in reprogramming. 
As our ability to target genomic elements in a sequence specific manner has been rapidly increasing following 
the developments in the CRISPR field, we will be able to study the contribution of the endogenous 
transposable elements to various cellular processes in more detail. 
 
6.5.2. Alu Elements 
Alu elements are among the most abundant human SINE sequences, with more than one million copies in 
the human genome. Alus were initially described as AluI restriction enzyme recognition site containing repeat 
sequences in renatured human DNA 579. Alu monomers, and the related B1 sequence precursors in mouse, 
were originally derived from the 7SL RNA by deletion of a central 7SL-specific sequence approximately 90 
million years ago 580,581. The full length Alu sequence consists of two similar but distinct Alu monomers that 
have been fused in a head-to-tail orientation, resulting in an approximately 300 bp transposable element 
sequence 582. The origin and amplification of Alu sequences happened within the past 65 million years in 
primates with majority of the Alu amplification occurring over 40 million years ago 583. 
Alu elements have been implicated in various forms of gene expression regulation, including alternative 
splicing, RNA editing and translational control 584. Alu genomic distribution is biased and Alu sequences are 
found enriched in genome topological boundary regions and near upstream regions and downstream intronic 
regions of specific classes of genes 585,586. Functionally some Alu and B1 elements have been implicated in 
genomic insulation 587,588. Particularly, a specific set of B1 elements have been reported to exhibit an AHR and 
SLUG mediated transcriptional activation dependent chromatin insulation by recruitment of PARP1 and CTCF 
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to the transcribed element 588. Alu sequences have also been described to have proto-enhance-like histone 
modification patterns and preferential interactions with gene transcription start sites, suggesting a direct 
role for Alu elements in transcriptional control 589. This is also implicated by TFIIIC and Alu sequence mediated 
recruitment of activated genes to transcription factories, and Pol III transcribed Alus having active enhancer 
function in specific neural genes 590,591. Alu elements also contain many binding sites for various transcription 
factors 592,593. Particularly, Alu sequences have been reported to bind YY1, which may link Alus to chromatin 
architectural features required for gene transcription control 594. 
Alu sequences have been reported to be enriched near the first genes expressed at human embryo genome 
activation and near pluripotent state specific genes 595,596. Alu elements also contain binding sites for many 
early embryo expressed factors, like totipotent cell PRD-like factors 597,598, HNF4 599, AHR 600, and retinoic 
acid receptors 601. It is therefore possible, that Alu sequences may function in controlling the acquisition of 
pluripotent state or differentiation. However, the impact of these elements on pluripotent reprogramming 
is currently unknown. Schematic representation of Alu element structure and selected transcription factor 
binding sites are presented in Figure 11. 
 
 
Figure 11. Structure of Alu elements. Alu element consensus sequences contain two head-to-tail fused 
monomers. Left Alu arm contains Pol III promoter core motifs and binding sites for many early embryo 
expressed factors. A and B boxes are Pol III promoter core domains binding TFIIIC. TFIIIC = Transcription factor 
for polymerase III C, AHR = Aryl hydrocarbon receptor, RAR = Retinoic acid receptor, PRDL = PAIRED (PRD)-like 





7. Aims of the Study 
 
Induction of pluripotency has been intensively studied during the past decade since its discovery. Although 
the process is generally robust, it can often result in suboptimal reprogramming outcomes. The general aim 
of this thesis was to investigate factors limiting pluripotent reprogramming and to develop new approaches 
to improve the outcome of the reprogramming process. 
 
The specific aims of this thesis were: 
 
1) To investigate the use of AAV as an episomal transgene delivery vector to produce integration-free 
induced pluripotent stem cells. 
 
2) To investigate the impact of age and passaging on pluripotent reprogramming efficiency. 
 
3) To develop the CRISPR gene activation system for targeting multiple endogenous genes as a tool for 





8. Materials and Methods 
 
8.1. Ethics Statement 
The generation and use of human induced pluripotent stem cell lines used in this study was approved by the 
Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District (nr. 423/13/03/00/08). 
 
8.2. Cell Culture 
Human skin fibroblasts, mouse embryonic fibroblasts, HEK239 and HEK239T cells were cultured in fibroblast 
medium consisting of Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 2 mM GlutaMAX, and 100 µl/ml penicillin-streptomycin. 
HEK293GPG cells, used for VSV-G pseudotyped -retrovirus production, were cultured in fibroblast medium 
supplemented with 2 mg/ml Puromycin, 6 mg/ml G418 and 1 µg/ml Tetracycline to repress viral protein 
expression. For retrovirus production, antibiotics were removed from the culture medium. 
Mouse iPSCs (I) were cultured on mitomycin-C treated mouse embryonic fibroblast (MEF) feeders in mES 
medium consisting of KnockOut high-glucose DMEM (at 4,500 mg/l) supplemented with 1 mM sodium 
pyruvate, 15% FBS, 2 mM GlutaMAX, 0.10 mM non-essential amino acids (NEAA), 0.1 mM -
mercaptoethanol, and leukemia inhibitory factor (LIF). Mouse iPSC were split using TrypLE Select. 
Human iPSCs (I, II, III and IV) were cultured on Matrigel coated cell culture plates in either MEF-conditioned 
hES medium consisting of KnockOut DMEM supplemented with 20% KO serum replacement, 2mM 
GlutaMAX, 0.1 mM-mercaptoethanol, 1% NEAA, and 6 ng/ml basic fibroblast growth factor (bFGF) (I), or 
on mitomycin-C treated MEF feeders in hES medium (I) or on Matrigel coated plates in E8 medium (II, III, IV). 
Cells cultured in hES medium (I) were split by combination of collagenase IV and mechanic dissociation, and 
cell cultured in E8 medium (II ,III, IV) were split by dissociation with 0.5 mM EDTA. 
All cell lines were cultured in an incubator at +37°C and 5% CO2. 
 
8.3. AAV Reprogramming (I) 
Recombinant Adeno-associated viruses were produced at the Biomedicum AAV Gene Transfer and Cell 
Therapy Core Facility as described by Zolotukhin et al. 602. Briefly, three 15 cm dishes per factor of HEK293T 
cells were transfected with three parts pDG plasmid, encoding AAV2 capsid proteins, and one part pSub-
CMV-WPRE or pSubCAG-WPRE plasmid containing the reprogramming transgenes. 34.5 µg of plasmid was 
used per plate and transfection was performed using JetPEI transfection reagent. Two days later cells were 
collected and lysed to release virus particles by three freeze-thaw cycles, DNAse treatment and 
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centrifugation. Viruses were purified from supernatant by iodixanol gradient ultracentrifugation, and virus 
amounts were quantified by qPCR. 
For human foreskin fibroblast (HFF; ATCC, CRL-2429) reprogramming attempts with rAAV2, cells were seeded 
on 6-well plates in fibroblast medium, 100 000 cells per well, and infected with Yamanaka factor encoding 
rAAV2 viruses 1 to 4 times every second day. On day four cells were split on mitomycin-C treated MEF feeders 
or Matrigel coated wells and medium was changed to hES medium. Cell culture medium was changed every 
second day. 
For mouse embryonic fibroblast reprogramming with rAAV2, cells were seeded on 6-well plates in fibroblast 
medium, 100 000 cells per well, and infected with Yamanaka factor encoding rAAV2 viruses 1 to 3 times every 
second day with multiplicity of infection (MOI) between 20 000 and 200 000 viral genomes per cell per factor. 
On day four cells were split on gelatin coated cell culture plates and medium was changed to mES medium. 
Emerging colonies were picked manually onto mitomycin-C treated MEF feeders in mES medium. 
 
8.4. Retroviral Reprogramming (II) 
VSV-G pseudotyped -retroviruses were produced by transfecting approximately 90% confluent 6-well plate 
wells of HEK293GPG cells with 3µg of pMXs plasmids encoding Yamanaka factors using FuGENE HD reagent. 
Cells were transfected twice to ensure robust transfection. After second transfection cell culture medium 
was changed to remove antibiotics and allow virus production. Virus containing media were collected 4, 5 
and 6 days after first transfection, pooled and filtered through 0.45 µm syringe filters. Fibroblasts were 
seeded on 6-well plates at 100 000 cells per well on day 4 of virus production. Fibroblasts were transduced 
with the viruses on days 5 and 6 overnight, with 1:1 mixture of virus medium and fresh fibroblast medium. 
Cells were split 3 days after the first virus transduction onto Matrigel coated plates and cell culture medium 
was changed to hES medium or E6 medium supplemented with 0.25 mM sodium butyrate. Emerging colonies 
were manually picked on Matrigel coated cell culture dishes in E8 medium (Life Technologies). 
 
8.5. Sendai Viral Reprogramming (II) 
Sendai viral reprogramming was performed using CytoTune Sendai viral reprogramming kit (Life 
Technologies). Briefly, 100 000 fibroblasts were infected with a MOI of 3 in fibroblast medium. Five to seven 
days later cells were split on Matrigel coated dishes and cell culture medium was changed to E6 medium (Life 
Technologies) supplemented with 0.25 mM sodium butyrate. Emerging colonies were manually picked on 




8.6. Episomal CRISPRa Reprogramming (III, IV) 
For episomal plasmid reprogramming human fibroblasts were dissociated with TrypLE into single cell solution 
and eletroporated with Neon transfection system (Thermo Fisher) using 100µl tips, 1 million cells, 6 µg total 
DNA amount and 1650 V, 10 ms and 3 x pulse settings. For OCT4 replacement with dCas9 activator (III), 1.5 
µg of each pCXLE-dCas9VP192-GFP-shP53 (Addgene plasmid #69535), GG-EBNA-OCT4 (Addgene plasmid 
#69537), pCXLE-hSK (Addgene plasmid #27078) and pCXLE-hUL (Addgene plasmid #27080) were used. For 
full CRISPRa reprogramming with episomal plasmids (IV), 2 µg of dCas9 activator plasmid and 4 µg of guide 
RNA plasmids were used. Electroporated cells were plated on gelatin coated plates and split onto Matrigel 
coated 10 cm dishes on day six (III) or directly plated on Matrigel coated dishes in fibroblast medium (IV). 
After four days cell culture medium was changed to mixture of fibroblast medium and hES medium 
supplemented with 0.25 mM sodium butyrate. Emerging colonies were manually picked on Matrigel coated 
24-well plate wells in E8 medium. 
 
8.7. Transposon CRISPRa Reprogramming (IV) 
For transposon CRISPRa reprogramming human fibroblasts were electroporated as described for episomal 
reprogramming, but with PiggyBac transposon plasmids and 3.5 µg total DNA amount. Plasmids used were 1 
µg PB-tight-DDdCas9VP192-GFP-IRES-Neo, 1 µg PB-CAG-rtTAM2-IN, 1 µg PB-EEA-5g-OSK2M2L1-PGK-Puro and 
0.5 µg PiggyBac transposase plasmid per electroporation. Electroporated cells were plated on gelatin coated 
cell culture dishes in fibroblast medium. Four days after electroporation cells were selected with 1 µg/ml 
Puromycin and 0.5 mg/ml G418 for two days after which antibiotic concentrations were halved. To induce 
reprogramming, cells were plated on Matrigel coated dishes in 1:1 mixture of fibroblast medium and hES 
medium supplemented with 0.25 mM sodium butyrate. To induce dCas9 activator expression cell culture 
medium was supplemented with 1 µM trimethoprim (TMP) and 2 µg/ml doxycycline (DOX). Fresh DOX was 
supplemented daily. Emerging colonies were manually picked on Matrigel coated plates in E8 medium 
without TMP and DOX. 
 
8.8. Alkaline Phosphatase Staining (I, II, III, IV) 
Cells were fixed with 4% paraformaldehyde (PFA) for 10 minutes after which cells were washed with 
phosphate buffered saline. After fixation cells were stained with NBT/BCIP solution in 0.1 M Tris HCl pH 9.5, 
0.1 M NaCl, 0.05 M MgCl2 buffer until purple precipitate formed. Reaction was stopped by washing the plates 






For immunocytochemical staining cells were fixed wit 4 % PFA for 30 minutes, permeabilised with 0.2 % 
Triton X-100 in PBS for 15 minutes and blocked with Ultra V Block (Thermo Fisher) for 10 minutes. Thereafter 
cells were incubated in primary antibody containing PBS with 0.1 % Tween 20 overnight in +6 °C with 
indicated primary antibody amounts or for 2 days with halved antibody amounts. Secondary antibody 
staining was done in PBS with 0.1 % Tween 20 for half an hour in room temperature in the presence of 
Hoechst33342. 
 
Table 1. Antibodies used in this work 
Antibody dilution source identifier article use 
LIN28A 1:250 Cell Signaling D84C11 III, IV ICC 
  1:250 Cell Signaling D1A1A IV ICC 
  1:100 Thermo Fisher MA1-016 III ICC 
NANOG 1:250 Cell Signaling D73G4 IV ICC 
  1:100 Thermo Fisher MA1-017 III ICC 
  1:100 Santa Cruz sc-30331 I ICC 
OCT4 1:500 Santa Cruz sc-8628 I, III, IV ICC 
  1:500 Cell Signaling C30A3 II, III ICC 
  1:100 Thermo Fisher MA1-104 III ICC 
  1:1000 Santa Cruz sc-9081 I WB 
SOX2 1:250 Cell Signaling D6D9 III, IV ICC 
  1:200 Millipore ab5603 I ICC 
  1:2500 Millipore ab5603 I WB 
KLF4 1:250 Sigma-Aldrich HPA002926 III, IV ICC 
  1:00 Abcam ab34814 I ICC 
  1:00 Abcam ab34814 I WB 
C-MYC 1:250 Cell Signaling D3N8F IV ICC 
 1:250 Abcam [Y69]ab32072 IV ICC 
 1:25 Santa Cruz (c-33) sc-42 I ICC 
TRA-1-60 1:50 Thermo Fisher MA1-023 II, IV ICC, live 
TRA-1-81 1:100 Thermo Fisher MA1-024 IV ICC 
TUBB3 1:500 R&D Systems MAB1195 IV ICC 
AFP 1:400 Dako A0008 IV ICC 
SMA 1:200 Sigma-Aldrich A2547 IV ICC 
VIMENTIN 1:500 Santa Cruz sc-5565 IV ICC 
SOX17 1:500 R&D Systems AF1924 III, IV ICC 
CDH1 1:500 BD Bioscience 610181 I, III ICC 
FOXA2 1:500 Santa Cruz sc-9187 III ICC 





F55A10 III ICC 
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GATA4 1:500 Santa Cruz sc-1237 III ICC 
MAFA 1:500 Abcam AB26405 III ICC 
SSEA3 1:100 Millipore MAB4303 II ICC 
SSEA1 1:50 Millipore MAB4301 I ICC 
DESMIN 1:50 Santa Cruz sc-14026 I ICC 
donkey anti-goat 1:500 Invitrogen A11055 IV 2nd 
  1:500 Invitrogen A11058 IV 2nd 
donkey anti-mouse 1:500 Invitrogen A21202 IV 2nd 
  1:500 Invitrogen A21203 IV 2nd 
donkey anti-rabbit 1:500 Invitrogen A21206 IV 2nd 
  1:500 Invitrogen A21207 IV 2nd 
ICC: immunocytochemistry, WB: western blot, live: live staining, 2nd; secondary antibody 
 
8.10. Reverse Transcription Polymerase Chain Reaction 
Total RNA was extracted using NucleoSpin RNA kit (Macherey-Nagel) according to manufacturer’s 
instructions. One or two micrograms of denatured RNA were used for cDNA synthesis using 0.5 μL Moloney 
murine leukemia virus (MMLV) reverse transcriptase, 0.2 μL Random Primers, 1 μL Oligo(dT)18 Primer and 
0.5 μL Ribolock RNase inhibitor for 90 min at 37°C. Mouse pluripotency factor RT-PCR (I) was run for 35 cycles 
with 60°C annealing temperature. Quantitative RT-PCR was performed as described by Toivonen et al. 603. 
Human pluripotency factor quantitative RT-PCR (III, IV) were run for 40 cycles with 57°C annealing 
temperature 25 sec extension time and human fibroblast qRT-PCR (II) were run with 60°C annealing 
temperature 30 sec extension time. 
 
Table 2. RT-PCR primers used in this work 
Factor forward reverse species article 
Oct4 TTGGGCTAGAGAAGGATGTG GAGTAGAGTGTGGTGAAGTG mouse I 
Sox2 GAAACGACAGCTGCGGAAA TCTAGTCGGCATCACGGTTTT mouse I 
Klf4 AACATGCCCGGACTTACAAA TTCAAGGGAATCCTGGTCTTC mouse I 
Myc TAACTCGAGGAGGAGCTGGA GCCAAGGTTGTGAGGTTAGG mouse I 
Nanog CTCAGCCTCCAGCAGATGC GGGATAGCTGCAATGGATGC mouse I 
Rex1 TGTCCTCAGGCTGGGTAGTC TGATTTTCCGACGTATGCAA mouse I 
OCT4 (tg) TCCCCCTGTCTCCGTCACCAC GCGGCCCAAAGGGAGATCCG transgene I 
SOX2 (tg) CCTACTCGCAGCAGGGCACC GCGGCCCAAAGGGAGATCCG transgene I 
KLF4 (tg) TAAACACACGGGGCACCGCC GCGGCCCAAAGGGAGATCCG transgene I 
Myc (tg) AAACGACAAGAGGCGGACAC GCGGCCCAAAGGGAGATCCG transgene I 
WPRE TGAGTTTGGACAAACCACAAC TTGTTGTTAACTTGTTTATTGCAGC transgene I 
p16 GTGAGAGTGGCGGGGTC TCGTGCTGATGCTACTGAGG human II 
p21 AGCTGCTCGCTGTCCACT CTGCGTTCACAGGTGTTTCT human II 
p53 TGTTTCCTGACTCAGAGGGG  GAGCGTGCTTTCCACGAC human II 
PUMA CACCTAATTGGGCTCCATCT GACCTCAACGCACAGTACGA human II 
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OCT4 TTGGGCTCGAGAAGGATGTG TCCTCTCGTTGTGCATAGTCG human II, III, IV 
SOX2 GCCCTGCAGTACAACTCCAT TGCCCTGCTGCGAGTAGGA human II, III, IV 
NANOG CTCAGCCTCCAGCAGATGC TAGATTTCATTCTCTGGTTCTGG human II, III, IV 
TDGF1 TCAGAGATGACAGCATTTGGC TTCAGGCAGCAGGTTCTGTTTA human II 
SeV GGATCACTAGGTGATATCGAGC ACCAGACAAGAGTTTAAGAGATATGTATC transgene II 
GAPDH GGTCATCCATGACAACTTTGG TGAGCTTCCCGTTCAGCTC human II 
CYCLOG TCTTGTCAATGGCCAACAGAG GCCCATCTAAATGAGGAGTTG human III, IV 
LIN28 AGGAGACAGGTGCTACAACTG TCTTGGGCTGGGGTGGCAG human III, IV 
KLF4 CCGCTCCATTACCAAG CACGATCGTCTTCCCCTCTT human III, IV 
CDH1 ATGAGTGTCCCCCGGTATCT GGTCAGTATCAGCCGCTTTC human III, IV 
FOXA2 AAGACCTACAGGCGCAGCT CATCTTGTTGGGGCTCTGC  human III, IV 
SOX17 CCGAGTTGAGCAAGATGCTG TGCATGTGCTGCACGCGCA  human III 
GATA4 GAGGAAGGAGCCAGCCTAGCAG CGGGTCCCCCACTCGTCA  human III, IV 
PDX1 AAGTCTACCAAAGCTCACGCG CGTAGGCGCCGCCTGC  human III 
NKX6.1 TATTCGTTGGGGATGACAGAG TGGCCATCTCGGCAGCGTG  human III 
NKX2.2 GAACCCCTTCTACGACAGCA ACCGTGCAGGGAGTACTGAA  human III 
SOX9 ATCAAGACGGAGCAGCTGAG GGCTGTAGTGTGGGAGGTTG  human III 
MAFA GCCAGGTGGAGCAGCTGAA CTTCTCGTATTTCTCCTTGTAC  human III 
GCK CCGCCAAGAAGGAGAAGGTA CTTCTGCATCCGTCTCATCA  human III 
MYC AGCGACTCTGAGGAGGAACA CTCTGACCTTTTGCCAGGAG human IV 
REX1 CGTTTCGTGTGTCCCTTTCAA CCTCTTGTTCATTCTTGTTCGT human IV 
ASCL1 ACTCGTCGGACGAGGGCTCTTA GCACTAAAGATGCAGGTTGTGCGA  human IV 
NEUROG2 ATCCGAGCAGCACTAACACG GCACAGGCCAAAGTCACAG  human IV 
dCas9 AAACAGCAGATTCGCCTGGA TCATCCGCTCGATGAAGCTC transgene IV 
mCherry CCACTACGACGCTGAGGTCAA TCGTTGTGGGAGGTGATGTCC transgene IV 
 
8.11. Embryoid Body Assay 
For mouse embryoid body (EB) assay (I), iPSCs were dissociated with TrypLE and plated on cell culture dishes 
for 30 mins to allow feeders to attach. Thereafter iPSCs were split onto non-adherent cell culture dishes in 
mES medium without LIF. Embryoid bodies were grown in suspension for 14 days after which cells were fixed 
and stained. 
For human embryoid body assay (III, IV), iPSCs were dissociated with EDTA and plated on non-adherent cell 
culture dishes in hES medium without bFGF supplemented with 5µM ROCK inhibitor (Y27632). The next day 
medium was changed to hES without bFGF and without ROCK inhibitor. Embryoid bodies were grown for two 
weeks after which cells were plated on gelatin coated cell culture dishes for a week to allow outgrowth. 




8.12. Guide RNA Design and Production (III, IV) 
Guide RNA sequences were designed using the Zhang lab CRISPR guide design tool (http://crispr.mit.edu/). 
Guides were targeted to sites -400 bp to -50 bp upstream of the transcription start site and selected for 
further testing based on their position and off-target score. Guide RNA expression cassettes were assembled 
in a PCR reaction containing PCR amplified U6 promoter template, tracrRNA and terminator containing 
template and a single stranded guide oligo containing 20 bp overlap with the flanking fragments. PCR reaction 
conditions contained 50 pmol forward and reverse primers, 2 pmol guide oligo, 5 ng U6 and tracrRNA 
fragments and were amplified with Phusion polymerase (Thermo Fisher) in 100 micro litre reaction volume. 
PCR reaction program was 98°C, 10 sec; 52°C, 30 sec; 72°C, 12 sec for 35 cycles. Successful PCR assembly of 
guide cassettes was checked with gel electrophoresis and guides were purified with a column and confirmed 
with sequencing. 
 
Guide RNA assembly reaction: 
5x HF buffer  20 µl   Thermal cycle: 
dNTP (2.5 mM) 8 µl   1x  98°C - 3’ 
gRNA (1uM)  2 µl   35x 98°C - 10’’ 
1aggc Fw (100 uM) 0,5 µl    52°C - 30’’ 
1aggc Rv (100 uM) 0,5 µl    72°C - 12’’ 
Phusion (Thermo Scientific) 1 µl   1x 72°C - 8’ 
U6 prom Tailed (5 ng) x    
Term tailed (5 ng) x 
H2O  x (up to 100 µl) 
Total  100 µl 
 





OCT4 1 GTGGAAAGGACGAAACACCG GGGGGAGAAACTGAGGCGA GTTTTAGAGCTAGAAATAG III, IV 
OCT4 2 GTGGAAAGGACGAAACACCG GGTGGTGGCAATGGTGTCTG GTTTTAGAGCTAGAAATAG III, IV 
OCT4 3 GTGGAAAGGACGAAACACCG GACACAACTGGCGCCCCTCC GTTTTAGAGCTAGAAATAG III, IV 
OCT4 4 GTGGAAAGGACGAAACACCG GGCACAGTGCCAGAGGTCTG GTTTTAGAGCTAGAAATAG III, IV 
OCT4 5 GTGGAAAGGACGAAACACCG TCTGTGGGGGACCTGCACTG GTTTTAGAGCTAGAAATAG III, IV 
SOX2 1 GTGGAAAGGACGAAACACCG TGTAAGGTAAGAGAGGAGAG GTTTTAGAGCTAGAAATAG III, IV 
SOX2 2 GTGGAAAGGACGAAACACCG TTTACCCACTTCCTTCGAAA GTTTTAGAGCTAGAAATAG III, IV 
SOX2 3 GTGGAAAGGACGAAACACCG GTGGCTGGCAGGCTGGCTCT GTTTTAGAGCTAGAAATAG III, IV 
SOX2 4 GTGGAAAGGACGAAACACCG CAAAACCCGGCAGCGAGGCT GTTTTAGAGCTAGAAATAG III, IV 
SOX2 5 GTGGAAAGGACGAAACACCG AGGAGCCGCCGCGCGCTGAT GTTTTAGAGCTAGAAATAG III, IV 
KLF4 1 GTGGAAAGGACGAAACACCG CGAACGTGTCTGCGGGCGCG GTTTTAGAGCTAGAAATAG III, IV 
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KLF4 2 GTGGAAAGGACGAAACACCG TATAAGTAAGGAACGCGCGC GTTTTAGAGCTAGAAATAG III, IV 
KLF4 3 GTGGAAAGGACGAAACACCG GCTGCCATAGCAACGATGGA GTTTTAGAGCTAGAAATAG III, IV 
KLF4 4 GTGGAAAGGACGAAACACCG GTTCGGTCGCTGCGCGACCA GTTTTAGAGCTAGAAATAG III, IV 
KLF4 5 GTGGAAAGGACGAAACACCG TCTTCGCGGGCTTCGAACCC GTTTTAGAGCTAGAAATAG III, IV 
MYC 1 GTGGAAAGGACGAAACACCG CCCTTTATAATGCGAGGGTC GTTTTAGAGCTAGAAATAG IV 
MYC 2 GTGGAAAGGACGAAACACCG TCTCGCTAATCTCCGCCCAC GTTTTAGAGCTAGAAATAG IV 
MYC 3 GTGGAAAGGACGAAACACCG GGTTCCCAAAGCAGAGGGCG GTTTTAGAGCTAGAAATAG IV 
MYC 4 GTGGAAAGGACGAAACACCG AGCTAGAGTGCTCGGCTGCC GTTTTAGAGCTAGAAATAG IV 
MYC 5 GTGGAAAGGACGAAACACCG GCGCGCGTAGTTAATTCATG GTTTTAGAGCTAGAAATAG IV 
LIN28A 1 GTGGAAAGGACGAAACACCG GTGTCAGAGACCGGAGTTGT GTTTTAGAGCTAGAAATAG III, IV 
LIN28A 2 GTGGAAAGGACGAAACACCG CCCATCTCCAGTTGTGCGTG GTTTTAGAGCTAGAAATAG III, IV 
LIN28A 3 GTGGAAAGGACGAAACACCG CGGGGTACTCAAGTCTTCTA GTTTTAGAGCTAGAAATAG III, IV 
LIN28A 4 GTGGAAAGGACGAAACACCG TAATTATCTGCCCGGGGGGT GTTTTAGAGCTAGAAATAG III, IV 
LIN28A 5 GTGGAAAGGACGAAACACCG TCTGATTGGCCAGCGCCGCC GTTTTAGAGCTAGAAATAG III, IV 
NANOG 1 GTGGAAAGGACGAAACACCG TCCCAATTTACTGGGATTAC GTTTTAGAGCTAGAAATAG III, IV 
NANOG 2 GTGGAAAGGACGAAACACCG TGATTTAAAAGTTGGAAACG GTTTTAGAGCTAGAAATAG III, IV 
NANOG 3 GTGGAAAGGACGAAACACCG TCTAGTTCCCCACCTAGTCT GTTTTAGAGCTAGAAATAG III, IV 
NANOG 4 GTGGAAAGGACGAAACACCG GATTAACTGAGAATTCACAA GTTTTAGAGCTAGAAATAG III, IV 
NANOG 5 GTGGAAAGGACGAAACACCG CGCCAGGAGGGGTGGGTCTA GTTTTAGAGCTAGAAATAG III, IV 
EEA 1 GTGGAAAGGACGAAACACCG CCCAGCACTTTGGG GTTTTAGAGCTAGAAATAG IV 
EEA 2 GTGGAAAGGACGAAACACCG AATCCCAGCACTTT GTTTTAGAGCTAGAAATAG IV 
EEA 3 GTGGAAAGGACGAAACACCG GCCTCCCAAAGTGC GTTTTAGAGCTAGAAATAG IV 
EEA 7 GTGGAAAGGACGAAACACCG GCTACTTGGGAGGC GTTTTAGAGCTAGAAATAG IV 
EEA 10 GTGGAAAGGACGAAACACCG GCCTCCCAAGTAGC GTTTTAGAGCTAGAAATAG IV 
TdT 1 GTGGAAAGGACGAAACACCG GAGTTCGAGATCGA GTTTTAGAGCTAGAAATAG IV 
TdT 2 GTGGAAAGGACGAAACACCG TTACGGGGCCGTCG GTTTTAGAGCTAGAAATAG  IV 
TdT 3 GTGGAAAGGACGAAACACCG AGCACGCCGTCGCG GTTTTAGAGCTAGAAATAG  IV 
TdT 4 GTGGAAAGGACGAAACACCG GGCCGCCCCTACGA GTTTTAGAGCTAGAAATAG  IV 
TdT 5 GTGGAAAGGACGAAACACCG CGTGATGAACTTCG GTTTTAGAGCTAGAAATAG  IV 
common ctrl 7 GTGGAAAGGACGAAACACCG GATTTTTAGTAGAGA GTTTTAGAGCTAGAAATAG IV 
common ctrl 8 GTGGAAAGGACGAAACACCG GTGGGAGGCTGAGGC GTTTTAGAGCTAGAAATAG IV 
common ctrl 9 GTGGAAAGGACGAAACACCG GAGTGCTGGGATTAC GTTTTAGAGCTAGAAATAG IV 
common ctrl 10 GTGGAAAGGACGAAACACCG GGTAGCTGGGATTAC GTTTTAGAGCTAGAAATAG IV 
common ctrl 11 GTGGAAAGGACGAAACACCG GCATGTTGGCCAGGC GTTTTAGAGCTAGAAATAG IV 
ASCL1 1 GTGGAAAGGACGAAACACCG CGGGAGAAAGGAACGGGAGG GTTTTAGAGCTAGAAATAG IV 
ASCL1 2 GTGGAAAGGACGAAACACCG AAGAACTTGAAGCAAAGCGC GTTTTAGAGCTAGAAATAG IV 
ASCL1 3 GTGGAAAGGACGAAACACCG TCCAATTTCTAGGGTCACCG GTTTTAGAGCTAGAAATAG IV 
ASCL1 4 GTGGAAAGGACGAAACACCG GTTGTGAGCCGTCCTGTAGG GTTTTAGAGCTAGAAATAG IV 
NGN2 1 GTGGAAAGGACGAAACACCG GGCGGTGGCGGGGGAGGAGG GTTTTAGAGCTAGAAATAG IV 
NGN2 2 GTGGAAAGGACGAAACACCG CAATGAAAAGAATAAGCCAG GTTTTAGAGCTAGAAATAG IV 
NGN2 3 GTGGAAAGGACGAAACACCG GGGAAAGGCGGTGAAGAAAG GTTTTAGAGCTAGAAATAG IV 
NGN2 4 GTGGAAAGGACGAAACACCG CGGAGCTGGCGAAGCCGCAG GTTTTAGAGCTAGAAATAG IV 
GATA4 1 GTGGAAAGGACGAAACACCG ACCTCCAAGGAATCCGGGGC GTTTTAGAGCTAGAAATAG III, IV 
GATA4 2 GTGGAAAGGACGAAACACCG CTCAACTCTCGATCTTGTGT GTTTTAGAGCTAGAAATAG III, IV 
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GATA4 3 GTGGAAAGGACGAAACACCG CAGCGAACCCAATCGACCTC GTTTTAGAGCTAGAAATAG III, IV 
GATA4 4 GTGGAAAGGACGAAACACCG AATGCCCAAGTGCTACCGCC GTTTTAGAGCTAGAAATAG III, IV 
GATA4 5 GTGGAAAGGACGAAACACCG CCTGTGGGAGTCACGTGCAA GTTTTAGAGCTAGAAATAG III, IV 
FOXA2 1 GTGGAAAGGACGAAACACCG AGTGCCGAGCTGCCCCGAGG GTTTTAGAGCTAGAAATAG III, IV 
FOXA2 2 GTGGAAAGGACGAAACACCG CGCGCGGCGCGGGGGCTAGT GTTTTAGAGCTAGAAATAG III, IV 
FOXA2 3 GTGGAAAGGACGAAACACCG TGCGGCACTTGTCCGCTCCG GTTTTAGAGCTAGAAATAG III, IV 
FOXA2 4 GTGGAAAGGACGAAACACCG TATAGCGCGGCGCGCTGGCG GTTTTAGAGCTAGAAATAG III, IV 
FOXA2 5 GTGGAAAGGACGAAACACCG AAATGGGCTGCCCCGGGTCT GTTTTAGAGCTAGAAATAG III, IV 
CDH1 1 GTGGAAAGGACGAAACACCG AGGGTCACCGCGTCTATGCG GTTTTAGAGCTAGAAATAG III, IV 
CDH1 2 GTGGAAAGGACGAAACACCG CAGTGGAATCAGAACCGTGC GTTTTAGAGCTAGAAATAG III, IV 
CDH1 3 GTGGAAAGGACGAAACACCG GTCTTAGTGAGCCACCGGCG GTTTTAGAGCTAGAAATAG III, IV 
CDH1 4 GTGGAAAGGACGAAACACCG TCAGAAAGGGCTTTTACACT GTTTTAGAGCTAGAAATAG III, IV 
CDH1 5 GTGGAAAGGACGAAACACCG GAGACAAGTCGGGGCGGACA GTTTTAGAGCTAGAAATAG III, IV 
REX1 8 GTGGAAAGGACGAAACACCG TAGCAATACAGTCACATTAA GTTTTAGAGCTAGAAATAG IV 
REX1 10 GTGGAAAGGACGAAACACCG CCGGGCAGAGAGTGAACGCG GTTTTAGAGCTAGAAATAG IV 
PDX1 1 GTGGAAAGGACGAAACACCG GCCCCACGTGGTTCAGCCGG GTTTTAGAGCTAGAAATAG III 
PDX1 2 GTGGAAAGGACGAAACACCG GCCTGGCTGGCCGCACTAAG GTTTTAGAGCTAGAAATAG III 
PDX1 3 GTGGAAAGGACGAAACACCG AGCAGGTGCTCGCGGGTACC GTTTTAGAGCTAGAAATAG III 
PDX1 4 GTGGAAAGGACGAAACACCG GTTTGCTGCACACTCCTGAA GTTTTAGAGCTAGAAATAG III 
PDX1 5 GTGGAAAGGACGAAACACCG GTTTTCGTGAGCGCCCATTT GTTTTAGAGCTAGAAATAG III 
NKX6.1 1 GTGGAAAGGACGAAACACCG GTAGCGCACTTTGAACAGCT GTTTTAGAGCTAGAAATAG III 
NKX6.1 2 GTGGAAAGGACGAAACACCG AAACTCTCCGGAGCCAGCCT GTTTTAGAGCTAGAAATAG III 
NKX6.1 3 GTGGAAAGGACGAAACACCG AGGACGCCTTGTGCAGCCCG GTTTTAGAGCTAGAAATAG III 
NKX6.1 4 GTGGAAAGGACGAAACACCG CCGAATCTCCACTTTGAAGT GTTTTAGAGCTAGAAATAG III 
NKX6.1 5 GTGGAAAGGACGAAACACCG GCTCTGCTCTTTCGGTCGCG GTTTTAGAGCTAGAAATAG III 
tetOp 1 GTGGAAAGGACGAAACACCG GTACCTTCTCTATCACTGAT GTTTTAGAGCTAGAAATAG III 
tetOp 2 GTGGAAAGGACGAAACACCG GGACTTCTCTATCACTGATA GTTTTAGAGCTAGAAATAG III 
tetOp 3 GTGGAAAGGACGAAACACCG GGGGAGACGTGCGGCCAGCT GTTTTAGAGCTAGAAATAG III 
 
8.13. Golden Gate Assembly (III, IV) 
 
Golden Gate assembly was performed as described by Cermak et al. 604. For Golden Gate reaction, gRNA 
cassettes were amplified with compatible ends using 1 to 5 aggc forward and reverse primers. PCR amplified 
guide cassettes were concatenated in the Golden Gate reaction into GG-dest backbone (Addgene plasmid 
#69538). Cloning reaction was performed with 150 ng of GG-dest plasmid and 50 ng of each of the guide PCR 
fragments. Reaction was run for 50 cycles of 2 min at 37°C, 5 min at 16°C, followed by enzyme inactivation 





Golden Gate reaction: 
T4 ligase buffer (10x) (Thermo Fisher) 2 µl  Thermal cycle: 
T4 DNA ligase (Thermo Fisher) 1 µl  50x 37°C - 2’ 
Esp3I (Thermo Fisher)  1 µl   16°C - 5’ 
DTT (10mM) (Promega)  2 µl  1x 80°C - 20’ 
guide PCR amplicon (up to 5)  x µl (50 ng of each) 
GG-dest plasmid  x µl (150 ng) 
H2O   x (up to 20 ul) 
Total  20 ul 
 






















































8.14. HEK293 Transfection 
For transfection, HEK293 cells were seeded on gelatin coated 24-well plates 100 000 cells per well. One day 
later cells were transfected with 500 ng of DNA using FuGENE HD reagent. For guide testing 500 ng of dCas9 
activator plasmid was mixed with 100 to 200 ng of guide cassette PCR amplicon before complexing with the 





9. Results and Discussion 
 
9.1. AAV-mediated Reprogramming (I) 
Due to the primarily episomal nature of the rAAV genomes, the system forms a potentially useful tool for 
inducing transgene-free iPSCs. AAVs are also non-pathogenic and non-toxic, which makes the vector 
attractive for pluripotent stem cell induction in the light of potential therapeutic applications. 
 
9.1.1. AAV2 Mediated Gene Transduction Induces Colony Formation (I) 
To test for AAV mediated gene transfer in pluripotent reprogramming, the reprogramming factors OCT4, 
SOX2, KLF4 and c-Myc were cloned into AAV vectors under both CMV and CAG promoters. Out of the tested 
serotypes (AAV2, AAV8 and AAV9) with a GFP control virus, AAV2 virus was found to transduce fibroblasts 
with the highest efficiency (I: Fig. 1a). AAV2 was therefore used for virus production of the reprogramming 
factors and all the reprogramming experiments were done with it. The expression of the transgenes was 
validated by immunocytochemistry and Western blot (I: Fig. S1). 
Human skin fibroblasts and mouse embryonic fibroblasts were transduced with the reprogramming factor 
encoding AAVs with varying multiplicities of infection between 20 and 200 000 viral genomes per cell per 
factor. Colony formation was observed from the transduced fibroblasts, however most of the human 
fibroblast derived colonies had non-iPSC-like morphologies (I: Fig. S2). The factors under a CAG promoter 
induced more robust colony formation than under CMV promoter. This may be due to higher expression of 
the CAG (or CAGG) than CMV promoter in many cells 605. Some of the AAV induced human colonies were 
expanded further and analysed for transgene expression. Particularly OCT4 and c-Myc transgenes were 
persistently expressed in the clones (I: Fig. S2d), indicating that persistent expression of only some of the 
reprogramming factors may have skewed the reprogramming process. This may also be due to problems in 
efficient transgene delivery, due to insufficient transduction efficiency, resulting in too early loss of some of 
the transgenic episomes. As the GFP transduction efficiency was at best 70% with the highest MOI tested (I: 
Fig. 1d), the fraction of cells containing all of the transgenic reprogramming factors may be too low, especially 
if multiple transductions are needed. More efficient AAV serotypes or inclusion of the reprogramming factors 
in fewer multicistronic vectors could help with the factor delivery 350,418. 
 
9.1.2. AAV2 Reprograms Mouse Cells to Pluripotency (I) 
The transduction of MEFs with the CAG driven reprogramming factors resulted in the formation of mouse 
iPSC-like colonies with MOI of 20 000 and 200 000 viral genomes per cell per factor (I: Fig. 1b). In total, 24 of 
the resulting miPSC colonies were propagated further and four of the clones were characterised for 
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pluripotency. These clones stained positive for SSEA-1 and Nanog, showed expression of pluripotent state 
transcription factors by RT-PCR and formed EBs positive for ectodermal, mesodermal and endodermal 
markers, demonstrating their pluripotent characteristics (I: Fig. 2). However, the analysed clones also showed 
persistent expression of the reprogramming transgenes (I: Fig. 2b), which may maintain the pluripotent 
features even if the pluripotent reprogramming may be only partial. Additionally, the persistent transgene 
expression indicates potential integration of the reprogramming factors. 
 
9.1.3. AAV Reprogrammed Mouse iPSCs Contain Integrated Vector Sequences (I) 
The AAV miPSCs were analysed by PCR from genomic DNA and Southern blot to detect potential integration 
of the reprogramming vectors. This demonstrated integration of multiple copies of the reprogramming 
vectors in all of the derived miPSC clones (I: Fig. 3). The fact that miPSC clones contained integrated vector 
sequences is not completely unexpected due to the high MOI required for colony formation and the 
estimated integration frequencies of approximately 0.2-1.0 × 10-3 per infectious vector genome 428. 
Furthermore, the reprogramming process appears to select for clones with the full set of reprogramming 
factors integrated, possibly due to more stable pluripotent state, as all of the analysed miPSC clones 
contained integrations of all of the reprogramming factors. Similar results have also been described by Chen 
et al. who reprogrammed mouse adipose derived mesenchymal stem cells with polycistronic tyrosine mutant 
AAV2 vectors 606. These miPSCs contained up to 3 integrations per clone of the reprogramming vector. Unlike 
the CAG driven reprogramming factors, the CMV driven construct used by Chen et al. ended up silenced in 
the resulting miPSC clones. This is likely a result of differences in the behaviour of the promoters, as CMV 
promoter is known to silence easier in embryonic stem cells than CAG 607. Due to the preferential integration 
of the rAAV delivered vectors in the reprogramming process, the system could be utilised to deliver 
transgenes meant for integration, for example for the generation of secondary reprogrammable inducible 
mouse cell lines under doxycycline-controlled promoter. This could potentially result in more efficient 
reactivation of the transgenes than for example lentiviral transgene delivery, as the rAAV backbone is not 
necessarily targeted to similar extent for silencing by the cells repressive machinery as transgenic retroviral 
elements 347. 
Why do the rAAV vectors integrate with such high frequency in reprogramming? As the genome of rAAV 
vectors is linear DNA before being circularised by the cell’s DNA damage repair machinery, the vectors 
provide suitable substrates for opportunistic integration into existing genomic double strand breakage sites. 
The reprogramming process itself has also been linked with increase in DNA damage 244. Therefore, it is 
possible that the reprogramming process increases the occurrence of genomic DNA DSB sites, providing more 
opportunities for the vectors to integrate. The potentially higher incidences of rAAV integration due to DNA 
DSBs combined with preferential reprogramming of colonies with stable expression of the reprogramming 
82 
 
factors, obviating the need for efficient re-transduction, most likely results in the high occurrence of detected 
vector integrations in rAAV reprogrammed iPSCs. 
 
9.2. The Effect of Aging on Reprogramming Efficiency (II) 
Efficient induction of pluripotency is important for robust generation of iPSC lines. This is particularly 
important for patient specific disease modelling cell lines where the source cell material may be of variable 
origin. To investigate the effect of donor age and time of cells in culture on reprogramming efficiency, we 
reprogrammed skin fibroblasts from 11 donors between 0 and 83 years of age. 
 
9.2.1. Donor Age and Cell Culture Time Correlates Negatively with Reprogramming Efficiency 
(II) 
We first reprogrammed passage 6 fibroblasts of all 11 donors using retroviral delivery of OCT4, SOX2 KLF4 
and c-Myc. The reprogramming efficiency was found to decrease by the age of the donor (II: Fig. 1C). The 
cells also demonstrated increase in doubling time indicative of slower cell proliferation (II: Fig. 2F,G). As the 
retroviral infection is cell proliferation dependent, the efficiency of transgene delivery could be affected by 
the age dependent decrease in proliferation rate. To this end, the subsequent inductions were made using 
Sendai viral delivery of the reprogramming transgenes. Next, the combined effect of both donor age and 
artificial in vitro aging by extended culture time were examined. Both increasing age and passage number 
negatively affected the reprogramming efficiency (II: Fig. 2C,D). The increase in passage number also 
correlated with increase in doubling time (II: Fig. 2F). The high passage samples also demonstrated shortening 
of telomeres indicative of replicative senescence (II: Fig. 2E). 
It is possible that the age-associated decrease in reprogramming efficiency is not caused by high age per se 
but may be caused by secondary age-associated effects like senescence induced changes in cell proliferation. 
A recent paper by Lo Sardo et al. did not detect effect of donor age on reprogramming efficiency of peripheral 
blood mononuclear cells (PBMC) by episomal plasmids 608. The reprogramming of the PBMC population may, 
thus, not be affected to similar extent by age and cell proliferation as fibroblasts. The problem with our 
fibroblast experiments and the blood cell reprogramming by Lo Sardo et al. is the relatively low number of 
donor samples used (11 and 16). It is possible that the trend with age, reprogramming efficiency and 
proliferation could be different if more reprogramming samples were used. This would, however, require 




9.2.2. Decrease in Reprogramming Efficiency is P21 Dependent (II) 
To decipher the mechanism behind the decrease in reprogramming efficiency and cell proliferation, the 
expression of a set of senescence associated markers was evaluated. P21 expression was found to be 
significantly upregulated in later passage samples and to correlate with the age of the fibroblasts (II: Fig. 3A-
C). This suggested increased P21 expression as a causative factor in decreasing the reprogramming efficiency. 
P21 is a well-known factor reducing the reprogramming efficiency. P21 is upregulated as a response to the 
reprogramming induced cellular stress and downregulation of P21 expression can improve reprogramming 
efficiency in a cell proliferation dependent manner 214,239. The effect of P21 on reprogramming efficiency was 
therefore tested with the aged fibroblasts. Knock down of P21 with siRNA transfection resulted in increase 
in reprogramming efficiency of late passage fibroblasts and allowed reprogramming of otherwise refractory 
late passage fibroblasts from old donors (81 and 83 years) (II: Fig. 3G and Fig. S3A,B). Additionally, forced 
overexpression of P21 in early passage young donor fibroblasts blocked cell proliferation and completely 
abrogated colony formation (II: Fig. S3E). This indicated a clear causative role of P21 in the reduction of 
reprogramming efficiency in the old and late passage fibroblasts. 
 
9.2.3. Cell Proliferation in Late Passage Reprogramming 
Cell proliferation rate appears to be a critical defining factor in human fibroblast reprogramming efficiency. 
The detected upregulation of P21 in late passage and aged fibroblasts is likely linked to the detected 
shortening of telomeres in the late passage cells, as P21 upregulation commonly results from telomere 
shortening and dysfunction 609. Knock out of P21 can bypass the telomere shortening induced replicative 
senescence in human fibroblasts 610. It is also possible to immortalise human fibroblasts by overexpression 
of telomerase. This approach also results in formation of cell populations that can reprogram with constant 
efficiency over extended period of time in culture 278. Therefore, when reprogramming aged human 
fibroblasts, it should be considered whether measures should also be taken to target the telomere-P21 axis, 
like overexpression of telomerase, ZSCAN4 or cell cycle promoting kinases 216,611. More in depth 
understanding of mechanisms in alternative cellular reprogramming approaches that are less dependent on 
active proliferation, like SCNT or heterokaryons, could also be beneficial for developing more efficient 
reprogramming methods. For example, the reprogramming of somatic cell nuclei by SCNT can rejuvenate 
telomeres in Telomerase-deficient mice 612. As oocytes contain the full set of factors required for 
reprogramming the epigenome of somatic cell nuclei into totipotent state, SCNT is not as dependent on 
stochastic cell cycle-dependent events that promote acquisition of pluripotent state in transgenic factor 
induced pluripotent reprogramming. Therefore, comprehensive targeting of gene regulatory networks, in a 
manner mimicking the SCNT process, may be beneficial for reprogramming cells in a less stochastic and cell 
proliferation-dependent manner. Whether cell proliferation is required for induction of pluripotency is 
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unclear. As the resulting cell population is normally actively dividing, proliferation will need to be promoted 
in the reprogramming cells. This could maybe be tested by inducing cells into a diapause mimicking state 
207,208. The experiments using heterokaryon formation by cell fusion, which does not required cell division, as 
a reprogramming tool would suggest that active cell proliferation is not absolutely required for 
reprogramming to pluripotency if the factor composition is otherwise optimal 613. 
As CRISPRa-mediated gene targeting has a high multiplexing capacity, this approach may provide useful also 
for reducing the cell cycle dependence of late passage fibroblast reprogramming, by promoting 
comprehensive pluripotency gene activation and reducing the need for stochastic cell cycle-dependent 
reprogramming events. 
 
9.3. CRISPR-mediated Gene Activation as a Reprogramming Tool (III, IV) 
CRISPR-mediated gene activation targets the endogenous gene loci for transcriptional activation. This 
property is likely beneficial for reprogramming applications, where reliable activation of endogenous gene 
regulatory networks is required for faithful recapitulation of target cell phenotypes. Particularly, the 
approach should be useful in transdifferentiation applications as these have been described to commonly 
have issues with either inefficient activation of the target cell gene expression program or incomplete 
silencing of the starting cell program 113. Although CRISPRa is commonly targeted to promoter areas to 
activate gene transcription, it can also be used to target endogenous gene regulatory elements for epigenetic 
editing. This allows targeting of particular loci to improve the specificity of resetting the endogenous gene 
regulatory programs, for example by targeting pluripotency factor binding sites to promote their accessibility. 
In addition to targeting characterised elements, the tool can be used to study the function of uncharacterised 
gene regulatory elements in reprogramming. Therefore, CRISPRa is a highly versatile tool and suitable for 
various reprogramming applications. Additional benefit of using CRISPRa-mediated gene activation for 
reprogramming is the high multiplexing capacity of the system. As the genes are targeted with short RNA 
molecules, the system can be used to maximise the number of targeted reprogramming factors, making it 
easier to promote cooperativity of these factors in the reprogramming process. 
 
9.3.1. CRISPRa Promotes Activation of Pluripotent Reprogramming Factors (III, IV) 
The development of a CRISPRa reprogramming system was initiated by building catalytically deactivated Cas9 
activator constructs by fusion of the dCas9 with various numbers of VP16 acidic activator peptide repeats (III: 
Fig. 1A). These were tested in the activation of endogenous OCT4 locus by targeting the dCas9 activator 
constructs to the OCT4 promoter proximal sequences. An increase in the transcriptional output of OCT4 
correlated with the increasing numbers of the VP16 repeats (III: Fig. 1B,C). This approach was also applied to 
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other pluripotent reprogramming factors, which could all be activated to various extent (III: Fig. 1E-G). The 
pluripotency factor promoter guide composition was further optimised by testing each guide separately and 
incorporating the best working guides into one vector for easier delivery into cells (IV: Fig. 2b,c). These guides 
were tested in HEK293 with dCas9VPH activator, containing additional P65-HSF1 activator domains in 
addition to the VP16 peptides, and found to mediate efficient activation of the canonical reprogramming 
factors (IV: Fig. 2d). In HFFs these guides mediated efficient activation of OCT4 and SOX2, whereas KLF4, MYC 
and LIN28A demonstrated poor activation (IV: Fig. 2d). The targeting of the gene promoters with pools of 
five guides was more efficient in activating the genes than any single guides (IV: Fig. 2b), similarly to what 
has been previously described 510–513. This demonstrated that CRISPRa can be used to efficiently target human 
pluripotency factors for transcriptional activation and that the reprogramming factor targeting guides can be 
combined for multiplexed targeting of the reprogramming factors genes with simpler vector constructs. 
 
9.3.2. CRISPRa Replaces Transgenic OCT4 in Reprogramming (III, IV) 
To test if the gene activation level was sufficient to have a practical impact on reprogramming, we replaced 
the transgenic OCT4 encoding plasmid in the episomal reprogramming of human fibroblasts with a 
dCas9VP192 (12 × VP16 activator peptide repeat) encoding plasmid and another plasmid containing five 
OCT4 promoter targeting guides. This resulted in efficient activation of the endogenous OCT4 transcription, 
which was sufficient for successful reprogramming of both neonatal and adult human skin fibroblasts with 
transgenic SOX2, KLF4, L-MYC, LIN28A and CRISPRa-mediated OCT4 activation (III: Fig. 2D-H and Fig. S2). 
Reprogramming of iPSC-derived neural stem cells (NSC) to pluripotency was also possible with dCas9 
activator-mediated targeting of OCT4 promoter (IV: Fig. 1), similar to what has been described for transgenic 
OCT4 overexpression 163. This demonstrated that full CRISPRa reprogramming of human cells was possible by 
OCT4 activation from specific cell populations. NSCs are developmentally close to pluripotent state and can 
be reprogrammed easier than more distant somatic cell types, the reprogramming of skin fibroblasts would 
thus be expected to require activation of additional reprogramming factors. 
 
9.3.3. Guide Optimization Promotes Full CRISPRa Reprogramming (IV) 
Our initial attempts at reprogramming human skin fibroblasts with CRISPRa were unsuccessful with 
combination of vectors targeting OCT4, SOX2, KLF4, LIN28A and NANOG for activation with plasmids 
encoding five guides per gene promoter. As the problem may have been in any of the components of the 
gene activation system, i.e. inefficient dCas9 activator or guide composition, we tried to improve all the 
possible aspects of the system. Particularly, novel dCas9 activator constructs were built, containing additional 
P65-HSF1 and P300 core domains 518,550, to try and improve the gene activation efficiency. Reprogramming 
factor targeting guide composition was also optimized to include only one to three of the best performing 
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guides per gene (IV: Fig. 2c). The activator was targeted to OCT4, SOX2, KLF4, LIN28A and MYC promoters, 
and an EGA enriched Alu-motif (EEA-motif) (IV: Fig. 1d), commonly found near the early human embryo 
genome activation expressed gene promoters 595. The combination of all these modifications resulted in the 
formation of the first CRISPRa-induced iPSC colonies. 
Once the CRISPRa reprogramming was initially established as a method for human fibroblast reprogramming, 
the effect of each of the separate components on the reprogramming efficiency was further analysed. 
The reprogramming efficiency was found to be the highest with the dCas9VP192 activator (IV: Fig. 3g). This 
was unexpected, as the reprogramming efficiency should generally increase upon higher reprogramming 
factor expression levels, and the more complex activator domains would be expected to promote more 
efficient target gene activation. Particularly, the VP192-P300 core fusion activation domain showed more 
efficient activation of OCT4 (IV: Fig. S4c). It is possible that the enzymatic modifications mediated by the P300 
core domain may have some detrimental global effect on the cells, as suggested by increase in histone 3 tail 
acetylation by the VP192-P300 construct (IV: Fig. S4e,f). Alternatively, detrimental local epigenetic effects in 
the promoter proximal areas of the genes targeted may be affecting the gene activation. To decipher what 
is happening at the targeted areas, the starting cell epigenetic status would need to be correlated with the 
epigenetic status of the areas at the target cell type, and the effect of the activation domains to the targeted 
areas would need to be analysed. Additionally, the endogenous loci may be targeted by the endogenous 
somatic cell factors, which may interfere with the artificial activation of the sites, for example by repressing 
the genes intended for activation. Initiating the reprogramming process can further cause stress to the cells, 
which normally results in reduction of cell proliferation by P53 and P21 mediated pathway. This may also 
result in downregulation of the endogenous MYC levels by P53 614,615. The interaction of the targeted genes, 
the somatic cell transcriptional machinery and the epigenetic state of the targeted genes may thus need to 
be taken into consideration when designing optimal CRISPRa-based reprogramming schemes. 
The guide composition included in the first successful CRISPRa pluripotent reprogramming scheme included 
only one guide each for MYC and KLF4. The activation of these two genes was inefficient in HFFs, possibly 
due to already high expression in the starting cells (IV: Fig. 2d). Therefore, the addition of an extra plasmid 
with KLF4 and MYC guides, and a second reprogramming factor containing plasmid with two LIN28A guides 
changed to KLF4 and MYC guides were tested for reprogramming. Both of these approaches worked better 
than the initial reprogramming guide plasmid (IV: Fig. S5), indicating that efficient KLF4 and MYC activation 
may be a limiting step in the CRISPRa-mediated reprogramming. As the number of possible guide 
combinations for gene activation in reprogramming is very large, it may be more practical for the near future 
to select the best functioning CRISPRa reprogramming guides functionally by library screening rather than try 




The inclusion of EEA-motif targeting guides was crucial for the efficient reprogramming with the CRISPRa 
method. The inclusion of these guides in the reprogramming cocktail increased the CRISPRa reprogramming 
efficiency of neonatal human skin fibroblasts by ten to thirty fold (IV: Fig. 3g), and was required for the 
reprogramming of the tested adult skin fibroblasts. Our initial hypothesis was that since this motif was 
enriched near the early embryo expressed genes, it would function upstream of the acquisition of pluripotent 
phenotype in the embryonic cells. However, it is not yet clear whether this is a mechanism that contributes 
to the effect of the EEA-motif targeting in the CRISPRa-mediated pluripotent reprogramming. 
 
9.3.4. Conserved Alu-motif Targeting Promotes Pluripotency Factor Activation (IV) 
To gain insight into the function of the EEA-motif targeting in CRISPRa reprogramming, we did RNA 
sequencing of the CRISPRa reprogramming cell populations with and without the EEA-motif targeting guides. 
This revealed EEA-motif targeting dependent set of genes at the early half of reprogramming (IV: Fig. 4d), 
and pluripotency associated set of genes at the latest time point (IV: Fig. 4c), which was dependent on both 
reprogramming factor targeting guides and EEA-motif targeting guides. The set of genes higher expressed at 
the early time point samples in an EEA-motif guide dependent manner also had EEA-guide 1 target sites 
enriched in their proximal sequences, indicative of a direct activation effect in an EEA-guide target dependent 
manner. This set did not contain any clear pluripotency associated factors and may therefore be more 
dependent on the combined function of EEA-motif targeting guides and somatic factors. The later time point 
samples did not show similar enrichment for EEA-motif targeting guides. Therefore, the later time point 
target genes are likely to be more prominently affected by the reprogramming process and possibly aided by 
the EEA-motif targeting. Alu and B1 sequences have, however, been reported to be enriched near 
pluripotency factor promoters 596, which may contribute to the EEA-motif targeting effect. It is possible that 
this effect is not detected in the RNA sample pools due to fibroblast background and possible transient effect 
of the EEA-motif targeting. 
To determine if the late stage upregulated reprogramming factor guide and EEA-motif guide dependent 
genes had a role in the EEA-motif targeting effect on CRISPRa reprogramming, a set of day 12 upregulated 
genes were tested for their impact on reprogramming efficiency. Of the tested genes, transgenic expression 
of NANOG and REX1 increased the CRISPRa reprogramming efficiency (IV: Fig. 5b). Both of these genes were 
also more efficiently activated in HEK293 by dCas9VP192 targeted to their promoter proximal areas in the 
presence of EEA-motif targeting guides (IV: Fig. 5c). This indicated that NANOG and REX1 are two likely 
targets that are mediating the EEA-motif targeting effect on pluripotent reprogramming, as their activation 
is improved by EEA-motif guides and their expression improves reprogramming efficiency. However, NANOG 
and REX1 are unlikely to be the only target genes of the EEA-motif guides due to the high numbers of these 
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sites in the human genome. Identification of additional EEA-motif targeting affected genes will likely require 
either a more efficient reprogramming system or purification of reprogramming intermediate populations. 
 
9.3.5. Inducible CRISPRa (III, IV) 
To gain more control over the timing of the CRISPRa-mediated gene activation, we constructed dCas9 
activator fused with DHFR-derived trimethoprim (TMP) stabilised degradation domain 616 (III: Fig. 3). Stable 
expression of this construct gave TMP dependent activation of targeted genes in HEK293 and human skin 
fibroblast cells (III: Fig. 3). The construct did, however, demonstrate some level of leakiness, possibly due to 
incomplete degradation of the fused dCas9 activator protein and the strong VP192 activator domain. This 
leakiness could be controlled by putting the destabilised dCas9 activator under a doxycycline (DOX) inducible 
promoter. The combination of both TMP and DOX inducible systems were sufficient to reduce the leakiness 
compared to both systems separately (III: Fig. 3b,c). The use of these systems separately allowed separate 
temporal control of the expression of two different sets of factors (III: Fig. 4f-h). 
To reprogram human skin cells with the inducible CRISPRa system, the TetON-DDdCas9VP192 activator was 
combined with the reprogramming factor targeting guides and the EEA-motif targeting guides in PiggyBac 
transposon vector system. This way neonatal human foreskin fibroblast cells could be selected after activator 
and guide delivery, and reprogramming could be induced by addition of TMP and DOX in the culture medium 
(IV: Fig. S8). This system could also be used to produce stable pluripotent stem cell clones, which could be 
re-reprogrammed after differentiation (IV: Fig. S8g-i). This inducible CRISPRa reprogramming system will 
likely be a useful tool for further investigation into the mechanisms behind the CRISPRa-mediated induction 
of pluripotency. 
 
9.3.6. What is the Mode of Action of EEA-motif Targeting? 
The EEA-motif is located in a conserved Alu consensus sequence in the left arm of the Alu element. The guide 
target sites targeted in this motif are located in between the A and B-boxes of the Pol III promoter of the Alu 
element and contain multiple characterised binding sites for a number of different transcription factors 
nearby 593. The elements themselves, particularly a specific subset of B1-elements, have been implicated to 
have insulator-like function that is activated by active transcription of the motif promoter 588. The chromatin 
looping associated factor CTCF is recruited to the activated B1 elements in a PARP-1 dependent manner 
leading to the establishment of insulation at these loci. In addition to CTCF, the Alu consensus motif 
sequences are known to contain binding sites for other chromatin architecture associated factors like YY1 
79,594, and TFIIIC, a transcription factor important for Pol III RNA polymerase initiation complex. TFIIIC and its 
interaction with cohesin have been linked to chromatin insulation at tRNA gene B-box sequences 617, and 
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TFIIIC and condensin II have been shown to support expression of TAD boundary associated genes 618. 
Therefore, it is quite likely that the function of the EEA-motif and its targeting in reprogramming may be 
associated with the control of chromatin 3D structure and the role of DNA conformation in gene 
transcriptional control. To gain a better idea of the function of the motif, chromatin conformation capture 
and proteomics analysis would need to be performed. This would also help elucidate the molecular 
mechanisms governing the EEA-motif function. This may, however, be additionally complicated by the 
context dependence of the possible chromatin interaction function, as the transcriptional effect of targeting 
these sites may be dependent on the presence of additional factors that cause transcriptional changes to the 
associated genes, i.e. pluripotent reprogramming factors. A role of Alu-motifs and TFIIIC in controlling 
chromatin 3D architecture is implied by the contribution of these elements to the activity dependent 
relocation of neuronal genes to transcription factories 590. Therefore, EEA-motif targeting may be promoting 
similar function in pluripotency-associated genes upon their activation by the reprogramming factors. It is 
also not clear whether the EEA-motif targeting effect by dCas9 is mediated by opening of the sequences near 
these elements or blocking of the binding sites in the guide target sites. Theoretically, both of these options 
could be possible. Blocking of, for example, TFIIIC could promote more efficient relocation of these sites to 
transcription factories (see Figure 12 model), or blocking of insulator function could promote enhancer-
promoter interaction over the insulated regions. On the other hand, opening of these regions could provide 
more accessibility to, for example, YY1 to mediate intra TAD interactions to promote active transcription. 
Activation of these regions could also promote activation of the insulator function for establishing 
pluripotency associated insulated boundaries. Our results by targeting the EEA-motif with dCas9 in HEK293, 
demonstrated a slight increase in ATAC-seq accessible regions at EEA-guide 1 sites (IV: Fig. 6f). This suggest 
a chromatin opening effect of the dCas9 protein. However, it does not rule out the possibility of blocking 
function. 
 
9.3.7. Model for Targeted Gene Activation in Reprogramming 
Cellular reprogramming by targeted activation of endogenous genes requires consideration of additional 
issues that may not be equally relevant for transgenic factor mediated reprogramming. In transgenic 
reprogramming, high expression of the reprogramming factors is usually sufficient to initiate the 
reprogramming process. As the CRISPR reprogramming is driven by the transgenic dCas9 activator complex, 
the function of the dCas9 and how it mediates the activation of its target genes are crucial for successful 
reprogramming. The reprogramming process normally requires simultaneous activation of a set of 
transcription factors. Therefore, the dCas9 activator has to function robustly at different target genes. It is 
not currently well known how the dCas9 activator targeting will affect the targeted genomic loci, particularly 
in a process where the transcriptional mechanisms that are maintaining the target gene expression may 
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depend on the changing cellular phenotype. In the case of reprogramming, the complexes that are promoting 
efficient transcription in somatic cells may be different from the ones in pluripotent cells, and optimisation 
of dCas9 activator function in somatic cells may not produce best result for inducing robust expression in 
pluripotent state. To understand this better, the mechanisms that are controlling the transcription will need 
to be studied in more detail. Considering the transcriptional activation of a gene from the phase separation 
model perspective 65, the possible differences in the factors controlling this phenomenon in somatic cells and 
in pluripotent cells may contribute to the stable transcription of the targeted genes. This may be part of the 
issue with the observed decrease in reprogramming efficiency with the P65-HSF1 containing activator 
domains (IV), but this issue would need to be further investigated. Additionally, targeting of other areas, such 
as enhancers and super enhancers, would be expected to further stabilise the expression of the artificially 
activated genes, as this could contribute to more efficient phase separation of the targeted loci. 
 
 
Figure 12. A schematic representation of a model for EEA-motif function in CRISPRa-mediated gene activation. 
Increased numbers of EEA-motifs near pluripotency genes may promote more efficient translocation and 
phase separation of these loci into transcription factories in the presence of EEA-motif targeting gRNAs. 
Binding of dCas9 into the Pol III promoter of the Alu left arm may interfere with TFIIIC function and chromatin 
cohesion, enabling changes in chromatin 3D architecture that promote active transcription. 
 
Conventionally, the transcriptional activation of the targeted genes has been considered to occur via the 
recruitment of the mediator and other Pol II recruiting complexes to the targeted promoters by the dCas9 
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fused transactivation domain. In this case, the activation efficiency would be expected to rise with the 
addition of extra activation domains. This is not, however, what has been observed. Instead the activation 
efficiency seems to plateau after a certain point 522. It is possible that the recruitment of the dCas9 activator 
to multiple sites near a gene will promote more efficient activation of the gene than extra activation domains. 
This appears to also be supported by the increased activation efficiency of targeted genes by pooled guide 
RNAs (IV: Fig. 2b). Accordingly, targeted CRISPR-mediated gene activation may therefore work by 
translocation of the physical gene locus into the actively transcribed nuclear areas, i.e. promoting the 
translocation of the genes to transcription factories. This would be mechanistically analogous to what has 
been described for activity dependent relocation of neuronal genes to transcription factories. Thus, it is also 
possible that the EEA-motif targeting in reprogramming mimics the function of the SINE motifs as described 
by Crepaldi et al. 590. Mechanistically this could mean that EEA-motif targeting may interfere with the TFIIIC 
/ condensin mediated DNA packaging and promote more efficient translocation of the pluripotency factor 
loci into transcription factories due to high number of dCas9 targeted EEA-motifs near these genes and 
simultaneous targeting of these genes for activation by the reprogramming factors. The exact mechanisms 
of the CRISPR reprogramming process will still need to be further studied. This will optimally require high 
efficiency inducible reprogramming systems, where reprogramming can be initiated in a large percentage of 
the cell population, in order to get sufficient numbers of reprogramming cells needed for comprehensive 
analysis of the CRISPRa reprogramming process. A model for EEA-motif mediated promotion of CRISPRa gene 




10. Conclusions and Future Perspectives 
 
Induction of pluripotency has been a revolutionising technology for biomedical research. The extensive 
amount of research invested in this technology during the past decade has led to rapid development of the 
cellular reprogramming field. The advent of the CRISPR era is likely to revolutionise the field further. With 
the capability to produce sequence specific genetic and epigenetic changes in chromatin and DNA, our ability 
to produce high quality reprogrammed and gene edited cells for research and potentially therapeutic 
applications will improve greatly. 
In this thesis we have demonstrated that rAAV vectors can be used to reprogram mouse embryonic 
fibroblasts to pluripotency. However, this method is associated with high frequency of vector integration, 
which limits its use for derivation of integration free iPSCs. This work highlights the potential of rAAV vector 
integration in some applications and urges consideration of the vector integration risk. If vector integration 
is not an issue for the planned application, the method can potentially be used for example for generation of 
iPSCs for secondary reprogramming experiments. As the integration of rAAV vectors is opportunistic, the 
vector integration could also be used for detecting DNA DSB sites generated during the reprogramming 
process. 
Comparison of reprogramming of aged and long term cultured human skin fibroblasts demonstrated the role 
of P21 in limiting the efficiency of reprogramming of old donor fibroblasts and cells that have been 
extensively expanded in culture. In order to improve the reliability of reprogramming from variable sources 
of human fibroblasts, P21 inhibition should be taken into consideration. Particularly, the inhibition of P21 
instead of P53 could be useful, as the P21 levels were already upregulated in the aged fibroblasts. This work 
was performed with relatively low number of samples and therefore further work with higher sample sizes 
should inform us more of the effect of aging on reprogramming efficiency. Moreover, inclusion of alternative 
cell types should give a better idea of the general applicability of P21 inhibition. Other effects than cell 
proliferation should also be taken into consideration. It is likely that P21 upregulation and inhibition of cell 
proliferation are not the only effects of aging on reprogramming and that additional factors, such as 
epigenetic changes, may contribute to the process. In order to avoid the negative effect of decreased 
proliferation more advanced reprogramming methods that are less dependent on cell proliferation need to 
be developed. 
By optimising dCas9 transcriptional activators, guide composition for endogenous reprogramming factor 
targeting and targeting of conserved Alu sequences, we were able to demonstrate CRISPRa-mediated 
reprogramming of human somatic cells to pluripotency. This is the first time functional reprogramming of 
human cells to pluripotency using CRISPRa has been described. CRISPRa-mediated reprogramming 
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technology is likely to have a great impact on the cellular reprogramming field. The system is unique as it 
allows targeting of endogenous loci for activation and simultaneous targeting of a large sets of genomic areas. 
This is not only useful for induction of pluripotency, but potentially also for transdifferentiation. It is likely 
that the CRISPRa method is not going to be used only by itself, but to be combined with transgenic 
transcription factors, RNAi and small molecular compounds to best guide the reprogramming process. This 
will aid in comprehensive targeting of the transcriptional programs for maximising the accuracy of resetting 
the cellular phenotype. One problem with the current approaches for CRISPRa reprogramming is the 
complexity of the guide targeting. Many possible target genes and guide sites in promoter and enhancer 
regions make it difficult to predict optimal reprogramming combinations. Therefore, for future development 
of CRISPRa reprogramming, it may be best to apply guide screens to select best working guides in a 
functionally relevant setting. Our CRISPRa reprogramming method relies on the targeting of conserved Alu-
motifs for efficient reprogramming. The function of these elements and their role in reprogramming and 
development has not yet been thoroughly studied. Therefore, deciphering the molecular function of these 
motifs is important for understanding their role in reprogramming and development. The targeting of these 
loci may also turn out to be useful for other reprogramming applications, such as SCNT or CRISPRa-mediated 
transdifferentiation. As transposable elements have restructured the gene regulatory networks during 
evolution, and commonly demonstrate tightly temporally controlled expression patterns, the possible role 
of other transposable elements in cellular reprogramming should be further studied. The CRISPRa 
reprogramming methods described in this thesis offer a great tool for that. 
In conclusion, this thesis work provides a number of novel tools and insights for improving the pluripotent 
reprogramming process of human cells. This will likely result in better quality of reprogrammed cells, 
improving the cellular models used for research purposes and potentially providing improved reprogrammed 
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